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About the title 
The title of this thesis comes from the countless conversations that I have had with 
other researchers over the course of this PhD research. During these conversations, 
when I would explain that my research is focused on PPI, I was always met with a 
similar reaction- ‘Oh yeah, I mean, I think PPI is a really nice thing to do but…’. The ‘but’ 
would then be followed with various reasons why they hadn’t incorporated any PPI into 
their research to date – ‘…I don’t understand why research funders are so set on it’ or 
‘…do we really know that it makes a difference to our research’ or ‘…nobody seems to 
know how to actually do it properly’. 
Over the last three years, I haven’t encountered anyone that didn’t think PPI was a nice 
thing to do. But at the same time, I have only met a handful of people that were 
confident that they could do it properly and that it would definitively lead to better 
quality research. Now that research funders, ethics committees and academic journals 
require PPI, I believe we need to lessen the distance between the semi-skeptics and the 
fully fledged PPI-ers. To do this, we must address their concerns. We need evidence on 
the methods and impact of PPI. 
 




This is for my Granny, Maureen Whelan (née O’Keefe), the eternal teacher who has 
inspired us all to pursue lifelong learning x 
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Background and Aims 
Patient and Public Involvement (PPI), defined as research carried out ‘with’ or ‘by’ 
members of the public rather than ‘to’, ‘about’ or ‘for’ them, is increasingly recognized 
as an essential component of health research. The rationale for PPI is based on a moral 
argument where the people whose lives are most affected by research should have a say 
in what is researched and how it is carried out, and a pragmatic argument that PPI can 
improve research quality. Although PPI is now required by many research funders, 
academic journals, and ethics committees, progress to achieve greater involvement has 
been patchy and slow. There is a lack of clarity on how to conduct ‘strong’ PPI and on 
why PPI should be used. Research is needed on suitable PPI methodologies and on the 
impact of PPI if we are to develop a shared understanding of what works, when, how and 
why. Therefore, the overarching aim of this thesis was to contribute to the evidence on 
the methods and impact of PPI by exploring PPI contributors’ experiences and 
contributions at the design, conduct and dissemination stages of trials.  
Methods 
At the design stage, two Studies Within A Trial (SWAT) were conducted within the 
intervention development phase of the Improving Diabetes Eye-screening Attendance 
(IDEAs) pilot trial. The first used a mixed methods convergent design to compare people 
with diabetes and healthcare professionals’ experiences of taking part in three different 
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types of consensus meetings to inform intervention development and assess whether 
their experiences differed according to group composition. The second used a qualitative 
design to compare people with diabetes and healthcare professionals’ contributions to 
the intervention content and assess whether their contributions differed according to 
group composition. At the conduct stage, a systematic review and narrative synthesis 
was conducted on trial researchers’ perceptions of the impact of PPI on trial retention. 
At the dissemination stage, a mixed methods SWAT, including an embedded randomised 
trial, was conducted within the Thyroid Hormone Replacement for Subclinical Hypo-
Thyroidism (TRUST) trial to identify, develop, and evaluate a patient preferred method 
of receiving trial results.  
Results 
Involving PPI contributors simultaneously with other stakeholders led to a perceived lack 
of common ground where both stakeholders felt reluctant to fully express their opinions. 
It also led to conflicting opinions which were difficult to incorporate into the intervention 
being developed. Researchers perceived PPI to have a positive impact on trial retention 
as it helped trial researchers to foster a trusting relationship and improve communication 
with trial participants. PPI was also perceived to improve trial retention by ensuring the 
trial location was suitable and accessible and enabling researchers to establish cultural 
appropriateness by ensuring that community customs, norms and social activities were 
considered in the research design. Although, PPI contributors were involved in the 
development of the trial result letter, the results of the embedded randomised trial 
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suggested that PPI did not make a difference to participants’ understanding of trial 
results.  
Conclusions 
This research shows that although there are a wide variety of methods used to involve 
PPI contributors, the method used can have an important influence on the impact of 
involvement. The results suggest that it may be more suitable and useful to involve PPI 
contributors separately rather than simultaneously with other stakeholder groups. This 
finding may assist researchers and PPI contributors in designing and conducting more 
meaningful and effective involvement activities. This research found that PPI can 
influence the research process by creating and fostering trust between researchers and 
participants and PPI contributors can help researchers to communicate more effectively 
with research participants. Although, the results suggest that PPI did not make a 
difference to participants’ understanding of results, suggestions for how researchers 
should approach future evaluations of the methods and impact of PPI have been put 
forward. This research paves the way forward for building an evidence base for PPI to 
ensure that a shared understanding of what works, when, how and why is developed 








1.1 Introduction  
Patient and Public Involvement (PPI) is increasingly recognized as an essential 
component of health research. In the UK, INVOLVE, the national advisory group 
supporting active public involvement in health services, public health and social care 
research defines PPI as ‘research being carried out ‘with’ or ‘by’ members of the public 
rather than ‘to’ ‘about’ or ‘for’ them’ (1). 
 
The rationale for PPI is based on two lines of argument. Firstly, a moral and ethical 
argument of ‘nothing about us without us’ where the people whose lives are most 
affected by research should have a say in what is researched and how it is done (2-4). 
Secondly, a pragmatic argument that PPI can improve the quality, relevance, and uptake 
of research (2, 5-8). It has been suggested that this can happen through: influencing 
research priorities; helping solve ethical dilemmas; helping with recruitment strategies; 
influencing how data is collected, analysed and interpreted to ensure a patient and 
public perspective; and ensuring communication and dissemination of outputs is in a 
language and format that is accessible to patients and the public (9).  
 
In recent years, several countries have been working to embed PPI principles and 
practices in health and social care research, and PPI is now required by many research 
funders, academic journals and ethics committees (3, 10). Despite this changing 
environment of PPI in health research and the potential for PPI to have a positive impact, 




PPI is a complex activity; there are a wide variety of involvement tasks and activities, as 
well as a wide range of methods used to involve PPI contributors. Evidence on what 
works, when, how and why is lacking (9). Although it is acknowledged that different PPI 
methodologies have an important role in shaping the impact of PPI (12), current reports 
on suitable and effective PPI methodologies are insufficient with many researchers 
arguing that PPI is too complex to be evaluated as ‘it depends’ on too many different 
factors  (13-15).  
 
Similarly, current reports on the impact of PPI are ‘piecemeal and inconclusive’ and are 
largely based on researchers’ reflections on the impact of working with PPI contributors 
(9, 16-18). Although these ad hoc and anecdotal reports allow us to develop an initial 
understanding of the potential impact of PPI, they can often conflate the aims of PPI with 
its achievements and seldom report any negative impacts (19, 20). Research funders that 
are contingent on having ‘strong’ PPI without clarity on how to conduct ‘strong’ PPI or 
on why PPI should be used can tempt researchers to exaggerate the scope of PPI in grant 
applications in order to obtain funding leading to tokenistic involvement. Research is 






This thesis aims to contribute to the evidence on the methods and impact of PPI by 
exploring PPI contributors’ experiences and contributions at the design, conduct and 
dissemination stages of trials. 
1.3 Objectives 
1. To identify a suitable and effective way to involve multiple stakeholders in 
research. 
• Compare people with diabetes and healthcare professionals’ (HCPs) 
experiences of taking part in different types of consensus meetings to 
inform intervention development (Chapter 3). 
 
• Identify and compare people with diabetes and HCPs’ contributions 
during different types of consensus meetings to inform intervention 
development (Chapter 4). 
 
2. To explore the impact of PPI on the research process. 
• Identify and compare people with diabetes and HCPs’ contributions 
during different types of consensus meetings to inform intervention 




• Systematically review trial researchers’ perceptions of the impact of 
PPI on participant retention in randomised controlled trials (RCTs) 
(Chapter 5). 
 
• Investigate methods of disseminating trial findings to participants by 
using a PPI approach to identify, develop and evaluate a patient 
based approach to receiving trial results (Chapter 6).  
 
 
1.4 Thesis outline  
This thesis contains seven chapters. This first chapter provides an overview of the 
structure of the thesis. Chapter 2 draws on a review of the literature to describe the 
current role of PPI in health research and presents the rationale for generating evidence 
on the methods and impact of PPI. Chapters 3-6 correspond to the aim and objectives 
outlined above (see Figure 1.1). Chapter 7 provides an overall discussion of the main 
findings, the strengths and limitations of the thesis, the implications and suggestions for 
future research. This chapter also includes a reflection on PPI during the COVID-19 




Figure 1.1: Overview of thesis including aim and objectives 
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2.1 Overview  
This chapter presents a brief overview of the current role of PPI in health research. First, 
PPI is defined and the rationale for PPI is described as well as the wide range of PPI 
approaches and methods. Second, the changing environment for PPI in health research 
is discussed. Third, the potential positive impacts of PPI are outlined along with the 
numerous and persistent challenges to PPI. Finally, the need for robust evidence on the 
methods and impact of PPI is presented.   
2.2. Patient and Public Involvement (PPI) 
2.2.1 Definition of PPI  
For this thesis, I have adopted the INVOLVE definition of PPI. INVOLVE is the national 
advisory group supporting active public involvement in health services, public health, 
and social care research in the UK. INVOLVE define PPI as ‘research being carried out 
‘with’ or ‘by’ members of the public rather than ‘to’, ‘about’ or ‘for’ them (1). In working 
with this definition, I have taken the most widely accepted and inclusive definitions of 
‘patient’ and ‘public’. The term ‘patient’ is used to refer specifically to those who have 
experience of disease or illness (21). The term ‘public’ encompasses all those associated 
with the use of health care including patients and potential patients, people who use 
health and social services; informal carers; parents/guardians; disabled people; 
members of the public who are potential recipients of health promotion programmes, 
public health programmes and social service interventions; and organisations that 
represent people who use services [6]. The terms ‘patient’ and public’ are being used to 
12 
 
denote roles in a specific situation, not categories of people, and are not mutually 
exclusive, as many individuals fulfil many roles, often at the same time (22).   
The term ‘involvement’ is intended to mean the active involvement of patients and 
members of the public in health research projects and in research organisations. Patients 
and members of the public can be actively involved by contributing to and/or making 
decisions about what research is conducted, how the research is carried out and how it 
is disseminated. 
PPI is distinct from patient and public participation in research which relates to the 
passive involvement of patients and members of the public, where they are recruited by 
researchers to become study participants or subjects and their data is collected, analyzed 
and published as study results. PPI is also distinct from patient and/or public engagement 
which similarly reflects a passive involvement of patients and members of the public, 
where researchers aim to raise awareness of research amongst patients and members 
of the public by disseminating research results, sharing knowledge, or engaging in one-
way communication.   
Values and principles of involvement  
INVOLVE highlights six values that should be carefully considered and implemented 
when conducting PPI: respect, support, transparency, responsiveness, diversity and 
accountability (23). These values and principles along with principles in practice have 
been summarised in Table 2.1 below. 
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Table 2.1: Summary of INVOLVE’s values and principles for public involvement in 
research 
Values  Summary principles  Principles in Practice  
Respect Researchers, research 
organisations and the 
public respect one 
another’s roles and 
perspectives 
• Public members’ skills, knowledge 
and experience are respected 
• The knowledge and experience of 
researchers and others involved in 
administering or managing 
research skills are respected 
• Public members are included as 
key partners of research 
• Public members are involved from 
the outset 
• Public members’ contributions to 
the research are recognised 
Support  Researchers, research 
organisations and the 
public have access to 
practical and 
organisational 
support to involve 
and be involved 
• Public members have access to 
learning and development to 
support their involvement in 
research 
• Researchers and others have 
access to learning and 
development to support public 
involvement in research 
• There is flexibility to support 
public involvement -public 
members’ expenses are covered, 
and they are informed in advance 
if payment will be offered for their 
time  
• Infrastructure within research 
organisations enables and 
supports public involvement in 
research 
Transparency  Researchers, research 
organisations and the 
public are clear and 
open about the aims 
for and scope of the 
involvement in 
research 
• Researchers and others involved 
in the research openly discuss 
with public members the purpose, 
scope, and expectations in 
advance of their involvement in 
the research 
• Researchers provide clear 
information to public members 
about their role and their input 
• Public members are open about 
their ability to contribute 
14 
 
Responsiveness Researchers and 
research 
organisations actively 
respond to the input 
of public members 
involved in research 
• Public members, researchers and 
others contribute to collaborative 
decision-making  
• Researchers and research 
organisations are committed to 
public involvement and are willing 
to act on the input of the public 
• Public members commit to their 
involvement in research and are 













• Public members, researchers and 
others understand and sign up to 
the principles of equality, diversity 
and inclusion as defined in the 
Equalities Act 2010 
• Researchers and research 
organisations ensure that public 
involvement opportunities are 
accessible to all 
• Information is presented in 
accessible and alternative formats 
and written in plain English 
Accountability  Researchers, research 
organisations and the 
public are 
accountable for their 
involvement in 
research and to 
people affected by 
the research 
• Researchers and research 
organisations have policies in 
place for the governance of public 
involvement in research and 
public accountability 
• Researchers and research 
organisations are accountable to 
public members involved in the 
research 
• Public members are accountable 
to researchers, research 
organisations and others for their 
involvement  
• Researchers, research 
organisations and public members 
assess the impact of public 




2.2.2 Rationale for PPI 
In the literature and policy discourse, PPI is justified by two general lines of argument. 
The first of these is an ethical or moral argument (2, 3). This argument incorporates ideas 
concerning democracy and rights, citizenship, power distribution, accountability, and 
empowerment. As part of this, a commonly cited argument is that as citizens and 
taxpayers, members of the public have the right to influence research that is being 
funded through public monies and that might have an impact on their health status (3, 
4). This includes how research is designed and undertaken and how research findings are 
disseminated and implemented once a study is complete. The slogan ‘nothing about us 
without us’, which is believed to be over five centuries old, encapsulates this argument 
(24). This rights-based argument is also seen as a means of empowering minority and 
disadvantaged groups in society (7, 25), and so, many authors have argued that careful 
consideration should be given to the appropriateness of methodologies used to involve 
these ‘seldom heard’ groups (26-28). 
The second line of argument is a pragmatic or consequentialist argument (2, 14, 29), 
where PPI, by bringing a real-world and lived-experience perspective, has the potential 
to improve the quality, relevance and impact of health research (2) via a number of 
mechanisms: increasing its relevance to patients; improving recruitment and retention 
rates of research participants; extending the range of people represented in research 
studies; and improving dissemination of findings beyond academic audiences (10).  
Previous authors have provided anecdotal accounts of how PPI can positively  contribute 
to research by suggesting relevant research questions and outcomes, ensuring that 
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consent forms and information sheets are user-friendly, and assisting with the 
recruitment of participants, data collection, data interpretation, and dissemination (5-
8).  
2.2.3 PPI approaches and methods 
PPI is a complex activity and there are a wide variety of approaches to involvement. 
These approaches vary depending on the theoretical model of involvement employed, 
the role of PPI contributors, the duration of involvement, the activities in which PPI 
contributors are involved, the specific methods used to involve and the relevant stage of 
the research process.  
2.2.3.1 Theoretical models of involvement  
PPI is a continuum from research with no involvement through to research that is 
initiated, undertaken and controlled by patients and members of the public (25). The 
number of components, levels or categories within this continuum varies depending on 
the theoretical model employed. 
In the UK and Ireland, the theoretical model of PPI most frequently employed is the 
‘levels of involvement’ model. This model was originally put forward by Boote, Telford 
and Cooper (7) and describes three levels of PPI: consultation, collaboration and user 
control. Consultation includes types of involvement that allow the researcher to obtain 
representatives’ views. At this level, what the representatives say can be influential, but 
they have no power to ensure the researcher acts on their views (7). Consultation is 
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largely focused on feedback, for example, asking representatives to review research 
protocols, participant information sheets and drafts of published papers. Consultation 
can be implemented at all stages of the research process using a variety of methods and 
on a range of scales; for example, drawing on the views of a small group of 
representatives through a focus group or a large group through administration of a 
questionnaire (7, 30-32).  
Collaboration involves an ongoing partnership between researchers and PPI contributors 
where contributors have more ownership of the research and can, at least in theory, 
contribute more directly to the direction of the research (7). Contributors may, for 
example, sit on a steering group for a research project, and help guide the project from 
its early planning stages through to dissemination. However, the exact nature of the 
collaboration differs between research projects. 
User controlled (also referred to as consumer-controlled) is research that is actively 
controlled, directed and managed by service users and their service user organisations 
(7). Service users decide on the issues and questions to be looked at, as well as the way 
the research is designed, undertaken and disseminated (30). Researchers become 
involved at the request of the service users themselves; or consumer organisations 
commission research into a topic of interest to them (7). This type of research requires a 
strong commitment on the part of service users and is the least common of the three 
‘levels of involvement’ (32).  
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The ‘levels of involvement’ model is a condensed version of Arnsteins ‘ladder of 
participation’ which has been a touchstone for policy makers and practitioners 
promoting user involvement for over 40 years (see Figure 2.1). Each rung on Arnsteins’ 
ladder represents increasing degrees of participation: from non-participation of 
manipulation and therapy; through to the tokenism of informing, consulting, placating, 
to citizen power through partnership, delegated power and citizen control (33). 
Arnsteins’ model frames citizen participation as an overt struggle for power between 
public sector managers and public activists and community members. This struggle 
continues to have some resonance but fails to engage with the complexity and nuances 
of PPI. These complexities have given rise to reinterpretations of the model including 
Wilcox’s five-rung ladder (34), Burn’s ladder of citizen empowerment which attempts to 
incorporate degrees of participation and quality of engagement (35) and Choguills’ 
adaptation for use in developing countries (36).  Despite different interpretations, 
refinements and revisions to Arnstein’s model over the years, they all retain an 
important common feature, a ‘hierarchal approach’ with ‘citizen control’ portrayed as 
the ideal form of involvement.  
While these different theoretical models include different conceptualizations of 
involvement, they notably all fail to capture the complexities of involvement such as the 
diversity of actors, the importance of process as well as outcome, and the integration of 
a systematic approach to engagement and feedback (37). Since its inception, the ‘levels 
of involvement’ model has been widely adopted and promoted by INVOLVE. In more 




Figure 2.1: Arnsteins’ ladder of citizen engagement   
 
terms of ‘approaches’ to involvement rather than ‘levels’. This shift in thinking 
encourages researchers and PPI contributors to recognize the complexities of 
involvement. It also encourages researchers to understand that the boundaries between 
categories are not so clear cut and research projects may combine two or three levels of 
involvement (32). For the purpose of this thesis, I have chosen to adopt a combination 
of consultation and collaboration approaches where wider groups of PPI contributors 
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will be consulted on specific aspects of each study and individual PPI contributors will be 
collaborators throughout the research.  
2.2.3.2 The role of PPI contributors 
PPI contributors’ roles vary from managerial roles (involvement in the set-up and day-
to-day running of the project), oversight roles (involvement in determining the direction 
of the research), and responsive roles (involvement guided by researchers) (9, 38, 39). 
Crocker et al. (2017) identified a range of distinct roles that may be played by individual 
PPI contributors at different stages in a research study (40):  
• The expert in lived experience- able to consider the acceptability and 
feasibility of proposals for the target population, having lived through the 
experience under study 
• The creative outsider- able to think ‘outside the box’ by bringing a fresh 
perspective 
• The free challenger- able to challenge researchers without fear of 
consequences 
• The bridger- able to make research more relevant and accessible by 
bridging the gap between researchers and the public, including patients 
• The motivator- helping to highlight the importance of a piece of research 
as a motivation for engagement 
• The passive presence- where just the presence of a PPI contributor has an 
influence on how researchers think 
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2.2.3.3 The duration of the involvement 
The duration, frequency and regularity of patient and public involvement varies across 
research projects and programmes (9, 38, 41). Involvement may be ad hoc (drawing on 
PPI at intervals as required), or long-term (spanning the duration of the project),  (9, 18, 
38, 42). Although, long-term involvement across the research cycle has been rarely 
reported on in the literature (41, 43).  
2.2.3.4 Involvement tasks and activities 
There are a wide range of tasks and activities in which PPI has been reported, these often 
vary depending on the stage of the research. Ball et al, provide an overview of the wide 
range of PPI tasks and activities that are evident in the literature (9). Some examples of 
tasks and activities during the  research preparation and design phase include 
identifying, generating and prioritising research topics or questions, providing input into 
funding decisions, contributing to the development of research proposals, advising on 
the development of surveys and interview guides, scope and search strategy for reviews, 
feasibility of conducting research in real-world settings, cultural issues that may need to 
be considered, sampling, ethical issues and patient information materials (39, 44-47).  
Examples during the study conduct stage include advising on recruitment and retention 
issues, actively engaging in participant recruitment, contributing to the conduct of 
literature reviews, collecting data from participants by conducting interviews, 
administering surveys and facilitating focus groups, contributing to data analysis tasks 
and helping researchers to identify key findings (39, 44, 47-49). 
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Examples at the dissemination and translation stage include contributing to drafting 
journal articles, reports, summaries (including lay summaries) and press releases, 
participation in the release of results and publications and determining avenues to share 
findings (38, 46, 48, 50, 51).  
2.2.3.5 The specific methods used to involve 
PPI contributors can be involved through diverse methods of involvement. Some 
examples highlighted in the literature include advisory group meetings, PPI group 
meetings (both face-to-face and virtual), expert workshops, working collaboratively with 
the research team, surveys, interviews, focus groups, consensus meetings, discussion 
forums, patient panels, use of facilitation tools (e.g. World Café and Dotmocracy) social 
media, online discussion forums, structured priority-setting exercises, ad-hoc advice via 
PPI panels, sitting on funding panels and grant review committees and corresponding 
and reviewing documents via email (9). The number of individuals involved can vary 
greatly, for example an advisory board usually has between one and five service users, 
whereas priority setting exercises can involve hundreds or even thousands (41). 
2.2.3.6 Stages of the research process  
PPI can be conducted at any stage of the research process from priority setting and 
drafting study protocols right through to conducting the study, interpreting the results 
and communicating and disseminating research findings (See Figure 2.2 below) (41, 46-
48, 50, 52-55). Shippee et al. (2015) conducted a systematic review on 202 articles 
relating to PPI in biomedical and health services research and identified that PPI was 
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conducted in three key phases of the research cycle: the preparatory phase, the 
execution phase and the translational phase. According to their proposed framework, 
each phase comprises several distinct stages. The preparatory phase involves patients 
and/ or the public in addressing the question of what to research through two stages: 
agenda setting and contributions to preparing or reviewing funding applications. The 
study execution phase includes PPI in four stages: study design and procedures, 
recruitment and participation, data collection and data analysis. The translational phase 
consists of post-analysis activities in three stages: dissemination, implementation and 
evaluation (53). Some frameworks cover similar stages and phases to those outlined by 
Shippee et al., while others focus on specific parts of the research cycle or organise stages 
where contributions can take place through an alternative lens (9). For example, Ray and 
Miller (2017) categorise PPI according to: what the scope of the research where 
involvement takes place is (e.g. for defining and prioritising a topic of research questions 
and hypotheses, defining an intervention, specifying outcomes to be measured); project 
methods (i.e. whether PPI contributors are involved in research design, implementing 
research methods, recruitment); and interpretation (analysis, making sense of the 
findings, synthesis, anticipating alternative interpretation or controversy)(56).  
There are variations in the degree to which PPI is conducted and reported across the 
different stages of the research cycle (9). For example, PPI is more frequently reported 
in the set-up and conduct stages of the research process than in the data collection, data 
analysis, dissemination and translation phases (39, 48, 53, 57) and there is a lack of PPI 




Figure 2.2: PPI at different stages of the research process (58). 
 
This thesis explores PPI contributors’ experiences and contributions at three distinct 
stages of the trial process: trial design, conduct and dissemination. The corresponding 
stages of the research process have been highlighted in yellow in Figure 2.2. However, 
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each of the studies presented in this thesis has had PPI involvement at different stages. 
This ranges from the study design stage right through to dissemination. Further details 
on PPI involvement in the different stages are presented throughout the following 
chapters in this thesis.  
2.2.4 The changing environment for PPI in health research 
In recent years, several countries have been working to embed PPI principles and 
practices in health and social care research, and PPI is now required by many research 
funders, academic journals and ethics committees (3, 10). 
In the UK, this movement has been led by INVOLVE, which was originally set up in 1996 
and is now integrated with the National Institute for Health Research (NIHR). In the US, 
this work is being carried out by the Patient-Centered Outcomes Research 
Institute (PCORI) and in Canada, the Strategy for Patient-Oriented Research (SPOR) has 
embedded PPI within the Canadian Institutes for Health Research funding calls.   
In January 2016, Irelands’ primary health research funder, the Health Research Board 
(HRB) launched its 2016-2020 strategy which referred to PPI as a core principle and 
contained the commitment to strengthen and develop PPI within the HRB and in HRB 
supported projects and programs (59). It was the first state funding body to formally 
launch an implementation plan for PPI. The implementation plan included asking all 
researchers to provide details in their research funding applications of any public 
involvement in the design, conduct or dissemination of their study, introducing public 
reviews of some its research funding applications and partnering with the Irish Research 
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Council (IRC) to launch a funding call which specifically aimed to support and promote 
PPI within Higher Education Institutions in Ireland-PPI Ignite (60). Five institutions were 
successful in the PPI Ignite call including: Trinity College Dublin (TCD), National University 
of Ireland Galway (NUIG), University of Limerick (UL), University College Dublin (UCD), 
and Dublin City University (DCU). The overarching aim of PPI Ignite was to build capacity 
in institutions that would provide researchers with the support they need to involve 
patients and the public in their research and convey this in their grant applications (61). 
In May 2020, the HRB and IRC opened a call for the establishment of a formal National 
PPI network. The overarching aim of the National PPI Network is to support and further 
build capacity for high quality PPI in health research throughout Ireland through a 
network that serves its members and benefits the wider community (62). The five PPI 
IGNITE institutions and two new partner institutions: University College Cork (UCC) and 
the Royal College of Surgeons Ireland (RCSI) prepared and submitted a joint application. 
If successful, the national PPI network will be established in March 2021.  
The Irish Research Council (IRC) have also made significant efforts to embed PPI within 
Irish research. Since 2007, it has supported ‘Campus Engage’, a national platform funded 
by the Higher Education Authority which aims to promote civic engagement activities in 
Irish higher education (63).  Although its focus is not primarily on PPI, its widespread 
promotion of engaged research and active citizenship has created a supportive 
environment for the advancement of PPI. As well as co-funding the PPI IGNITE and 
National PPI Network calls with the HRB, the IRC is also in the process of developing 
protocols to include PPI as a requirement in its research funding applications and this is 
likely to be rolled out shortly. 
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Academic journals have also begun to embed PPI in health research. For example, in 
2014, the British Medical Journal (BMJ) launched its patient partnership strategy, seeking 
‘to promote patient partnership by walking the talk’ (64, 65). The partnership strategy 
was informed by an international patient advisory panel and launched several innovative 
editorial practices, including patient peer review and patient co-production of 
educational articles. In 2015, as part of the patient partnership strategy, journals in the 
BMJ’s portfolio began requiring authors to include a PPI statement in their academic 
publications. If patients were not involved in the research, authors must clearly state 
their reasons for the omission.  
Research ethics committees also stipulate that members of the public be involved in 
research design and study conduct (64). However, this practice varies by organisation 
and country. In the UK, most ethical review boards now require PPI to be considered in 
the development of ethical approval applications (64). While research ethics committees 
in Ireland have not formally adopted this approach, one of the key objectives proposed 
in the National PPI network application which was recently submitted to the HRB/IRC is 
to embed PPI in institutional policies and structures including University Ethics 
committees (62).  
2.2.5 The potential positive impacts of PPI 
Current reports on the impact of PPI in health research have been described as 
‘piecemeal and inconclusive’ and are largely based on researchers’ reflections on the 
impact of working with PPI contributors (16-19). These accounts are ad hoc and 
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anecdotal and can conflate the aims of PPI with its achievements, and seldom report any 
negative impacts (19, 20). Some studies have conducted more robust processes of 
assessing impact. For example, gathering views of PPI contributors and academic 
researchers via interviews, pre and post involvement questionnaires and focus groups 
(16, 66). However, most of these studies have asked simple questions about whether 
involvement makes a difference and do not specifically evaluate the impact of PPI on 
particular aspects of the research process, or contain any evidence of impact (67). For 
example, researchers may report that involving PPI contributors helped to ensure that 
study materials were more understandable and accessible to members of the public but 
will not provide any details of the improvements that were made or contain any evidence 
of impact. Nevertheless, these reports have allowed us to develop an initial 
understanding of the potential impact of PPI. These impacts can be classified into three 
main categories: perceived impacts on the research process, impacts on researchers and 
impacts on PPI contributors. 
2.2.5.1 Perceived impact on the research process  
According to qualitative studies on the perceived impact of PPI in trials, researchers and 
PPI contributors believe that PPI can help to improve the relevance of research by 
ensuring that research funds are appropriately prioritised and that the evidence that 
research produces is of interest to patients and members of the public (44). It has also 
been suggested that PPI can improve the acceptability and accessibility of research by 
improving the clarity of participant information, removing jargon and making it more 
salient to potential participants (26, 68-70). A paper presenting researchers’ reflections 
29 
 
of participatory action research with young injecting drug users highlighted that PPI has 
the potential to improve recruitment rates and facilitate more representative sampling 
as it can help researchers to access ‘hard to reach’ populations through PPI networks 
(71). The same paper also suggested that PPI can shorten the timeframe of research by 
improving the design of study protocols and expediting ethical approval (71). PPI has also 
been suggested to improve research dissemination. For example, a multi-method 
evaluation of the impact of consumer involvement in the London Primary Care Studies 
Programme reported that PPI increased the impact of research by broadening the 
opportunities for dissemination (72). 
2.2.5.2 Impact on researchers 
A qualitative case study of researchers’ experiences of user involvement reported that 
PPI helped them to understand the views and experiences of research participants and 
helped them to connect to the ‘real world’ (73). Researchers have also reflected on how 
PPI allowed that to understand participants’ cultures which gave them greater respect 
and helped them to develop a good rapport with the community (71, 74, 75). 
Researchers have also described gaining new insights into their research areas which 
helped to challenge their assumptions (75). A questionnaire study of researchers’ and 
PPI contributors’ perceptions of PPI impact during one randomised controlled trial 
highlighted that researchers’ felt PPI had enabled them to develop new research ideas 
and focus on issues that were important to the community they were researching (76). 
Researchers have also reported that PPI helped them to develop new skills and find new 
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ways of working. Some researchers reported gaining facilitation, communication and 
conflict resolution skills and provided support and advice to PPI contributors (71, 75).   
2.2.5.3 Impact on PPI contributors 
A systematic review of the conceptualisation, measurement, impact and outcomes of 
PPI in health and social care research classified the impacts on PPI contributors into three 
main areas: personal benefits, impact on their level of knowledge and impact on their 
level of skill (77).  
Papers reporting PPI contributors’ reflections report personal benefits including feeling 
empowered (78, 79), listened to and valued (69, 80), more positive  (81, 82), more 
confident (69, 81, 82) and feeling a sense of fulfillment and satisfaction (83-85). Service 
users reflections on being involved in a research advisory group experienced a sense of 
mutual support from being part of a team (83). Another study reporting PPI contributors’ 
reflections reported that they appreciated the social interaction with others (84). 
Contributors have also felt they had given something back and had made a difference 
(69, 86, 87). Impacts on their level of knowledge include reports of gaining access to 
better information about their condition, and having the opportunity to exchange and 
compare this information with others (69, 83). This, in turn, allowed them to better 
manage their condition and solve related problems (88, 89). PPI contributors have also 
reported gaining a greater understanding of the research process (4, 69, 81) which led 
to increased levels of trust in the research process (90, 91). Impact on their level of skills 
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include gaining skills in research methodology (4, 92), public speaking (69, 83) and 
listening to other people’s perspectives (81, 93). 
2.2.6 Challenges to PPI 
Despite the changing environment of PPI in health research and the potential for PPI to 
have a positive impact, progress to achieve greater involvement is ‘patchy and slow’ (11).  
In 2018, Price et al. conducted a review of PPI statements in BMJ journals before and 
after the PPI reporting requirement was introduced (64). In the year before the PPI 
reporting requirement, 0.5% of research articles reported PPI activity. In the year 
following the requirement, 11% of research articles reported PPI activity. Although the 
new requirement was associated with an increase in reporting PPI, the numbers are 
much lower than the journal’s target (65). The review also found that PPI statements 
varied greatly in quality and content, with some articles demonstrating a lack of 
awareness and understanding of the concept of PPI (64).  
The challenges to effective involvement are numerous and persistent. Ball et al. have 
categorized these challenges into four types (9). These include systemic challenges in the 
research system, challenges related to the capacity of individuals to engage, 
administrative and management challenges, and challenges related to culture values and 
attitudes. An overview of the different types of challenges and examples of each type 
are presented in Table 2.2 below.  
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Table 2.2: Challenges to involving patients and the public in research as summarized by 
Ball et al. (9) 
 Type of challenge  Examples  
1 Systemic challenges in the 
research system, related to 
the governance of PPI in 
research and to knowledge 
management. 
• inappropriate financial resourcing of PPI 
activities 
• poor reporting on PPI processes and 
limited monitoring and evaluation  
• insufficient coordination and shared 
learning between different PPI bodies 
• limited patient and public awareness 
about engagement needs and 
opportunities 
2 Challenges related to the 
capacity of individuals to 
engage 
• lack of experience, knowledge, skills or 
confidence 
• lack of access to training 
• health and wellbeing related challenges 
such as inability to travel to research 
meetings. 
3 Administrative and 
management challenges 
• limited administrative support for 
implementing PPI processes such as 
organising meetings and timely payment 
of contributors 
• lack of in-built mechanisms for giving 
feedback to PPI contributors 
4 Challenges related to culture, 
values and attitudes 
• tokenism 
• dismissive attitudes of some researchers 
• challenges to managing expectations of 
PPI contributors about the nature and 
scale of engagement 
• managing power dynamics in teams 
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2.3 The need for evidence on the methods and impact of PPI  
‘The scope and scale of patient and public involvement in research is expanding but 
we lack a shared understanding of what works, when, how and why’ (9) 
Many of the deeply rooted challenges outlined above call for change in research cultures 
primarily in the knowledge, attitudes and expectations of researchers and patients/ 
members of the public (13). Within the health research community, opinion about the 
value of PPI appears divided, with some researchers proactively embracing and 
implementing PPI and others arguing that it represents a threat to the quality or 
robustness of research design and data collection (94). Those that are currently 
proactively implementing PPI mainly do so based on the moral and ethical argument. 
They inherently believe that PPI is of intrinsic value, and, as such needs no further 
justification (13). As Arnstein noted almost 50 years ago- ‘The idea of citizen participation 
is a little like eating spinach; no one is against it in principle because it is good for you’ 
(33). However, current increasing demands for PPI from research funders, journals and 
ethics committees require PPI to be universally adopted within the health research 
community, not just by those that believe it ‘is a good thing to do’. Funding applications 
that are contingent on having ‘strong’ PPI without clarity on how to conduct ‘strong’ PPI 
or on why PPI should be used can tempt researchers to exaggerate the scope of PPI in 
grant applications in order to obtain funding (55). This often results in superficial 
engagement and inefficient use of resources, also known as tokenistic involvement (13, 
55, 95-98). It is thought that this type of ‘tick-box’ involvement is neither meaningful nor 
effective and does not allow PPI to reach its full potential (11, 75, 94, 96, 97). Lack of 
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public awareness and understanding of research and PPI has also been identified as a 
significant barrier to meaningful involvement which can result in researchers finding it 
difficult to recruit PPI contributors and ensure diversity amongst PPI contributors (13, 
99). 
2.3.1 Why focus on PPI in trials?  
Randomised controlled trials (RCTs) are widely accepted as the ‘gold standard’ for 
measuring the effectiveness of interventions (100). In an RCT, trial participants are 
randomly assigned to one of two groups; one (the experimental group) receiving the 
intervention that is being tested, and the other (the comparison or control group) 
receiving an alternative (conventional) treatment. The two groups are then followed up 
to see if there are any differences between them in outcome. The results and subsequent 
analysis of the trial are used to assess the effectiveness of the intervention, which is the 
extent to which the treatment, procedure, or service does patients more good than harm 
(101). RCTs can test the effectiveness of clinical or behavioural interventions. Clinical 
interventions include new medicines, therapies, devices, diagnostic techniques and 
surgical procedures, as well as optimising existing products and procedures to promote 
better health and welfare (102, 103). Behavioural interventions are studies in which the 
primary purpose is to evaluate attempts to influence behaviour or the consequences of 
any resultant behaviour change.  Behavioural interventions are becoming increasingly 
important to public health as lifestyle behavioural risk factors contribute strongly to a 
wide range of health problems (104). For the past half century, RCTs have reshaped 
medical knowledge and practice as they are viewed as the most stringent way of 
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determining whether a cause‐effect relation exists between an intervention and an 
outcome (100, 105).  
There are two main reasons why this research focuses specifically on PPI in trials rather 
than in health research more broadly. The first of these reasons is practical. Given the 
increasing international focus on trial methodology research as a way to address trial 
methodological issues and inefficiencies, over the last number of years the area has seen 
increasing investment from research funders (106). In Ireland, the Health Research Board 
Trial Methodology Research Network (HRB TMRN) was established to strengthen trial 
methodology and reporting on the island of Ireland so that they become ‘more relevant, 
accessible and influential for patients and other service users, practitioners, policy 
makers and the public’ (107). Since 2016, the HRB TMRN have run an annual Study 
Within A Trial (SWAT) funding call which funds researchers to conduct self-contained 
research studies that are embedded within a host trial to evaluate or explore alternative 
ways of delivering or organising a specific aspect of the trial process (108). Over the past 
three years of this doctoral research, I have learnt that most researchers have to ‘bend’ 
or ‘adapt’ their research to fit with funding calls that are available to them. Laudel has 
named this process ‘the art of getting funded’ (109). And, so, although my primary 
research interest is PPI, I adapted this to fit with the SWAT funding calls which provided 
me with the much-needed resources to conduct and evaluate PPI. Three chapters in this 
PhD thesis are based on SWATs which were funded by the HRB TMRN SWAT programme.   
Secondly, trials have a number of features that lend themselves particularly well to the 
evaluation of PPI. The enduring history of public activism in trials existed long before the 
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phrase or concept of ‘Patient and Public Involvement’ was coined. Examples include 
HIV/AIDS activism and Breast Cancer Activism from the 1970s, both of which led to a 
multitude of changes in how trials are designed and conducted (110, 111). Furthermore, 
given the patient‐focused and patient‐facing nature of trials, they are regarded as 
particularly likely to benefit from PPI (44, 67). Although PPI is increasingly being required 
in all types of research and not just patient-facing research, as we are in the early stages 
of evaluating the methods and impact of PPI, it makes sense to do this in the context of 
research that is accessible and visible to patients and the public. This has been 
particularly evident during the COVID 19 pandemic in recent months where trial 
protocols and ethical dilemmas have been part of public consciousness and everyday 
conversations.  
2.3.2 PPI methods- moving beyond the ‘it depends’ argument 
‘We must move forward pragmatically, to ensure that evaluation efforts are not 
paralysed by the misguided perception that PPI is too controversial or complex 
to be studied.’                                                   
          Dr Antoine Boivin, British Medical Journal, 2018 (14) 
In the PPI literature, PPI approaches and methods are often referred to as the ‘context 
and process’ of involvement (12, 77). Although it is acknowledged that the context and 
process of involvement have an important role in shaping the impact of PPI (12), some 
researchers have argued that these features are too complex to be evaluated as ‘it 
depends’ on too many different factors  (13-15)  .  
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It is now time to move beyond the ‘it depends’ argument. In 2017 a priority setting 
exercise, the METHODICAL study, identified sixteen critically important research 
priorities for PPI in trials. The number one priority identified was ‘Developing strong and 
productive relationships between researchers and PPI contributors’ (112). The top five 
research priorities are presented in Table 2.3 below. The methods we use to involve PPI 
contributors may play an important role in developing these strong and productive 
relationships. For example, whether we involve groups of PPI contributors or mixed 
groups of PPI contributors with other stakeholders, may lead to different experiences and 
productivity. Generating evidence on suitable PPI methodologies and how different 
methodologies can shape the impact of PPI is essential if we are to develop ‘a shared 
understanding of what works, when, how and why’ (9). 
Table 2.3: Top 10 Methodological priorities for PPI in clinical trials defined by Kearney et 
al. (112) 
Ranking Topic Title 
1. Developing strong and productive working relationships between 
researchers and PPI contributors 
1. PPI practices in selecting trial outcomes of importance to patients 
1. A systematic review of PPI activity in improving the accessibility and 
usefulness of trial leaflets and information sheets for clinical trial 
participants 
4. Adapting PPI to the particular needs of individual clinical trials 
4. The resources needed for PPI activity including time and money. 
4.  PPI practices to address the challenges of recruiting and retaining 




2.3.3 PPI impact- who will the evidence benefit? 
Current evidence on the impact of PPI in trials mirrors the limited evidence on PPI in 
health research more broadly (75). Current reports are mostly based on perceived 
impact rather than on any evidence of impact (38, 44, 113). PPI costs time and money 
and therefore pragmatic claims need scrutiny and evaluation (114, 115). In 2018, Boivin 
writes ‘a vast amount of public money and human capital is invested in health research. 
Since PPI is increasingly seen as pivotal to improving the value and relevance of research, 
we need to get serious about how it is done and equally serious about how it is evaluated’ 
(14). 
Evidence on the impact of PPI is needed so that those critical of PPI can understand the 
benefits, costs, and risks before they undertake anything more than a tokenistic 
approach to obtaining grants (13, 14, 42, 116). For researchers already engaging with 
patients and the public, this evidence is necessary to understand how best to do PPI and 
fully reap the benefits of working together and avoid any harmful consequences (14, 94, 
116). This evidence will benefit research funders and grant reviewers as they would be 
better equipped to  judge the appropriateness as well as the quality of researchers’ plans 
for PPI in grant proposals (16). And finally, this evidence will benefit members of the 
public as they can learn if, and how, their contributions can make a difference (12).  
2.4 Chapter summary 
The scope and scale of PPI is expanding but we lack a shared understanding of what 
works, when, how and why (9). The overarching aim of this thesis is to contribute to the 
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evidence on the methods and impact of PPI by exploring PPI contributors’ experiences 
and contributions at the design, conduct, and dissemination stages of trials.  
Two chapters of this thesis are based on SWATs conducted within the Improving 
Diabetes Eye-screening Attendance pilot trial (IDEAs) (117). Chapter 3 compares people 
with diabetes and healthcare professionals’ experiences of taking part in three different 
types of consensus meetings to inform intervention development and assesses whether 
their experiences differ according to group composition. Chapter 4 compares the 
contributions of people with diabetes and healthcare professionals during the three 
meetings and assesses whether their contributions differ according to group 
composition.  
‘PPI practices to address the challenges of recruiting and retaining trial participants’ has 
been identified as one of the top five priority research topics for PPI in trials (118). 
Chapter 5 presents a systematic review and narrative synthesis on researchers’ 
perceived impact of PPI on participant retention in RCTs.  
The results of clinical trials have not traditionally been shared with clinical trial 
participants and uncertainty persists around what information should be shared, how 
results should be shared, and who should be responsible for sharing the results (119, 
120). Chapter 6 presents a SWAT that was conducted within the Thyroid Hormone 
Replacement for Subclinical Hypo-Thyroidism Trial (TRUST), a trial of thyroxine versus 
placebo in people aged 65 years and older (121). The SWAT uses a mixed methods 
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approach, including an embedded randomised controlled trial, to explore the impact of 
PPI on participants’ understanding of clinical trial results. 
Chapter 7 provides an overall discussion of the main findings, the strengths and 
limitations of the thesis, the implications and suggestions for future research. This 
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Guidelines recommend involving intervention users in the intervention development 
process. However, there is limited guidance on how to involve users in a meaningful and 
effective way. 
Objective 
The aim of this Study Within A Trial was to compare participants’ experiences of taking 
part in one of three types of consensus meetings – a people with diabetes only, 
combined people with diabetes and healthcare professionals (HCPs) or HCP only 
meeting. 
Design 
The study used a mixed methods convergent design. Quantitative (questionnaire) and 
qualitative (observation notes and semi‐structured telephone interviews) data were 
collected to explore participants’ experiences. A triangulation protocol was used to 
compare quantitative and qualitative findings. 
Participants 
People with diabetes (recruited via multiple strategies) were randomly assigned to 
attend the people with diabetes or combined meeting. HCPs (recruited through 
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professional networks) attended the HCP or combined meeting based on their 
availability.  
Results  
16 people with diabetes and 15 HCPs attended meetings, of whom 18 participated in a 
telephone interview. Participants’ questionnaire responses suggested similar positive 
experiences across the three meetings. Observation and semi-structured interviews 
highlighted differences experienced by participants in the combined meeting relating to: 
perceived lack of common ground; feeling empowered versus undervalued; needing to 
feel safe; and going off task to fill the void.  
Conclusions 
The qualitative theme ‘needing to feel safe’ may explain the dissonance (disagreement) 
between quantitative and qualitative data. In this study, involving patients and HCPs 
simultaneously in a consensus process was not found to be as suitable as involving each 





For interventions to be successfully implemented in practice, they need to be acceptable, 
engaging and feasible to implement (123). Intervention development guidelines 
recommend involving all appropriate intervention users to maximise the chances of 
successful implementation (124). User involvement is a broad term that includes (but is 
not limited to) those receiving e.g. patients and members of the public and delivering 
the intervention e.g. healthcare professionals (HCPs). 
Consensus methods are a way of involving multiple users simultaneously in the 
intervention development process (125-127). Different users may have different 
priorities and preferences when making decisions about the content and delivery of an 
intervention (128, 129).  For example, patients and members of the public may be 
concerned about how an intervention will be received by the target population, whereas 
HCPs may be more concerned about the cost involved (both time and money) (129). 
Group dynamics are complex, and some user groups may find it more difficult to voice 
their priorities and perspectives compared to others (130). Despite increasing emphasis 
on user involvement, limited guidance exists on how to involve users in a meaningful and 
effective way. To our knowledge, no research has been conducted on patients and HCPs 
experiences of being involved in consensus methods and whether their experiences 
differ according to group composition.  
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The aim of this Study Within A Trial was to compare participants’ experiences of taking 
part in one of three types of consensus meetings – a people with diabetes only, 
combined people with diabetes and HCPs or HCP only meeting. 
3.3 Methods  
This Study Within A Trial (SWAT) was conducted within the ongoing Improving Diabetes 
Eye-screening Attendance (IDEAs) study.  IDEAs is a feasibility study of a multifaceted 
intervention in general practice targeting HCPs and people with diabetes to improve the 
uptake of retinopathy screening. As part of the development phase of IDEAs, three 
separate consensus meetings were held to discuss the acceptability and feasibility of the 
proposed intervention content and suitable modes of delivery. Recommendations from 
each meeting were used to refine intervention components that could be delivered in 
general practice. The first consensus meeting consisted of people with diabetes only; the 
second meeting consisted of a combination of people with diabetes and HCPs; the third 
meeting consisted of HCPs only.   
Study design 
The SWAT used a mixed methods convergent design to understand and compare 
participants’ experiences of taking part in the consensus meetings (Figure 3.1). A one‐
phase design was used, where quantitative (experience survey) and qualitative 
(observation notes and semi‐structured interviews) methods were used during the same 
timeframe and were given equal weight in the analysis (131).    
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Quantitative and qualitative data were collected and analysed separately. Results were 
merged during interpretation (mixed methods phase). A triangulation protocol was used 
in this phase to compare key concepts identified in each dataset that related to 
participants’ experiences of taking part in the meetings (131, 132). The Good Reporting 
of A Mixed Methods Study (GRAMMS) framework and the Consolidated Criteria for 
Reporting Qualitative Studies (COREQ) were used to guide reporting of the findings (133, 
134). 
Recruitment of participants  
People with diabetes were recruited using an information flyer developed by the 
research team and a graphic designer (Appendix 1.1). The flyer was distributed using a 
range of recruitment strategies previously identified by Vat et al. (99) (Appendix 1.2).  
All individuals who contacted the study team about involvement were sent a 26-item 
demographic survey (Appendix 1.3 for survey questions and results). The individuals who 
returned a demographic survey were randomly assigned (using an online random 
number generator) to the meeting for people with diabetes only or the combined 
meeting.  
HCPs were recruited through professional networks known to the SWAT and IDEAs study 
teams. HCPs were initially sent an email or letter inviting them to take part in the 
consensus meeting. This was followed by a phone call to confirm their attendance. HCPs 





Figure 3.1: Procedural diagram of the convergent study design 
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Semi-structured consensus meetings 
Before the meetings, the IDEAs study team (FR, SMH) developed 1) a short summary of 
existing evidence on barriers to and enablers of attendance at diabetic retinopathy 
screening, and interventions to address non-attendance and 2) a survey asking 
participants to rate intervention components according to acceptability (like it, think it 
makes sense) and feasibility (think it can be done). The survey was based on measures 
developed by Weiner et al (135). Materials were reviewed by adult literacy experts (Irish 
National Adult Literacy Agency) and a Patient and Public Involvement (PPI) group from 
another research project and revised based on their feedback. Before the meeting, the 
evidence summary and survey were sent to all meeting participants in electronic or 
paper format depending on participants’ preferences. Survey responses were collated 
and analysed descriptively by a member of the IDEAs study team (FR) and a summary of 
the results was prepared to be presented at each meeting. 
Each consensus meeting was held from 6.30-8.30pm in University College Cork. Before 
each meeting (at 6pm), the lead SWAT researcher (ER) held an informal briefing for 
people with diabetes on key medical and research terms, the aim of the meeting and 
their role as patient contributors. Each meeting was facilitated by an experienced 
facilitator (male). During the meetings, a summary of the survey results was presented 
to participants, followed by a series of small group discussions facilitated by FR, SMH, 
and EP. Participants were asked how each intervention component would work in 
practice and which mode of delivery would work best. Each small group was asked to 
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nominate a lead to feed back their discussion to the larger group. Each group discussion 
was audio recorded.  
Quantitative strand  
Experience questionnaire 
At the end of each meeting, all participants were asked to complete a questionnaire 
about their experience of the meeting. The objective of the questionnaire was to 
understand individual experiences of taking part in the meeting, asking them to rate how 
they felt about their participation and the participation of other group members; how 
decisions were made by the group; and the potential impact of the decisions that were 
made. We were unable to find a suitable validated instrument that was appropriate for 
our questionnaire objective and context (one-off participatory research process). 
Therefore, we developed our own questionnaire based on sample items from a non-
validated survey instrument published by Schulz et al. (136). For additional information 
on the questionnaire development, please see Appendix 1.4. The original phrasing of the 
sample items was maintained, with the exception of some questions that were changed 
to statements to fit with a Likert Scale format. Agreement with each statement was 
measured on a five‐point Likert scale ranging from ‘strongly disagree’ to ‘strongly agree’. 
The questionnaire also contained an open‐ended comment box for any other comments 
or suggestions. At the bottom of the questionnaire, participants were invited to ‘opt in’ 
if they were interested in participating in a follow‐up interview on their experiences of 
taking part in the meeting.  
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Quantitative data analysis 
Questionnaire responses were entered into SPSS software (version 24) and analysed 
using descriptive statistics. The five response categories were collapsed into three 
categories – ‘Agree’, ‘Neither agree nor disagree’ and ‘Disagree’.  
Qualitative strand  
Observation notes  
The SWAT lead researcher (ER) observed each consensus meeting and took 
comprehensive field notes. The objective of the observation was to understand how 
members participated and interacted with other meeting members and how they made 
decisions for the development of the intervention (group dynamics and decision‐making 
processes). An observation guide and grid were used to guide note‐taking and as a 
reminder of the events and issues of most importance (Appendix 1.5) (137). The 
observation guide contained two overarching questions: ‘How is the group working 
overall?’ and ‘How is the group making decisions?’. The observation grid contained six 
constructs informed by group dynamics and decision‐making processes literature (138‐
141). These constructs were: participation/non‐participation, 
dominance/submissiveness, in‐groups/out‐groups1, body language and facial 
 
1 An in-group is a social group to which a person psychologically identifies as being a member. An out-
group is a social group with which a person does not identify. 
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expressions, gaze, and effect of expert/lay knowledge. After each meeting, the 
researcher met with the group facilitators to discuss and document their experiences and 
perspectives as supplementary information.  
Semi-structured interviews 
Within two weeks of the consensus meetings, semi‐structured telephone interviews 
were conducted with the consensus meeting participants who agreed to take part in an 
interview in the experience questionnaire. The objective of the interviews was to gain 
insights into individual experiences of taking part in the meeting in terms of: how 
comfortable they felt in the meeting; how they felt members of the group interacted with 
each other; and how they felt they worked together to make decisions (i.e. whether there 
was agreement, conflict, synergy). Interviews were audio‐recorded (see Appendix 1.6 for 
Interview Topic Guide). Interviews were conducted by ER, a young female PhD candidate. 
All participants were familiar with ER as she facilitated the briefing session prior to the 
consensus meetings. At the beginning of each interview, the SWAT lead researcher (ER) 
stressed to participants that she was independent to the trial study team that were 
running the consensus meetings and therefore would not be offended if they described 
negative experiences.  
Qualitative data analysis  
Field notes were collated, and audio recordings were transcribed verbatim. All qualitative 
data were managed using NVivo software (version 12). Thematic analysis was carried out 
following Braun and Clarke guidelines (142). Firstly, an extensive familiarisation process 
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was conducted by two researchers (ER, EP), where notes and transcripts were read and 
re‐read multiple times. ER open coded all the observation notes and transcripts (using 
semantic and latent codes) and developed three separate sets of codes‐ one set for each 
meeting. The pattern and meanings of codes were then examined across the three 
meetings to identify one set of candidate or potential themes relating to participants’ 
experiences and group dynamics. Themes were developed using a conventional or 
‘bottom‐up’ approach, whereby themes were developed directly from the data (142). ER 
discussed each theme with EP to revise, refine and define themes.  
Mixed methods phase  
After separate analysis of quantitative and qualitative data (as described above), the data 
were compared using a triangulation protocol. Triangulation provides a visual and 
tabular representation of the findings from qualitative and quantitative data, allowing 
for a clearer comparison and broader interpretation (143). The steps taken to create the 
triangulation protocol are outlined in Table 3.1 below. 
Table 3.1: Steps taken to create triangulation protocol 
 Step Activity 
1. Collate key findings 
from each dataset  
This was done by examining the original data, 
interpretation and reports of analysis. For quantitative 
data, each questionnaire item was deemed as a 
separate key finding.  For qualitative data, multiple 
key findings were identified within each theme, as 
themes were too broad in their descriptions to 
compare directly to quantitative findings. 
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2.  Group key findings 
into concepts 
Key quantitative and qualitative findings were grouped 
together into concepts according to how they related 
to participants’ experiences and group dynamics (e.g. 
freedom of expression, balance of participation).   
3. Create table for 
triangulation protocol 
A table was created with each column representing 
the data source (questionnaire, observation and 
interview) and each row representing a key concept. 
4. Map key findings to 
table  
Key findings were then mapped to the table to 
examine where findings from each method agreed 
(convergence), offered complementary information on 
the same issue (complementarity), appeared to 
contradict each other (dissonance) or appeared in one 
method and not the other (silence) (144). 
5. Explore inter-method 
discrepancies 
This was done by examining the methodological rigour 
of each method and re-examining the data in light of 
the discrepancy (145). 
 
Patient and Public Involvement (PPI) component 
A PPI partner (GF) was involved in the SWAT from the outset. The PPI partner is a person 
with diabetes, previously known to the lead author (ER). She contributed to the initial 
discussions about the study which ultimately informed the SWAT grant application, 
reviewed the application and made changes to its content. GF was also involved in the 
development of materials used to recruit PPI contributors and assisted the research 
team with recruitment by posting recruitment flyers online via social media networks. In 
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addition, she contributed to and reviewed each draft of this manuscript and is a co-
author on this publication.  
Ethics  
The study received ethical approval from the Social Research Ethics Committee (SREC) at 
University College Cork. Written informed consent was obtained from all participants 
prior to taking part in the consensus meetings and completing the questionnaire. 
Telephone consent was obtained from participants prior to taking part in the interviews.  
 
3.4 Results  
Participants  
A total of 36 people contacted the research team expressing an interest in the SWAT. Of 
these, twenty completed the recruitment survey (see Appendix 1.3 for recruitment 
survey results). These twenty people were randomly assigned to either the people with 
diabetes only meeting (4 with type 1 diabetes and 6 with type 2 diabetes) or the 
combined meeting (6 with type 1 diabetes, 3 with type 2 diabetes and 1 carer). All 10 
people attended the people with diabetes only meeting (attendance rate 100%) and 6 
people with diabetes attended the combined meeting (attendance rate 60%). An 
invitation to attend was sent out to 50 HCPs (practice nurses, diabetes nurse specialists, 
general practitioners and specialist physicians), of which 8 attended the combined 
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meeting and 7 attended the HCP only meeting (attendance rate 30%). Further details on 
the recruitment and response rates for each stage of the data collection are shown in 
Figure 3.2 below. 
 
Figure 3.2: Flow diagram of recruitment and response rates  
 
Quantitative results 
All consensus meeting participants (n=31) completed the experience questionnaire 
(response rate 100%). Table 3.2 shows the results of the questionnaire stratified by 
meeting type (people with diabetes only, combined and HCP only). The descriptive 
statistics presented in Table 3.2 demonstrate that there were no differences in 
participants’ self-reported experiences of the three meetings. All participants across the 
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3 groups agreed with the statements ‘I felt comfortable expressing my opinion in the 
group’, ‘I felt my opinions were listened to and considered by other group members’ and 
‘ I did not feel pressured to go along with the decisions of the group even though they did 
not agree’. Some participants agreed with the statements that ‘I thought that certain 
individuals spoke more than others in the group’ and ‘I felt that certain individuals had 
more influence over the decision-making process than others’. A number of participants 
expressed doubt that they could influence the decisions made during the meeting.  
Table 3.2: Results of the participant experience questionnaires stratified by meeting 
type 








I felt comfortable expressing 
my opinion in the group 
People with diabetes 10 (100) - - 
Combined  14 (100) - - 
HCP 7 (100) - - 
I felt my opinions were 
listened to and considered by 
other group members 
People with diabetes  10 (100) - - 
Combined  14 (100)  - 
HCP  7 (100) - - 
I felt part of the group (like I 
belonged to the group) 
People with diabetes  10 (100) - - 
Combined* 12 (92.3) - 1 (7.7) 
HCP  7 (100) - - 
I felt pressured to go along 
with the decisions of the 
group even though I did not 
agree 
People with diabetes - 10 (100) - 
Combined - 14 (100) - 
HCP - 7 (100) - 
I felt a sense of trust and 
openness between group 
members 
People with diabetes  10 (100) - - 
Combined  13 (92.9) - 1 (7.1) 
HCP  7 (100) - - 
People with diabetes 
only 
3 (30) 6 (60) 1 (10) 
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I thought that certain 
individuals spoke more than 
others in the group 
Combined 4 (28.6) 6 (42.8) 4 (28.6) 
HCP 3 (42.9) 3 (42.9) 1 (14.2) 
I felt that I could influence 
the decisions made by the 
group 
People with diabetes 7 ((70) - 3 (30) 
Combined 8 (57.1) 1 (7.1) 5 (35.7) 
HCP* 4 (66.7) - 2 (33.3) 
I felt that certain individuals 
had more influence over the 
decision-making process than 
others 
People with diabetes  3 (30) 6 (60) 1 (10) 
Combined 2 (14.3) 9 (64.3) 3 (21.4) 
HCP 1 (14.3) 3 (42.9) 3 (42.9) 
I have increased my 
knowledge about important 




8 (88.9) - 1 (11.1) 
Combined 10 (71.4) 1 (7.1) 3 (21.4) 
HCP 6 (85.7) - 1 (14.3) 
By working together, we can 
influence decisions that 
affect the research process 
People with diabetes 
only 
10 (100) - - 
Combined 13 (92.9) - 1 (7.1) 
HCP 7 (100) - - 
By working together, we can 
influence decisions that 
affect people with diabetes 
People with diabetes  10 (100) - - 
Combined 14 (100) - - 




In total, 18 questionnaire respondents agreed to be contacted for a follow-up interview. 
Interviews were conducted with participants from the people with diabetes only (n=6), 
combined (n=7) and HCP only (n=5) meetings. Interviews were, on average, 34 min in 
duration (range 18–56 min). 
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Four themes were developed from the qualitative data relating to participants’ 
experiences and group dynamics: perceived lack of common ground; feeling empowered 
versus undervalued; needing to feel safe; and going off task to fill the void. 
Perceived lack of common ground  
In the people with diabetes only meeting, there were differences between participants 
in terms of diabetes type, length of diagnosis and education level. In the HCP only 
meeting, differences included profession (e.g. medical doctor, practice nurse, diabetes 
nurse specialist), experience of working with people with diabetes, and size, location and 
nature of their practices. During the interviews, participants from these two meetings 
described these demographic, geographical and clinical differences as ‘small’ 
differences, which they welcomed as they felt it allowed them to bring different 
perspectives to the topics they were discussing. They focused on the common ground 
they shared with other meeting participants and identified with one another based on 
the shared experience of living with diabetes or caring for people with diabetes. They 
felt that they were all ‘singing from the same hymn sheet’ (P3, person with diabetes, 
people with diabetes only meeting) and described being able to come together to make 
decisions that incorporated different perspectives: 
“It was interesting to hear their views. We were all on the same page, but 
we were coming from different angles and we used that then; we came 
together and made the decisions together.” (P2, person with diabetes, 
person with diabetes only meeting) 
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In contrast, a lack of common ground was reported by participants in the combined 
meeting. This created a division in the group, a ‘them’ and ‘us’ attitude, which was 
evident in the interview and observation data. In the interview data, people with 
diabetes stated that there was a ‘complete clash of perspectives’ (P9, person with 
diabetes, combined meeting) between people who lived with the condition and HCPs 
who cared for people with diabetes. HCPs reported that people with diabetes and HCPs 
were ‘two different sides of the divide’ (P11, HCP, combined meeting). The observation 
data also suggested a division between people with diabetes and HCPs in the combined 
meeting. At the beginning of the meeting, people with diabetes and HCPs sat on opposite 
sides of each small table. During the small group discussions, participants expressed their 
opinions as collective opinions of their stakeholder group. Rather than expressing 
individual opinions (e.g. ‘I think that…’or ‘My experience is…’), people with diabetes 
spoke on behalf of all the people with diabetes in the group, and HCPs spoke on behalf 
of all HCPs in the group (e.g. ‘We feel that… don’t we?’ and ‘As people with diabetes, we 
think that…’). Moreover, during the small group discussions, each stakeholder group 
focused their gaze on the other stakeholder group, resulting in people with diabetes and 
HCPs talking at each other, at opposite sides of each table. This was in contrast to the 
people with diabetes only and HCP only meeting, where members focused their gaze on 
all members around the table. 
Participants’ lacking a sense of shared experience was accompanied by differences in 
perceptions around the balance of participation. During all three meetings, it was 
observed that some participants spoke more frequently and for longer than others. In 
the interviews, participants from the people with diabetes only and HCP only meetings 
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perceived this unbalanced participation as a natural consequence of any group dynamic. 
They mainly attributed it to different personalities. In contrast, HCPs from the combined 
meeting attributed the unbalanced participation to people putting too much emphasis 
on their own personal experiences:  
“It was very much centred around them [people with diabetes] and a lot of 
the offerings that I had in terms of experience were nothing in comparison 
to what they felt as people that have the problem. Which is fine. But that 
wasn’t really the point. The point is that I don’t have diabetes, that is not 
my personal experience. But I am still the one left in the room everyday 
trying to deal with patients… But I just couldn't come out with it on the 
night. I just didn't. It wasn't going to be heard.” (P12, HCP, combined 
meeting)  
Feeling empowered versus undervalued  
In the interviews, participants from the people with diabetes and HCP only meetings 
reported learning from other meeting members and feeling empowered by the event. In 
the people with diabetes only meeting, participants stated that they learned from one 
another about how they can better manage their condition and about the difference 
between type 1 and type 2 diabetes. Those who had been diagnosed with diabetes for a 
long time described gaining a renewed compassion for those who were newly diagnosed. 
Participants from the HCP only meeting reported learning about the importance of 
encouraging their patients to attend screening, about the roles of different HCPs, and 
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about the cultural difficulties and language barriers that some practices face due to a 
high number of non-English speaking patients.  
There were also some reports of learning in the combined meeting. People with diabetes 
said they gained a new insight into the work practices of HCPs – in particular, the 
increased workload experienced by HCPs. The HCPs reported gaining an insight into the 
struggles of having to live with a medical condition: 
“I put in a couple of thousand eye drops a year, it doesn't mean anything to me 
like. But it obviously means something for patients who are having to go through 
this – and you know the awkwardness of getting appointments and driving to and 
from appointments and getting a lift and all that side of things.” (P14, HCP, 
combined meeting)  
However, participants from the combined meeting reported feeling undervalued by the 
other stakeholder group. People with diabetes felt that HCPs did not understand how it 
feels to live with a chronic illness, describing ‘a complete clash of the reality of living with 
diabetes versus a medical professional's perspective’ (P7, person with diabetes, 
combined meeting). Among some of the HCPs, there was a sense that any contributions 
they made during the meeting were not valued by people with diabetes because the 
experience of living with diabetes was deemed more important than the experience of 
caring for people with diabetes:  
“I've worked in four different GP practices at this stage and all very different. And 
yet I felt like as if any value that I had to add to the conversation was kind of 
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almost either misheard or not really heard, or almost felt not quite as relevant 
because of their personal experiences. Which is fair enough. But that was not 
what the meeting was about.” (P13, HCP, combined meeting) 
Needing to feel safe to express honest opinions 
In the interviews, participants from the people with diabetes only and HCP only meetings 
reported an open, honest, relaxed and non-judgemental environment, where everyone 
had a voice and was heard. This environment made participants feel safe and 
comfortable to express their opinions. They also indicated that the small group 
discussions added to their feelings of safety as people who do not like speaking in public 
felt less intimidated about expressing their opinions: 
“I’m not one really for expressing my opinions. I am kind of … I wouldn’t put my 
hand up the first time, let’s say. But I did feel very comfortable expressing my 
opinion in the small group.” (P15, HCP, HCP only meeting)  
Conversely, participants from the combined meeting reported feeling uncomfortable 
and unable to express their opinions as they were conscious of the other stakeholder 
group in the room. Both people with diabetes and HCPs said they felt they had to ‘hold 
back’ their opinions. People with diabetes reported feeling that they could not be honest 
about the ‘non-compliant’ (P9, person with diabetes, combined meeting) aspects of 
managing their diabetes as the HCPs may judge them for it: 
“I don’t think when you are sitting at a table with HCPs that you’re going to be 
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discussing the non-compliant things you do… It’s probably not the best 
environment, let’s say, to get out some of the smaller things that people do that 
may not be approved by the other group in the room.” (P8, person with diabetes, 
combined meeting) 
On the other hand, HCPs were conscious of confidentiality issues: they were concerned 
that if they mentioned a particular case, people with diabetes could potentially identify 
who that patient was, since ‘[this location] is a very small place’ (P11, HCP, combined 
meeting):   
“I felt a bit kind of reticent about how free [I could talk about my experiences as 
a healthcare professional] … It’s different when you are divulging, you know, 
work practices and difficulties and challenges and personal experiences at work, 
when it is other medical professionals. But when you have effectively patients 
there, it is like a big difference.” (P13, HCP, combined meeting) 
In addition, the HCPs indicated that they did not feel comfortable talking about the 
service that they worked in as they felt anxious that people with diabetes would confront 
them on the long waiting times or other issues they had with that particular service.  
Going off task to fill the void  
Analysis of interview data indicated that participants across all three meetings felt they 
were able to work together. They reported that the content for discussion was relevant 
to them as users and providers of health services.  
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However, the observation data show that although members of the combined meeting 
appeared to work together, both stakeholder groups were defensive about what 
intervention components would not work and at times in the meeting nothing seemed 
feasible. This resulted in each stakeholder group feeling uncomfortable in asserting what 
they felt the other group should or should not do. To fill this void, participants began to 
go off task as they focused their discussions on the ‘other’. The ‘other’ took different 
forms throughout the meeting: the screening service, people with diabetes who were 
not in the room (e.g. those with type 2 diabetes), and funding and resource limitations 
in general practice. Even though they were being asked to discuss and make 
recommendations on how the intervention would work in primary care, the combined 
meeting participants resorted to making recommendations about how screening uptake 
could be increased on a national basis through nationwide TV and radio campaigns.  
Mixed methods results 
The results of the mixed methods analysis are presented in Table 3.3. Six key concepts 
relating to participants’ experiences and group dynamics were identified from the 
datasets: freedom of expression; understanding and respect; balance of participation; 
learning; productive collaboration; and group cohesion. When key findings were mapped 
to the overarching concepts, there were four instances of dissonance (where data 
appeared to contradict each other), two instances of convergence (where data agreed) 
and two instances of complementarity (where data offered complementary information 
on the same issue). There were no instances of silence (where data appeared in one 
method and not in the other).  
65 
 
The four instances of dissonance between quantitative and qualitative data were wholly 
due to the fact that in the questionnaire participants reported positive experiences of 
taking part in the meetings, whereas the observation and interview data highlighted 
some negative experiences and divergent opinions. For example, in relation to freedom 
of expression, the questionnaire data showed that in all three meetings, participants 
reported feeling comfortable expressing their opinions and reported a sense of trust and 
openness between group members. In the observation data, participants in the 
combined meeting did not appear to be comfortable asserting what the other 
stakeholder group should/should not do as part of the intervention. Furthermore, in the 
interview’s participants reported feeling uncomfortable and unable to express their 
opinions as they were conscious of the other stakeholder group in the room.  
The instances of complementarity were largely due to the design of the data collection 
tools.  The questionnaire items were designed to be concise and did not require the 
participants to give any additional details. Whereas in the interviews, participants had 
the opportunity to expand and give more detail. For example, in the key concept 
learning, the questionnaire item asked participants to indicate how much they agreed 
with the statement ‘I have increased my knowledge about important topics since 
participating in this group’, whereas in the interviews participants had the opportunity 
to expand and give specific examples of what they had learned (e.g. people with diabetes 
learned how they can better manage their condition, HCPs leaned about the importance 




Table 3.3: Results of mixed methods analysis (triangulation protocol) 
Key concept Quantitative 
strand 
Qualitative strand  
Questionnaire Observation notes Interviews 
Freedom of 
expression  





opinions and felt a 




In the combined 
meeting, 
participants did not 
appear to be 
comfortable 






In the people with 
diabetes only and 
HCP only meetings, 
participants 
reported that it was 













unable to express 
their opinions as 
they were conscious 
of the other 
stakeholder group 








were listened to 
and considered by 
other group 




made by the group 















more than others 
and had more 
influence over the 
decision-making 
process   




than others and for 
longer lengths of 
time 
In the people with 
diabetes only and 





saw it as a natural 
consequence of any 
group dynamic 
 







Key concept Quantitative 
strand 
Qualitative strand  
Questionnaire Observation notes Interviews 
unbalanced 
participation to 
people putting too 
much emphasis on 
their own personal 
experiences  




their knowledge as 
a result of 
attending 
In all three 
meetings, 
participants 
appeared keen to 
learn from one 
another as they 








from one another 
and provided 







In all three 
meetings, 
participants 
reported that they 
were able to work 
together to 
influence decisions 
that affect the 
research process 
and people with 
diabetes 
In the combined 
meeting, although 
participants 
appeared to work 
together, each 
stakeholder group 
did not make any 




do. Instead, they 
made 
recommendations 
that were not 





In all three 
meetings, 
participants 
reported being able 
to work together as 
they felt the 
content for 
discussion was 
relevant to them as 
users and providers 










were part of the 
group (like they 
belonged to the 
group) 
 
In the combined 
meeting, it was 
evident that there 
was a division 
between both 
stakeholder groups 
(e.g. both groups 
spoke at each 
other across each 
table as opposed 
to with each other 
around each table).  
 
 
In the people with 
diabetes only and 
HCP only meetings, 
participants 
reported that there 




added that this was 
a good thing as it 
allowed them to 
bring different 
perspectives to the 





Key concept Quantitative 
strand 
Qualitative strand  
Questionnaire Observation notes Interviews 
 
In the combined 
meeting, people 
with diabetes 
reported that there 








diabetes and HCPs 
were ‘two different 
sides of the divide’ 
 
3.5 Discussion  
Summary of key findings  
The aim of this study was to compare participants’ experiences of taking part in the three 
consensus meetings. The results of the questionnaire suggested that participants had 
largely positive experiences of taking part in the consensus meetings and there were no 
differences in participants’ experiences between the three meetings. However, results 
of the observation and interviews highlighted that participants in the combined meeting 
had different experiences to those in the other two meetings. The perceived lack of 
common ground between people with diabetes and HCPs in the combined meeting led 
participants to feel undervalued by the other stakeholder group as they felt that the 
other group did not understand their perspective. Participants in the combined meeting 
were reluctant to express their opinions and were defensive about what would/ 
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wouldn’t work in terms of developing the intervention. As a result, participants in the 
combined meeting went off task and made recommendations which were not entirely 
relevant for the intervention. In this study, involving patients and HCPs simultaneously 
in a consensus process was not found to be as suitable as involving each stakeholder 
group separately. 
Links to existing literature 
In the people with diabetes only and the HCP only meetings, participants welcomed their 
diversity as it allowed them to hear different perspectives on the topics they were 
discussing. This finding is consistent with existing literature, with many theorists arguing 
that knowledge diversity can improve group performance by enhancing a group’s ability 
to be creative and to discover novel solutions (146-148).  In these meetings, participants 
focused on their common ground and described being able to come together to make 
decisions that incorporated a range of perspectives. Previous research suggests that 
congruent groups- that is, when group members are socially tied and share the same 
information – are more likely to be productive and successful (149).  
The perceived lack of common ground between people with diabetes and HCPs in the 
combined meeting created a ‘them’ and ‘us’ scenario, with participants reluctant to 
express their opinions. This raises questions about whether too much difference within 
groups is counterproductive or divisive. Existing research on the productivity of 
incongruent groups - that is, when social and knowledge subgroups are present within a 
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group has found that sub-groups can create a divide between group members, 
undermining the groups’ ability to work together and be productive (149).  
Some HCPs in the combined meeting felt their contributions were not valued by people 
with diabetes because the experience of living with diabetes trumped the experience of 
caring for people with diabetes. This finding may reflect the changing nature of the 
patient/HCP relationship over the last 20 years – from a paternalistic model where the 
patient seeks help and is compliant to the professional who makes the decisions, to a 
more patient-centred approach (150). This approach expects HCPs to enter the patient’s 
world and to see the illness through the patient’s eyes (150). This prioritisation of the 
patient experience has benefited patient outcomes (151). However, as HCPs are often 
responsible for delivering interventions, their perspectives in the intervention 
development process are crucial for maximising intervention feasibility. Involving 
multiple users in the intervention development process is not about understanding 
which perspective is more valid or more important, it is about understanding all the 
different perspectives so that the intervention is more acceptable, engaging and feasible 
to implement.  
Strengths and Limitations 
One of the strengths of this study was the use of a mixed methods, convergent design 
which produced a more complete understanding of participants’ experiences and group 
dynamics. It also allowed for the cross‐validation of findings from each method resulting 
in more substantiated findings than sequential designs or quantitative or qualitative 
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approaches alone (131). The qualitative theme ‘needing to feel safe’ may explain the 
instances of dissonance between quantitative and qualitative data as participants 
completed the questionnaire at the end of each meeting while they were still sitting close 
to other participants. Some small groups even filled out the questionnaire together. As 
a result, participants may not have felt comfortable voicing concerns. In the interviews, 
on the other hand, participants may have felt safer in a one-to-one environment with a 
researcher who they were already familiar with. The fact that the researcher stressed 
that she was independent to the consensus meeting research team and her informal 
approach may have made them more comfortable to speak openly about their 
experiences of taking part in the meeting.  The timing of the questionnaire may have also 
played an important role. The questionnaire was handed out at the end of the meeting, 
late in the evening. Participants may have been eager to get home and they may not 
have fully thought about the responses they were providing. Whereas, in the interviews, 
participants had time to reflect on their experiences and a provide a more 
comprehensive account as a result. This is consistent with Krosnick’s theory of survey 
satisficing which is based on the assumption that optimal survey completion involves 
doing a great deal of cognitive work, so if the participant is not fully motivated to 
complete the survey, he or she is likely to offer responses that seem reasonable and easy 
to defend (152). Although questionnaires are a frequently used tool to evaluate 
consensus meetings, our findings suggest they may not always provide a comprehensive 
assessment of participants’ experiences. This is consistent with a number of previous 
studies on evaluating participant experiences (153-155).  
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This study is not without limitations. First, the questionnaire that was used to understand 
participants’ experiences was based on non-validated questionnaire items. We were 
unable to conduct exploratory factor analysis to validate our questionnaire as our sample 
size did not meet the minimum criteria of 10 participants per questionnaire item (156). 
However, given the increasing importance of evaluating PPI and other participatory 
research activities (14), the questionnaire could be a useful tool in future studies which 
aim to understand stakeholders’ experiences in similar participatory research contexts. 
Use of the questionnaire in future studies may allow for reliability testing and validation 
to be carried out (157, 158).  
Second, although the experience questionnaire suggested that there were no differences 
in participants’ experiences between the three meetings, due to the number of 
participants, there was limited power to detect a difference (n=31). Thus, the 
comparison of participants’ questionnaire responses between the groups is used as only 
an indicator of participants’ experiences. Given the small sample, we cannot rule out the 
possibility that differences between the groups could be detected had a larger sample 
size been used.  
Despite using a range of strategies to recruit a representative sample of people with 
diabetes, another potential limitation of this study was the absence of people with type 
2 diabetes in the combined meeting. As the attendance rate of people with diabetes at 
the combined meeting (60%) was much lower than the people with diabetes only 
meeting (100%), it is plausible that people with type 2 diabetes did not attend because 
they knew there would be HCPs attending. Existing research has established that people 
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with type 1 and type 2 diabetes have different experiences when managing their 
condition and engaging with HCPs (159-161).  Therefore, the involvement of people with 
type 2 diabetes in the combined meeting could have potentially changed the nature of 
the relationship between patients and HCPs and led to different participant experiences 
and group dynamics.  
 
Finally, participants were given a choice to participate in an in-person or telephone 
interview. All participants chose telephone interviews due to time constraints and 
location convenience. This could be another potential limitation as researchers have 
previously expressed concerns about whether telephone interviews are appropriate for 
qualitative research (162, 163). These concerns are largely due to the absence of visual 
cues which may result in the loss of informal communication and contextual information, 
the inability to develop rapport or to probe and the misinterpretation of responses (163). 
In this study, the quality of telephone data cannot be compared to in-person data as no 
in-person interviews were conducted. However, the researcher had considerable 
experience conducting phone interviews, maintained a friendly and engaging tone 
throughout and as mentioned previously,  participants were found to be open and frank 
about their experiences.  
 
Implications  
The results of this study provide much-needed evidence on how different ways of 
involving patients and healthcare professionals can lead to differing participant 
experiences and group dynamics. Patient and public involvement (PPI) in research is 
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increasingly becoming a requirement in health research and for many research funders. 
INVOLVE, a national advisory body funded by the National Institute for Health Research 
(NIHR) in the UK, defines public involvement as research being carried out ‘with’ or ‘by’ 
members of the public rather than ‘to’, ‘about’ or ‘for’ them (1). In this study, the lines 
between research participation and involvement were blurred, as is often the case with 
PPI (164). People with diabetes were research participants in the consensus meetings, 
experience questionnaire and semi-structured interviews. However, their role in the 
consensus meeting was to discuss and make decisions about the intervention content 
and mode of delivery which could be viewed as PPI (33, 165). This study shows that the 
context and nature of involvement can have important implications for its impact. These 
findings are not only relevant to health intervention researchers but to all individuals 
interested in involving patients and members of the public in health research, policy and 
in the planning and development of health care more broadly.   
3.6 Conclusion  
Although the results of the experience questionnaire showed no differences in 
participants experiences across the three meetings, the results of the observation and 
interviews highlighted that participants in the combined meeting had different 
experiences. In this study, involving patients and HCPs simultaneously in a consensus 
process was not found to be as suitable as involving each stakeholder group separately. 
The study provides much-needed evidence on how different ways of involving patients 
and healthcare professionals can lead to differing participant experiences and group 
dynamics.  
Racine, E. 2020. ‘It’s a nice thing to do but…’: exploring the methods and impact 
of patient and public involvement (PPI) in trials. PhD Thesis, University College 
Cork. 
Please note that Chapters 4 & 5 (pp. 75-156) are unavailable due to a 
restriction requested by the author.  
CORA Cork Open Research Archive http://cora.ucc.ie 
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6. Participants’ perspectives and preferences on clinical trial 
result dissemination: The TRUST Thyroid Trial 
 







William H. Smithson 











While there is an increasing consensus that clinical trial results should be shared with 
trial participants, there is a lack of evidence on the most appropriate methods. The aim 
of this Study Within A Trial (SWAT) is to use a patient and public involvement (PPI) 
approach to identify, develop and evaluate a patient-based approach to receiving trial 
results for participants in the Thyroid Hormone Replacement for Subclinical Hypo-
Thyroidism Trial (TRUST), a trial of thyroxine versus placebo in people aged 65 years and 
older. 
Methods 
Mixed methods study with three consecutive phases. Phase 1 iteratively developed a 
patient-based approach using semi-structured focus groups and a consensus-orientated-
decision model, a PPI group to refine the method and adult literacy review for plain 
English assessment. Phase 2 was a single-blind parallel group trial. Irish TRUST 
participants were randomised to the intervention (patient-based approach) and control 
group (standard approach developed by lead study site). Phase 3 used a patient 





Participants want to receive results of clinical trials, with qualitative findings indicating 
three key themes including ‘acknowledgement of individual contribution’, ‘contributing 
for a collective benefit’ and ‘receiving accessible and easy to understand results’. Building 
on these findings, the patient-based approach was developed. TRUST participants 
(n=101) were randomised to the intervention (n=51) or control group (n=50). The 
questionnaire response rate was 74% for the intervention group and 62% for the control 
group.  There were no differences in patient understanding between the two 
approaches. 
Conclusions 
We have demonstrated that it is feasible to involve trial participants in the development 
of result dissemination materials. Although, in this study PPI did not influence patients’ 






Patient and public involvement (PPI) is increasingly recognised as an essential 
component of clinical research. In the UK, the national advisory group supporting active 
public involvement in health services, public health and social care research (INVOLVE) 
defines PPI as ‘research being carried out ‘with’ or ‘by’ members of the public rather than 
‘to’ ‘about’ or ‘for’ them’(1). In clinical trials, PPI has been defined as experimenting with 
participants instead of experimenting on participants (259). PPI may occur at any stage 
during the research process from priority setting and drafting study protocols right 
through to conducting the study, interpreting the end results and communicating and 
disseminating research findings (52, 53). Research funders increasingly expect that PPI is 
prioritised and resourced within studies. This increasing expectation has heightened the 
risk of researchers carrying out ‘tick-box’ PPI rather than ‘meaningful’ involvement (96). 
There are many moral and ethical arguments being made for PPI. Many believe that as 
citizens and taxpayers, members of the public have a right to influence research that is 
being funded by public money (3). PPI researchers are also making pragmatic arguments 
for PPI and providing anecdotal accounts about how PPI can make research more 
relevant, accessible and acceptable to participants (8).The ethical arguments are often 
seen as sufficient regardless of any pragmatic impact. However, PPI costs time and 
money, therefore pragmatic claims need scrutiny (114). More substantive evidence is 
needed to evaluate the potential impact of PPI on the conduct and outcomes of research 
(96, 260). In 2001, the need to establish if PPI leads to actual, rather than merely 
perceived benefits for research processes and output was identified. Over fifteen years 
later, this need remains. 
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In clinical research, the results of clinical trials have not traditionally been shared with 
clinical trial participants. A recent survey carried out on a large registry of health research 
participants, found that while 95.6% of respondents said researchers should always or 
sometimes offer the results to participants, only 33% of respondents actually received 
the results of studies in which they had participated (119). An upcoming European Union 
Clinical Trial Regulation requires sponsors to provide summary results of clinical trials in 
a format understandable to laypersons, including participants (261). However, there is a 
lack of evidence on the most appropriate methods of sharing results with participants. 
Uncertainty persists around what information should be shared, how results should be 
shared and who should be responsible for sharing the results. Since the findings of 
clinical research often exist in a complex context of scientific exchange and debate, it is 
important that the information shared is accessible and relevant to participants (120). 
The increasing understanding of the importance of sharing research results with study 
participants is somewhat linked to a wider movement towards transparency in trials. This 
movement is largely promoted by initiatives such as SPIRIT, CONSORT and AllTrials. The 
SPIRIT Statement provides guidance to researchers to improve the completeness and 
quality of trial protocols (262), the Consolidated Standards of Reporting Trials 
(CONSORT) Statement is an evidence based, minimum set of recommendations for 
reporting randomised trials (263), and the AllTrials initiative calls for all past and present 
trials to be registered and their full methods and summary results reported (264). Some 
of these initiatives also include recommendations for disseminating results to research 
participants. For example, the SPIRIT statement states that study results must be 
released to participating physicians, referring physicians, patients and the general 
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medical community (262). The Thyroid Hormone Replacement for Subclinical 
Hypothyroidism Trial (TRUST) was a multi-centre, double blind, placebo controlled, 
phase III clinical trial testing the efficacy of thyroxine replacement in subclinical 
hypothyroidism in older community dwelling adults (121). The results of the TRUST trial 
were published in the New England Journal of Medicine on 3rd of April, 2017 (121). This 
Study Within A Trial (SWAT) was conducted at the Irish TRUST trial site prior to and after 
publication of results.  
The aim of this SWAT was to investigate methods of disseminating trial findings to 
participants by using a PPI approach to identify, develop, and evaluate a patient-based 
approach of receiving trial results. 
6.3 Methods 
Study design 
This was a sequential mixed methods study with three phases. In this study, methods 
were combined for complementarity, where each method addressed a different aspect 
of the study aim (265). The first phase used a qualitative approach to identify and 
develop a patient-based approach to disseminating the results, the second phase used a 
SWAT intervention to compare the dissemination approaches and the third phase used 
a quantitative patient understanding questionnaire to evaluate the patient-based 





The study sites for the TRUST trial were the University of Glasgow, Scotland (lead site); 
Leiden Academy on Vitality and Ageing, The Netherlands; Leiden University Medical 
Centre, The Netherlands; University of Berne, Switzerland; and University College Cork, 
Ireland. A total of 738 participants with subclinical hypothyroidism were recruited to the 
trial over a three-and-a-half year period from 2013–2017 (121). The trial completed 
recruitment in November 2016 and the results were published in April 2017 (121). 
This SWAT was conducted at the Irish TRUST site. The hub centre for the Irish TRUST site 
was located at the Mercy University Hospital, Cork where 38 participants were recruited. 
A further 77 participants were recruited from five satellite sites. 
Population 
As this SWAT was embedded in an ongoing clinical trial the study sample was determined 
by the TRUST Thyroid trial. There were 115 TRUST participants recruited in the Irish site, 
11 of these participants withdrew over the course of the trial. Our study sample included 
all remaining TRUST participants (n=104). 
Phase One: Identification and development of patient-based approach (qualitative and 
PPI phase) 
The first phase of the study used a qualitative approach to iteratively identify and 
develop a patient-based approach to disseminate the results of TRUST trial. This was 
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done in three separate stages: qualitative focus groups, a PPI group and an adult literacy 
review. 
Focus groups 
Three semi-structured focus groups were conducted with four to eight TRUST trial 
participants per group. All Cork-based patients (n = 38) were contacted via letter and 
invited to participate. A €20 shopping voucher was given to all participants to cover travel 
expenses. Each session was led by trained qualitative researchers (WHS, ER, CH). A topic 
guide was used to guide the focus groups. The topic guide was reviewed and refined by 
all members of the SWAT research team (see Appendix 4.1: Focus group topic guide). 
The Consensus-Oriented-Decision-Making (CODM) model was used to guide the group 
to reach a consensus (267). The CODM model is accepted as a flexible model for reaching 
decisions (267). In this study some of the steps were initiated by the focus group 
facilitator and others occurred naturally as a follow on from the previous step. Below is 
an outline of each of the seven steps of the CODM model and how they were used in this 
study: 
1. Framing the topic: The focus group facilitator introduced the idea of sharing 
results with participants and provided some context on the reasons why results 
are/ are not shared with participants. 
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2. Open discussion: The facilitator asked the group whether or not they think 
results should be shared with trial participants and whether or not they would 
like to receive the results of the TRUST trial. 
3. Identifying underlying concerns: The previous discussion naturally followed on 
to participants asking questions and expressing concerns about the result 
method, content and language that would be used. 
4. Collaborative proposal building: The group worked together to agree on the 
important elements of the results in terms of result method, content and 
language. 
5. Choosing a direction: This step occurred naturally as part of the previous step. 
6. Synthesizing a final proposal: The facilitator re-iterated the proposal the group 
had agreed upon and asked the group for feedback. 
7. Closure: This step occurred naturally as part of the previous step. 
Analysis. Focus group recordings were transcribed verbatim and entered into NVivo 
Version 11 for data management during thematic analysis. Braun and Clarke guidelines 
(268) for conducting thematic analysis were followed. Initial focus group transcripts were 
analysed independently by two researchers (ER and AC). Each transcript was read 
multiple times (data familiarisation) and initial codes were identified. These codes were 
then used to identify emerging themes. Both researchers discussed emerging themes 
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and conducted further refinement. The refined themes were then discussed and agreed 
upon with other members of the research team (ER, CH, AC, KMS). Researchers (ER, CH, 
AC) then used the focus group findings to develop an initial draft of a patient-based 
approach for the dissemination of results (see Appendix 4.2: Draft one of patient-based 
result letter). 
PPI group 
A PPI group was established to develop and refine the content of the patient-based 
approach for the dissemination of results. During the focus groups, three TRUST trial 
participants volunteered to take part in the PPI group. In addition to these three PPI 
partners, an additional partner was identified from a previous qualitative research study 
undertaken by the research team. This individual was keen to learn more about research 
and expressed an interest in being involved in future projects. While this individual had 
previous experience of taking part in research (as an interview participant), she had no 
experience of taking part in a clinical trial or being involved as a PPI partner. Originally, 
we intended to conduct these sessions in a group format, due to difficulties with PPI 
partners’ schedule commitments, one-to-one sessions were conducted. At the one-one 
session, a researcher (ER) and the PPI partner discussed the layout, content and language 
of the initial draft of the result method. Researchers and PPI partners worked together 
to edit different sections of the document. These discussions were not audio recorded 
but comprehensive field notes were taken by the researcher (ER). These notes were then 
collated by the researcher and used to further ensure that the results letter reflected PPI 
partners’ perspectives and preferences. 
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Adult literacy review 
While the PPI group had significant input into the format and language used in the 
patient-based approach, the research team felt that it would be of additional benefit to 
collaborate with the National Adult Literacy Agency (NALA) to ensure the document 
adhered to national ‘Plain English’ standards. These standards ensured that the 
information presented to trial participants was sufficiently easy to read and understand 
(literacy). This would help to ensure that trial participants were able to make sound 
health decisions based on the information presented (health literacy) (269). This review 
was an iterative process with several drafts exchanged for editing. Although the review 
was taken as an additional step to the published protocol for the study, the research 
team felt it was helpful to further ensure that the document was accessible and easy to 
understand. 
At the end of the first phase of the study, a final draft of the patient-based result letter 
was approved by researchers, PPI group and adult literacy experts (see Appendix 4.3: 
Final draft of patient-based result letter). 
Phase Two: Dissemination of trial results (intervention phase) 
The second phase of the study used a SWAT intervention to disseminate the results of 
the TRUST Thyroid Trial to trial participants. This was done using a prospective, 
randomised, single blind, parallel trial design. It is important to note that when the term 
randomisation is used, it refers to the allocation of patients to intervention/control 
within the SWAT and not the TRUST Thyroid trial. Irish TRUST participants were 
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randomised to intervention or control groups using an online random number generator. 
The intervention group received the patient-based letter format (see Appendix 4.3: Final 
version patient-based results letter) and the control group received a copy of the TRUST 
results press release, which was made available by the lead study site on the TRUST 
Thyroid Trial Website (see Appendix 4.4: Standard results letter). Participants were 
blinded to their intervention group. One member of the research team was un-blinded 
in order to perform the randomisation and distribute the results of the trial. As they were 
un-blinded to perform these two important tasks, they were not involved in the data 
analysis or interpretation in any way. 
Phase Three: Evaluation of patient –based approach (quantitative phase) 
The third phase of the study used a quantitative patient understanding questionnaire to 
evaluate the patient-based approach to disseminating trial results. The questionnaire 
was developed in consultation with experts in the area of subclinical hypothyroidism and 
scale (questionnaire) development (PK and KMS). The early development of the 
questionnaire was guided by a consultation document, which accompanies the EU 
Clinical Trials Regulation No 536/2014 (270). This document highlights the information 
which should be presented to trial participants in the trial summary at the end of a trial. 
However, initial questionnaire items were modified to allow for psychometric testing. 
The final questionnaire contained 12 questions; six items were measured on a five-point 
LIKERT scale, there were four multiple-choice questions and two vignettes. The first six 
items measured patients’ perceived understanding of results; the four multiple choice 
measured patients’ actual understanding of results by requiring them to select the 
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correct answer. To further test participants’ understanding of the trial results, two 
vignettes describing two typical patient case studies of older adults with subclinical 
hypothyroidism were provided with a question on whether a doctor should prescribe 
thyroxine for the hypothetical patient described. The questionnaire was reviewed by the 
PPI group to assess content and face validity. It then underwent further review by NALA 
to ensure adherence to the national ‘Plain English’ standard. The final version of the 
questionnaire can be seen in Appendix 4.5: Patient understanding questionnaire. 
The questionnaire was sent to all Irish TRUST participants (intervention and control 
group) one week after they received the results of the trial. A reminder questionnaire 
was sent to non-responders 3 weeks later. 
Analysis. The primary outcome was the difference in levels of patient understanding 
between the intervention and control groups. This measured the impact of PPI on patient 
understanding of end of trial results. The psychometric properties and construct validity 
of the questionnaire were examined with exploratory factor analysis. Principal 
component analysis (PCA) was conducted on the six LIKERT scale items. Internal 
consistency of the questionnaire was investigated using Cronbach's alpha coefficient. 
Completed questionnaires were entered into SPSS software (version 24) and analysed 
using descriptive and inferential (Chi-square test and Fishers Exact) statistics. The 
researcher carrying out data input and analysis was blinded to the participants' allocation 
status. 
Costs of conducting PPI 
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The lead researcher (ER) kept a detailed account of all direct costs associated with 
conducting PPI for the purpose of this study. These costs included researcher salary, 
travel and expenses for PPI participants, adult literacy review and printing and postage 
costs. 
This paper has been written in adherence to the Guidance for Reporting Involvement of 
Patients and Public 2 (GRIPP 2) (208). The GRIPP 2 checklist is a tool, developed to 
improve the reporting of patient and public involvement in research and guide the 
development of a transparent, consistent and high-quality PPI evidence base. The Good 
Reporting of a Mixed Methods Study (GRAMMS) framework was also used to inform the 
reporting of the findings (271). 
6.4 Results 
Characteristics of the trial participants stratified by participation in the different stages 




Table 6.1: Characteristics of trial participants stratified by participation in the different 
stages of the study. 
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1A subgroup of Irish TRUST participants (n=38) were invited to focus groups. 
2RR=Response Rate 
3 Total Irish TRUST participants (n=104) excluding PPI partners (n=3) = n=101. 
 





Three focus groups were held with 19 out of 38 participants accepting an invitation to 
join. Participants who attended the focus groups were similar in age, gender, education 
level to those who did not attend. 
Focus group findings indicate that participants want to receive the results of the trial in 
which they are taking part. Three main themes emerged in relation to participants’ 
perspectives of and preferences for receiving trial results: ‘acknowledgement of 
individual contribution’, ‘contributing for a collective benefit’ and ‘receiving accessible 
and easy to understand results’. 
Acknowledgement of individual contribution 
Many participants reported feeling they had made an individual contribution to the trial 
in terms of their time and personal information while attending the trial study visits. As 
such, participants felt that receiving the results of the trial would provide an 
acknowledgement of this individual contribution: 
‘Yes, I mean it’s kind of instinctive… when you go into a [clinical trial] and you 
spend and  invest that time in it. I mean okay I had the time to invest but you 
know at the end of the day, [receiving the result] is kind of like your pay off.’ (FG2 
P3) 
Contributing for a collective benefit 
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While participants spoke about making an individual contribution to the trial, they felt 
that their involvement contributed to a collective benefit or greater good. Participants 
reported that receiving the results of the trial would help them to feel that they had 
contributed to this greater good: 
‘I’m not really interested in my own personal results but as the results of the 
scheme as a whole. You know the idea is, does the study help or hinder old people 
and that’s what I want to know’ (FG2 P1) 
This feeling of contributing for a collective benefit was further reinforced when 
participants discussed their desire to understand how the results of the trial will be 
implemented by medical experts and ultimately how it will affect others who have the 
condition: 
‘I would like to know, if they found out, okay, do we treat these people or not. 
That would be good. Do we treat them, or don’t we treat them? I think that is 
what it’s all about’ (FG3 P4) 
Receiving accessible and easy to understand results 
Participants expressed a clear need to receive the results of the trial in an accessible and 
easy to understand way. This preference applied to the format, language and content of 
the patient-based approach. 
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The majority of participants said they would like to receive the results in a letter format 
posted to them directly from the TRUST trial. Participants felt that this method would be 
accessible to them as they could read the results ‘in text’ (FG3 P4) and keep 
a ‘hardcopy’ (FG P1). While participants wanted an official statement of the results in a 
letter format, they also felt it was important to add a personal element to the letter. 
They suggested this could be done by offering participants a phone number that they 
could call if they wished to discuss any further issues or concerns with the TRUST study 
team: 
‘Could you attach a helpline on to it? If you know, somebody had some kind of 
serious medical question or that they thought was a bit personal element or 
whatever. That they’d like to talk to a medical person or whatever. Instead of just 
talking to your GP, maybe that would add another dimension of care around the 
TRUST’ (FG2 P3) 
Participants agreed that the format, content and language of the results letter needed 
to be easy to read and understand. All participants wanted the letter to be no longer 
than 2–3 pages and presented in a question and answer format. Participants believed 
the content of the results letter should include ‘pertinent information’ (FG1 P7) relating 
to the trial itself, the study drug (including side effects) and the results of the trial. They 
stressed the importance that this information needed to be informed by medical experts 
and ‘from a good authoritative source’ (FG2 P2) but it should be presented to them in a 
language that fits their current context and could be easily understood by those who do 
not have scientific or medical backgrounds. 
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‘Just in ordinary language that we can understand ourselves, you know that we 
don’t want big and long explanation or that, just that we can pick it up straight 
away that it’s without any huge number of pages. Just the bare, to me anyway, 
answers to the questions.’ (FG3- P2) 
It was evident from the focus groups that participants want to receive the results of the 
trial both to acknowledge their individual contribution to the trial and also help them to 
feel that they had contributed to a greater good. Participants expressed a clear 
preference to receive the results in an accessible and easy to understand way. These 
results were used by the researcher (ER) to develop an initial draft of the results letter 
(see Appendix 4.2: Draft one patient-based result letter). 
PPI group 
The initial draft of the results letter was then further iteratively developed by the PPI 
group. There were four PPI partners in total (three trial participants and one older adult) 
Each partner took part in one-to-one session. Each session contained an open discussion 
between the researcher (ER) and PPI partners on the layout, content and language of the 
document. Researchers and PPI partners worked together to write, re-write, edit and 
change different sections of the document. 
Health literacy review 
This draft was then iteratively reviewed and approved by health literacy experts from 




Phase Two: Dissemination of trial results (intervention phase) 
There was a total of 101 Irish TRUST participants randomised to the SWAT intervention. 
Trial participants from the PPI group (n = 3) were excluded from randomisation as they 
reviewed the content of the intervention method prior to the intervention. The 
intervention group (n=51) received the patient-based letter format (see Appendix 4.3: 
Final version patient-based results letter) and the control group (n=50) received a copy 
of the TRUST results press release, which was made available by the lead study site on 
the TRUST Thyroid Trial Website (see Appendix 4.4: Standard results letter). 
Phase Three: Evaluation of patient-based approach (quantitative phase) 
The overall response rate for the patient understanding questionnaire was 68% (69/101). 
The response rate for the intervention group was 74% (38/51) and the response rate for 
the control group was 62% (31/50). There were no significant differences in age, gender 
and education between those who returned the questionnaire and those who did not. 
Post hoc power calculations showed that the study was underpowered to detect an 
effect. Power for each of the patient understanding components ranged from .01 to. 58. 
Table 6.2 below shows the results of patients’ perceived understanding of the purpose 
and context of the TRUST Thyroid Trial. Due to low participant numbers across the five 
Likert responses, the questionnaire response bands have been contracted from ‘Strongly 
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Agree’ and ‘Agree’ to ‘Yes, ‘Strongly Disagree’ and ‘Disagree’ to ‘No’ and ‘Neither agree 
nor disagree’ to ‘Neutral’. The results show that patients’ perceptions of understanding 
are similar between the intervention and control groups. Subgroup analysis showed 
patient’s understanding was not significantly impacted by age, gender or educational 
level. 
Table 6.2: Patient perceptions of understanding presented by group1. 
Item  Group  Yes No Neutral p-
value 
I understand why the 


















I understand why I was 


















I know why the medicine 
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I understand how doctors 
will use the results of the 
TRUST Thyroid trial to 























Figure 6.1 shows patients’ actual understanding of the primary aim, side effect and 
results of the TRUST Thyroid Trial. Almost 82% (n=31) of the intervention group and 65% 
(n=20) of the control group correctly understood the primary aim of the TRUST trial 
(p=0.108). Almost 40% (n=15) of the intervention group and 36% (n=9) of the control 
group correctly understood the associated side effects of the active drug (p=0.734). In 
total 50% of the intervention group (n=19) and 58% of the control group correctly 
understood the results of the trial (p=0.504). There were no differences in patient 
understanding of trial results between the intervention and control groups. 
 
 
Figure 6.1: Patient understanding of primary aim, side effect and trial result of the 
TRUST Thyroid Trial presented by group1. 
1 Patient understanding of primary aim, side effect and trial result was assessed using 


































In terms of patient understanding of hypothetical patient case studies, 43% (n=13) of the 
intervention group gave the correct answer to Vignette A; this was lower than the control 
group (62.1%, n=18, p=0.15). In total 77% (n=23) of the intervention group gave the 
correct answer to Vignette B, this was higher than the control group (66%, n=19, 
p=0.344). 
Psychometric testing 
An exploratory principal components analysis (PCA) was conducted on the patient 
understanding questionnaire to determine its usefulness as a measure of perceived 
understanding. The Kaiser-Meyer-Olkin (KMO) measure verified the sampling adequacy 
for the analysis, KMO= .83. Bartlett’s test of sphericity indicated that the correlation 
matrix was significantly different from an identity matrix, X2 (.852) = 283.92, p<.001. An 
examination of eigenvalues greater than Kaiser’s criterion of one, suggested the 
extraction of one factor; this was supported by inspection of Cattell’s scree plot. An 
examination of the constituent items for this factor structure also indicated that items 
loaded most highly on a single factor. This single factor represents a measure of 
perceived understanding of trial results. PCA was then conducted using an oblique (direct 
oblimin) rotation, specifying the extraction of one factor. This model explained a 
combined 69.58% of the variance in patients understanding of the TRUST thyroid trial. 
Cost of conducting PPI 





While PPI is increasingly recognised as an important element of clinical research, 
evidence on optimal methods and potential impact is lacking (53, 260). Previous research 
conducted on the impact of PPI has largely focused on the experiences of participants 
and researchers (190) and on the research process in broad terms (77). In this study, our 
primary outcome was specific: a quantitative measure of patient understanding of trial 
results between those who received the patient-based approach and the standard 
approach. To our knowledge there has been no previous research conducted on the 
impact of PPI on patient understanding of trial results. 
The involvement of clinical trial participants in this study offered insightful perspectives 
on the information needs of the study population in terms of receiving end of trial 
results. Study findings show that trial participants want to receive the results of the 
clinical trial in which they had participated. This is supported by much of the available 
literature on patients’ preferences of receiving results, with up to 90% of participants in 
previous studies reporting a desire to receive results (272). Focus group findings showed 
that participants felt that receiving results would provide an acknowledgement of their 
individual contribution to the trial. This finding complements previous commentaries 
about result sharing being an ‘ethical imperative or ‘moral obligation’. Fernandez et al. 
points out that many participants place their trust in science and researchers owe a debt 
to participants to fulfil their trust and recognise their altruism (120, 273). 
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Unsurprisingly, findings also show that participants want to receive results that are 
accessible and easy to understand. In this study, the preferred format of receiving results 
was a letter posted to them directly from the TRUST trial. This preference is also 
consistent with the literature on patient preferences of receiving results. A previous 
study investigating preferences of individuals taking part in a cardiac rehabilitation trial 
found that 80% of trial participants preferred to receive the results by post (274). The 
patient-based approach identified in this study was feasible for researchers to develop 
with significant involvement from trial participants and adult literacy experts. 
Previous studies exploring participants’ reactions found that sharing trial results with 
participants can cause some negative impacts such as anxiety, anger, guilt, upset and 
confusion (275-277). As far as researchers in this study are aware, providing results did 
not cause any negative impacts. This may have been due to the fact that the TRUST trial 
had a low risk of morbidity or mortality compared to some of the other studies citing 
negative impacts. Both result methods contained the telephone number, email address 
and postal address of the research team and participants were urged to contact should 
they have any questions or concerns relating to the study. The research team did not 
receive any queries. 
Previous systematic reviews highlight the lack of evidence on economic analysis of PPI 
and call for researchers to consider the costs of its implementation (77, 98). As discussed 
previously research funders are increasingly demanding that PPI be carried out in 
research. However, the costs of PPI are often underestimated and can cause a significant 
financial burden on research project budgets (77, 98, 278, 279). It is extremely important 
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that researchers plan PPI at the grant proposal stage and estimate the costs 
appropriately. If these costs are not correctly estimated during the initial stages of 
developing research proposals, they may cause a financial burden on PPI partners. 
Participants in this study were not paid for their time but were provided with a €20 
voucher to cover travel expenses. When PPI is not the primary focus of a study, 
researchers do not consider the cost implications at the beginning of the study and are 
often tied with limited resources to carry out PPI (278-280). INVOLVE, the national 
advisory group supporting active public involvement in health services, public health and 
social care research in the UK, have recommended that PPI partners should be paid for 
their involvement (281). Despite this, existing research suggests that institutional 
difficulties make negotiating the mechanisms of paying participants very difficult (278). 
One study reported that in order for participants to be remunerated for their efforts, 
they needed to be registered as employees, a process that incurred much paperwork 
and time delays (278). This study outlines the cost of conducting PPI and includes a full 
breakdown of costs (see Appendix 4.6: Costs of conducting PPI). This breakdown 
provides a template to other researchers who plan to carry out and evaluate PPI as part 
of their research. It is important to note that not all costs associated with carrying out 
the study were included in this amount. For example, the only salary costed was that of 
the research assistant. The expertise provided by other members of the study team were 
not included in the total cost as they were being paid by the University or other research 
grants. The total cost of conducting this study was €8,049 which is not insignificant but 
should be considered in the context of the cost of large-scale trials. 
183 
 
6.5.1 Strengths and Limitations of the study 
While this study provides important insights into patients’ preferences of receiving trial 
results, it is not without limitations. Firstly, existing PPI literature states that ‘to 
understand the research needs and challenges, PPI has to engage people who are able 
to offer perspectives from the study population’ (52). All PPI partners in this study were 
active members of the research community as they had taken part in the TRUST trial and 
had agreed to long-term follow up. This is a strength of the SWAT as they were able to 
offer perspectives from the study population, however it does have an important 
implication for their reporting of understanding the results of the trial. They may be more 
inclined to rate their understanding as high because of their investment in the trial (282), 
thus potentially minimising differences between the intervention and control conditions 
and minimising inferences that can be drawn about the intervention. Previous research 
suggests that people that actively choose to engage in research either as research 
participants or involvement partners are more likely to be middle-class and highly 
educated (18, 283). In this study, those that attended the focus groups and PPI group 
were similar in education level to those that did not attend. This is not surprising 
considering the entire study sample had already actively volunteered to take part in the 
TRUST trial. 
Secondly, the results of the patient understanding questionnaire show that the levels of 
patient understanding were similar between the two groups. However, this study was 
underpowered to detect an effect. As this was a Study Within A Trial (SWAT), the power 
was limited by the sample size that was available to us from the trial (n=115). 
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Furthermore, validation of the patient understanding questionnaire was limited by the 
sample size in this study. While validation of the questionnaire was limited, exploratory 
factor analysis provided some evidence that the questionnaire is a useful tool for 
measuring patient understanding of trial results. The developed questionnaire can be 
tailored for use in other trials in future examinations of patients understanding of trial 
results. This would provide insight into patient understanding and provide further 
validation data. 
Thirdly, all SWAT participants were aged 65 and over. The layout, format and language 
of this patient-based approach which was identified and developed may only be relevant 
for this study population. Other trial populations may prefer to receive the results via 
email, online or in person from a member of the study team (120). The evidence on 
patient preferences of receiving trial results is limited, therefore further research is 
needed to explore patient preferences of receiving trial results amongst different study 
populations. 
It is also important to point out that the control group in this study received a copy of 
the trial results in a press release format. Most trial participants do not receive this. 
While this control method was a step further than normal procedure, the researchers in 
this study felt this was appropriate. The information presented in the press release was 
similar to that of the patient-based approach. However, the format and layout of the 
press release was different. Information was written in four long paragraphs separated 
by individual headings. It was also much shorter (1 page in total) that the patient-based 
approach (3 pages in total). Given the fact that press releases are written by public 
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relations professionals with a view to communicating effectively and efficiently, this may 
have potentially minimised differences between the intervention and control conditions. 
The primary outcome of this study was assessing the impact of PPI on patient 
understanding of results, however, this was not the only potential impact. In hindsight, 
we adopted a limited approach to PPI in this study as we did not involve our PPI partners 
from the outset of the SWAT. Involving PPI partners in the development of core outcome 
sets for this SWAT could have identified other more appropriate primary outcome 
measures (284). 
The aim of this SWAT was to investigate methods of disseminating trial findings to trial 
participants by using a PPI approach to identify, develop and evaluate a patient-based 
method of receiving trial results. The PPI approach actively involved focus group 
participants in making decisions about the result method and worked with PPI partners 
to co-develop the result letter. However, PPI partners were not involved in other aspects 
of the research process such as research design, data collection or analysis. This is partly 
due to the fact that PPI is a relatively new concept in clinical trials. As the majority of the 
literature has only been published in the last 12 months, there is little evidence available 
on the impact of PPI and no gold standard or comprehensive guidelines for researchers 
to follow (274). Thornton (259) suggests that in order for PPI to develop it is important 
to record its social and cultural history by collecting comprehensive databases and 
undertaking ongoing reviews of the impact of PPI. This paper along with the study 
protocol have been written in adherence with the Guidelines for Reporting Involvement 
of Patients and the Public (208), thus providing templates for involving patients and the 
public in clinical trial design and development. This study is an important step forwards 
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in documenting the process of conducting PPI as part of a SWAT and evaluating its 
impact. Future research is needed to further develop PPI in clinical trial settings. As there 
is currently no gold standard or comprehensive guidelines for researchers to follow when 
evaluating the impact of PPI, further research is needed. This research should involve PPI 
partners in the development of core outcome sets for evaluating PPI impact. These 
would significantly enhance the literature in the area. 
6.6 Conclusion 
Patient and Public Involvement (PPI) is advocated for every step of the trial process. We 
have demonstrated that it is feasible to involve PPI partners in the development of 
dissemination materials. Sharing clinical trial results with participants in a format 
understandable to laypersons will soon be a legal requirement11. However, there is a 
significant lack of evidence as to the most appropriate methods of sharing results with 
participants. The study identified and developed a patient-based approach to 
disseminating clinical trial results for trial participants. Although, in this study PPI did not 
influence patients’ final understanding of results, it documents the process of conducting 
PPI within the clinical trial setting. This process may be useful for other trialists interested 









This thesis aims to contribute to the evidence on the methods and impact of PPI by 
exploring PPI contributors’ experiences and contributions at the design, conduct and 
dissemination stages of trials. Current reports on the methods and impact of PPI are 
‘piecemeal and inconclusive’ (9). This research demonstrates how we can progress from 
relying solely on researchers’ anecdotal reflections and limited qualitative studies on the 
perceived impact of PPI towards developing a more robust evidence base on the 
methods and impact of PPI on three specific stages of the trial process: design, conduct 
and dissemination. To do this, a suite of study designs were used including qualitative, 
mixed methods, systematic review and narrative synthesis, and an embedded 
randomised controlled trial. This research also demonstrates that it is feasible to conduct 
and evaluate PPI in the design, conduct and dessemination of trials while following the 
core principles of PPI as defined by INVOLVE (23).  
This final chapter summarises the main findings, the strengths and limitations of the 
thesis, the implications, and suggestions for future research. This chapter will also 
present a reflection on PPI during the COVID-19 outbreak and will close with a brief 
conclusion.  
7.2 Summary of main findings  
This research shows that while there are a wide variety of approaches and methods used 
to involve PPI contributors, the approach or method used can have an important 
influence on the impact of involvement. The systematic review on the perceived impact 
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of PPI on trial retention highlighted that PPI contributors are often involved 
simultaneously with other stakeholders on trial advisory committees and stakeholder 
advisory boards. However, the research on PPI involvement during intervention 
development showed that involving PPI contributors simultaneously with other 
stakeholders (healthcare professionals) can lead to a perceived lack of common ground 
where both stakeholder groups can feel undervalued by the other group and reluctant 
to express their opinions. Furthermore, there were more instances of conflicting 
opinions when both types of stakeholders were involved simultaneously in the same 
group, than when each stakeholder group was involved separately. In this research, 
these conflicting opinions were difficult to disentangle and led to researchers being 
unsure about how to incorporate their opinions into the final intervention that was 
developed. These findings suggest that it may be more suitable and useful to involve PPI 
contributors separately rather than simultaneously with other stakeholders. This 
learning is an important contribution to the existing limited evidence on suitable PPI 
methodologies and is consistent with existing literature on the productivity of 
incongruent groups that is, when groups contain smaller subgroups of individuals with 
conflicting knowledge or experiences. These subgroups can create a division between 
group members, undermining the groups’ ability to work together and be productive 
(149).  
This research found that PPI can influence the research process by creating and fostering 
trust between researchers and participants. The systematic review showed that 
researchers perceived PPI to have a positive impact on trial retention as PPI contributors 
helped research teams to develop trust with participants. When advising on the delivery 
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and content of trial result dissemination materials, although trial participants wanted the 
results in a format that was easy to understand, they stressed the importance that this 
information be informed by medical experts and from a source they could trust. Previous 
research has highlighted that trust between research participants and researchers is 
paramount to successful research (250). Factors affecting trust can vary greatly 
depending on the study target community. For example, a previous study exploring 
factors affecting trust between research participants and research teams found that non-
indigenous people were more likely to base their trust on the general reputation and 
credentials of the institution in which the research was taking place whereas non-
indigenous people tended to base their trust on the face-value and likeability of the 
researcher (251). PPI contributors also advised the research team on how they can 
capitalise on existing trusting relationships between patients and healthcare 
professionals to improve health outcomes. When advising on who should deliver the 
message to attend retinopathy screening, people with diabetes recommended that the 
GP deliver the message as people have a relationship with, and trust, their GP and are 
much more inclined to listen to them. The results contained in this thesis shows how PPI 
contributors can help researchers to develop and adapt specific trust building measures 
to suit the particular trial context and target population.  
This research found that PPI contributors can help researchers to communicate more 
effectively with research participants. When advising on how a message to attend 
diabetic retinopathy screening should be delivered to people with diabetes, PPI 
contributors recommended that a letter would be the most direct way of contacting 
participants as it comes to the house so you have to open and read it. They also gave 
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insights on how the letter would be received from a patient perspective such as sending 
the letter in a plain envelope so people would not feel apprehensive about opening a 
letter from their GP practice that could contain negative results. Similarly, the systematic 
review highlighted that PPI contributors across different trial contests advised on the 
mode, frequency and format of study reminders and helped to ensure trial materials 
were understandable when they were not in trial participants primary language. 
Furthermore, trial participants advising on trial dissemination materials recommended 
that the results be sent in a letter format. They also stressed the importance of 
communicating in a format that was accessible to participants and easy to understand. 
Throughout this research, the lines between individuals taking part in the research as 
research participants and being involved in the research as PPI contributors were 
blurred, as is often the case with PPI (12, 164). For example, although people with 
diabetes took part in the consensus meetings as research participants, their role was to 
discuss and make decisions about the intervention content and mode of delivery which 
fits with the PPI definition and principles (33, 165). Similarly, although TRUST trial 
participants took part in focus groups, their task was to outline their preferences for trial 
result dissemination which was ultimately used to develop the result dissemination 
method which can be defined as PPI. These lines were further blurred with the added 
complexity of evaluating the impact of PPI. For example, PPI contributors became 
research participants when they completed the experience survey or patient 
understanding questionnaire. Researchers evaluating PPI should be mindful of these 
blurred lines and ensure they establish clear role expectations with PPI contributors so 
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contributors are fully informed as to when they are expected to be involved as PPI 
contributors and take part in the research as research participants. 
7.3 Strengths and limitations  
In addition to the strengths and limitations discussed in each chapter, the overall 
strengths and limitations of the thesis are outlined below.  
This thesis generates evidence on the methods and impact of PPI in randomised trials. 
This includes qualitative, mixed methods and an embedded randomised controlled trial. 
The reporting of these designs was strengthened by the use of relevant reporting 
checklists: Consolidated Criteria for Reporting Qualitative Studies (COREQ), Good 
Reporting of A Mixed Methods Study (GRAMMS) framework and Enhancing 
Transparency in Reporting the Synthesis of Qualitative Research (ENTREQ) statement 
(133, 134, 209). This thesis demonstrates how appropriate methodology can be 
employed to overcome previous limitations and provide evidence on the methods and 
impact of PPI in the context of trials.  
Secondly, the extensive and continued involvement of PPI contributors is a key strength 
of this research. Throughout each of the studies presented in this thesis, I employed a 
combination of the consultation and collaboration approaches to involvement as defined 
by the ‘levels of involvement’ theoretical model originally put forward by Boote, Telford 
and Cooper and adapted by INVOLVE (7, 32). I consulted and collaborated with PPI 
contributors to devise the study design and development (Chapters 3, 4 and 5), inform 
study recruitment materials and processes (Chapters 3 and 4), design study materials 
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and data collection processes (Chapter 4 and 6), interpret data synthesis (Chapter 5), 
inform the content, layout, format and delivery of research findings (Chapter 6) and 
review and contribute to drafts of peer reviewed manuscripts (Chapters 3, 4, 5 and 6). 
The involvement of PPI contributors also shaped my attitude as an early career 
researcher. Although trial methodology research ultimately aims to improve the health 
of patients and the public by improving how trials are carried out, the non-patient facing 
nature of trial methodology research often meant that I felt disconnected from the 
community whose health I was aiming to improve. Conducting PPI helped me to connect 
with that community and realise the purpose of my research.   
The results of this research are timely. This research was conducted as the supportive 
environment for PPI continues to be created by research funders, academic journals and 
research ethics committees. As many researchers are now required to incorporate PPI 
as an integral part of their research, there is an emerging appetite amongst the research 
community to increase their understanding of effective PPI methods and its impact on 
the research process. This research has contributed to the development of a supportive 
environment for PPI in health research as I have had the opportunity to present this work 
at various national and international conferences in the areas of PPI, health services and 
public health (Appendix 6), record a podcast series to promote PPI in research (see 
Appendix 5), publish blog posts on the HRB Open and Structured Population and Health 
Services Education (SPHeRE) platforms (see Appendix 5) and deliver an educational 
seminar for researchers at University College Cork (see Appendix 5). Throughout these 
activities, the research was well received and won a number of awards (see Appendix 8).  
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This research captures the complex nature of PPI. The definition of involvement adopted 
throughout the duration of this research was the INVOLVE definition of PPI. INVOLVE 
defines PPI as ‘research being carried out ‘with’ or ‘by’ members of the public rather than 
‘to’, ‘about’ or ‘for’ them’(1). This broad definition was considered the best fit for this 
research as it allows for the inclusion of participatory research approaches and activities 
that share the same principles as PPI but may not necessarily be labelled as PPI in the 
literature. For example, the inclusion of people with diabetes and healthcare 
professionals in the studies presented in Chapters 3 and 4 of this thesis fits with the 
Community Based Participatory Research (CBPR) approach which aims to include all 
relevant stakeholders as partners, rather than excluding health professionals from the 
process (285). Additionally, previous systematic reviews have tended to focus their 
search terms solely relating to ‘patient’, ‘public’ and ‘involvement’, however the 
systematic review presented in Chapter 5 of this thesis included search terms relating to 
a wide range of participatory research approaches including CBPR and participatory 
action research. The inclusion of a wide variety of terms allowed for the transfer of 
learnings from participatory research approaches which have a much longer history in 
the social sciences compared to that of the relatively recent tradition of PPI in health 
research (286).   
There are a number of limitations to the research carried out in this thesis. Some of the 
survey instruments used to collect quantitative data in this thesis were not validated. 
Given that PPI is a relatively recent phenomenon and the majority of the evidence on 
evaluating the impact of PPI has been published in the last three years, validated tools 
to evaluate its impact are non-existent. The questionnaire that was used to understand 
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participants experiences in Chapter 3 was based on non-validated questionnaire items 
from a previous study aiming to evaluate dimensions of group dynamics within 
community-based participatory research partnerships. I was unable to conduct 
exploratory factor analysis as the study sample size did not meet the minimum criteria 
for validation. The questionnaire used to evaluate participants’ understanding of trial 
results in Chapter 6 was also not validated. Although exploratory factor analyses 
provided some evidence that the questionnaire is a useful tool, this would need to be 
further explored in future studies that aim to evaluate the impact of PPI on participants’ 
understanding of trial results.  
Despite using a range of strategies to recruit PPI contributors for each study, another 
potential limitation is the lack of diverse PPI contributors. For example, the absence of 
people with type 2 diabetes involved in the combined consensus meeting of people with 
diabetes and healthcare professionals could have changed the nature of the relationship 
between patients and HCPs and led to different participant experiences and group 
dynamics. There was also an absence of individuals from ‘hard to reach’ or ‘seldom 
heard’ communities. For example, although members of the travelling community are 
twice as likely to have diabetes than members of the general population (287), no 
members of the travelling community were involved in this research. Diversity has been 
noted as a significant issue in PPI and needs to be considered in all research studies to 
allow a broad range of perspectives to be taken into account and to promote equal 
access to opportunities for public involvement (288). I made significant efforts to 
promote involvement opportunities (see Appendix 1.2) and ensure the location of 
involvement activities was easy to find and access. One way to promote involvement 
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activities would be to collaborate with community representative organisations and 
community groups and work together with them to promote and conduct involvement 
activities away from formal project or organisational structures (289).  
 
7.4 Implications  
While research funders, ethics committees and academic journals increasingly require 
PPI (3, 10), the results of this research will have important implications for researchers, 
patients and members of the public and research funders.  
 
The findings suggest that involving PPI contributors simultaneously with other 
stakeholder groups may not be the most suitable approach to involvement as it can lead 
PPI contributors to feel undervalued and reluctant to express their opinions. Although 
further research is needed to explore whether this finding can be applied to other 
research contexts, it could potentially be generalizable well beyond randomised 
controlled trials. Patients and members of the public are increasingly being involved in 
health and social care research simultaneously with other stakeholders in the form of 
project steering committees, research advisory boards, community advisory boards etc. 
(9, 30). Therefore, researchers need to pay careful attention to the methods used to 
involve PPI contributors to ensure they are comfortable contributing and are enabled to 
make meaningful contributions to research decisions. This will enable researchers to 
avoid tokenistic involvement and help research funders to judge the appropriateness and 




Secondly, the findings show that PPI contributors can make unique and original 
recommendations that are subsequently incorporated into the intervention 
development process. The findings also show that PPI can potentially improve trial 
retention through a number of different mechanisms. Again, these findings can be 
applied beyond the trial context. Participant follow-up has been identified as a significant 
barrier in longitudinal study designs (290). Researchers conducting longitudinal studies 
or otherwise aiming to follow-up research participants can work together with PPI 
contributors to strengthen these identified mechanisms to ensure successful follow-up.  
 
For researchers that are reluctant to conduct PPI, this evidence on the impact of PPI can 
help to fully understand the benefits of involvement so they can undertake more than 
just a tick-box approach to obtaining grants (16, 42). For researchers already conducting 
PPI, this evidence highlights important opportunities for maximizing PPI impact (14, 16).  
 
For members of the public, Popay et al. states that they will benefit from robust evidence 
on the impact of PPI as they can understand how their contributions make a difference 
(12). However, it is likely that the publication format of this research (peer-reviewed 
publications and academic thesis) will not reach the public domain. Although I made 
some attempts to ensure that evidence on the methods and impact of this thesis were 
available to members of the public, including the podcast series, seminar and blog posts 
presented in Appendix 5, further efforts need to be made to share this robust evidence 
with members of the public and PPI contributors. For example, researchers are 
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increasingly designing and delivering PPI training courses for PPI, incorporating evidence-
based findings into these training courses would better equip contributors to become 
involved and help to establish clear expectations around what involvement can achieve.  
 
7.5 Suggestions for future research 
This research has important implications for how researchers should approach future 
evaluations of the methods and impact of PPI. Table 7.1 outlines the specific 
recommendations for future research from each of the chapters in this thesis. However, 
this research also has broader implications for future research on the methods and 
impact of PPI. The complexities of the context and process of involvement can result in 
researchers thinking that PPI is too controversial or complex to be studied (14). This 
research suggests that nothing is too complex if we use the right methods. The use of 
mixed methods designs in this thesis allowed for an in-depth exploration which resulted 
in a more complete understanding than using qualitative or quantitative methods alone. 
The systematic review and narrative synthesis identified preliminary mechanisms for PPI 
impact that can be further tested to generate more robust evidence of impact. Although 
the results of the embedded randomised trial suggested that PPI did not make a 
difference to participants’ understanding of results, this is not the first embedded 
randomised controlled SWAT to show limited evidence of the impact of PPI. In 2017, 
Cockayne et al. conducted a randomised methodology trial to evaluate the effectiveness 
of optimised patient information sheets on the recruitment of participants in a falls  
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Table 7.1: Suggestions for future research from each chapter  
Chapter 
# 
Finding / Limitation Suggestions for future research 
Chapter 
3 
Involving people with diabetes and 
HCPs simultaneously in a 
consensus process was not found 
to be as suitable as involving each 
stakeholder group separately. 
 
Given the wide range and complex 
nature of factors that could have 
influenced this finding, future 
research should explore stakeholders’ 
experiences and group dynamics in 
other participatory research contexts.  
The questionnaire used to 
evaluate participants’ experiences 
was not validated. 
The questionnaire can be easily 
adapted for use in other research 
contexts. Future research using the 
questionnaire would allow for 




Involving people with diabetes and 
HCPs simultaneously in a 
consensus process was not found 
to be as useful as involving each 
stakeholder group separately. 
Future research should examine the 
contributions of different 
stakeholders in other research 
settings to determine whether this 
finding can be generalisable beyond 
the context of this study.  
Practice administrators were 
identified as playing a key role for 
the successful implementation of 
the intervention. 
Future primary care research needs to 
involve practice administrators to 




Several mechanisms were 
identified, through which PPI could 
potentially improve trial retention.  
 
Future embedded randomised trials 
could compare the involvement of PPI 
contributors in making decisions 
about the mechanisms identified in 
this study (intervention) to standard 
trial conduct (control) on trial 
retention (outcome). Such 
quantitative evaluations could be 
enhanced using qualitative methods 




Participants in this study were 
aged 65 and over. The layout, 
format and language of this 
patient-based approach which was 
identified and developed may only 
be relevant for this study 
population. 
Further research is needed to explore 
patient preferences of receiving trial 
results amongst different study 
populations. 
 
PPI partners were not involved the 
design of the study.  
Future research evaluating the impact 
of PPI in trials could involve PPI 
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partners in the development of core 
outcome sets for evaluating PPI 
impact. These would help to ensure 
that the research questions being 
asked are of importance to both trial 
researchers and trial participants.  
Exploratory factor analysis of the 
patient understanding 
questionnaire provided some 
evidence that the questionnaire is 
a useful tool for measuring patient 
understanding of trial results. 
The developed questionnaire can be 
easily tailored for use in other trials in 
future examinations of patients’ 
understanding of trial results. This 
would provide insight into patient 
understanding and provide further 
validation data. 
 
prevention trial  which similarly showed PPI to have no effect (202). While it is plausible 
that PPI did not have an effect, there is also a possibility that purely quantitative 
approaches to evaluate the impact of PPI that do not incorporate contextual factors and 
the specific mechanisms by which PPI has an impact into their design may weaken the 
evidence of impact or produce no evidence of impact (66). Future quantitative methods 
to evaluate the impact of PPI should be enhanced with qualitative methods to ensure 
that contextual factors and specific mechanisms for impact/ no impact are considered 
which would result in a deeper understanding (291). For example, this research 
identified building trust as a potential mechanism for PPI to have a positive impact on 
trial retention. Future embedded randomised trials could measure this impact by using 
a quantitative validated instrument to measure participants’ trust and conduct 
qualitative interviews with trial participants to further explore whether actions taken as 
a result of PPI input had an influence on their trust levels. Furthermore, realist evaluation 
is one of several theory-based approaches to evaluation developed within the social 
sciences, which seeks to address dynamism and context, rather than control for them, 
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to explain what works for whom in which circumstances (292). As the findings of this 
research highlight the interplay between the context, process and outcomes of PPI, 
further evaluations of PPI methods and impact could also adopt a realist approach. 
7.6 Reflection on PPI during the COVID-19 outbreak 
Just like our lives, our deaths should not be defined by our health conditions. 
Written on 25th March, 2020. 
444 confirmed cases of COVID 19 on the island of Ireland. 
16 people have died as a result of the virus. 
As a PhD student, I have spent the last 3 years looking at ways to involve more patients 
and members of the public in the health research process. I have worked on a number 
of different research projects aiming to create and facilitate equal partnerships between 
researchers, healthcare professionals and patients/ members of the public. I have spent 
this time finding ways for everyone’s voices to be heard and bridging the gaps between 
the people who live with health conditions and the researchers and healthcare 
professionals who aim to help them. From these experiences, I have learnt that Patient 
and Public Involvement (PPI) can democratize the research process and lead to real 
insights that have the potential to improve the quality, relevance, and accessibility of 
health research to the wider public. 
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One thing I have learnt during this time is the importance of language. If we really want 
to work together to achieve common objectives, we need to use the right language. A 
language that is accepted and understood by all partners involved in the process and a 
language that does not stigmatize. Language is perhaps the most valuable tool we have 
as humans. It is important in not only conveying our meaning, but also as an instrument 
of positive change.  
Working with people with diabetes, for example, I have learned to refer to them as 
‘people with diabetes’ and not ‘patients’ or ‘service-users’. They may visit a doctor or 
‘use’ a service for a few hours each year and so they rightly argue that this should not 
define who they are. The term ‘diabetic’ has also been dissipated, again their lives should 
not be defined or labelled by a health condition 
Using language that is inclusive and values-based can lower anxiety, build confidence, 
educate, and empower. Poor communication can be stigmatising, hurtful and 
disempower. To put it simply, language can be unifying or divisive. Our terminology and 
tone are vital when trying to level the power dynamic and bring everyone together to 
work on a common goal.   
Throughout this difficult and unprecedented time, it has been so uplifting to see 
members of the public, healthcare professionals, politicians etc. rally together to achieve 
a common cause. To fight the COVID-19 virus. Today’s trending hashtags on Twitter 
include #wearewithyou, #proudtobeirish, #weareinthistogether and #weshallovercome. 
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But if you look closely enough, you can find traces of language which does not have the 
same unifying effects. Each day, the number of deaths due to COVID-19 are reported on 
followed by the same three words- ‘underlying health condition’. Every time I hear these 
three words, I ask myself why are they necessary? What is their purpose?  
To inform us? So that we can evaluate the potential risk? If the intention is to inform 
then a mere three words do not give us enough information. What underlying health 
conditions? How severe were they? Would they have died if they hadn’t contracted 
COVID-19? If the information is intended to inform then it could be presented in a more 
informed way. Perhaps, a separate statement could be issued which lists each health 
condition and the percentage of those that have died with each condition. 
Of course, it is likely to be the case that some people are more at risk of developing 
serious complications from the virus than others but sweeping statements that imply 
that all ‘underlying health conditions’ carry the same risk do not inform us nor allow us 
to evaluate our own risk or the risk to those we care about.  
Nor do they unite us. These three words are powerful enough to divide the population 
into two groups. Those with an underlying condition that can live in dread of what may 
happen to them if they get the virus. And those without an underlying condition that can 
bask in their increased sense of security. In reality, we are all at risk, whether we have an 
underlying condition or not. For every death that has occurred as a result of COVID-19, 
there is a lot more than an ‘underlying health condition’ lost, there are families, friends, 
neighbours and colleagues that have been deeply affected. 
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In a country that is spectacularly working together, we need to get rid of these kinds of 
daily utterances that tease us apart. Some of us may have an underlying health condition 
and some of us do not. It doesn’t mean that certain people’s lives are more expendable 
or that their right time to die is any nearer or further away.  
7.7 Reflection on the INVOLVE definition of PPI  
Throughout the course of this research, I adopted the INVOLVE definition of PPI. 
INVOLVE defines PPI as ‘research being carried out ‘with’ or ‘by’ members of the public 
rather than ‘to’, ‘about’ or ‘for’ them’ (1). This definition was integral to my research 
because although PPI is currently somewhat of a ‘buzz’ term in the health research 
community, there is still some confusion around what PPI is (and what it is not!). So, 
whether I was writing an abstract or manuscript draft, or speaking at conferences or 
educational seminars, my opening line was always the INVOLVE definition. The INVOLVE 
definition is everything we want PPI to be -broad ranging, inclusive, non-offensive. Even 
the use of the phrase ‘rather than’ instead of ‘as opposed to’ results in a more friendly 
and non-confrontational tone. I repeated the definition over and over again. I liked 
saying it and I always felt that people liked reading and hearing it.  
To me, the INVOLVE definition successfully conveys the culture and ethos of PPI. But as 
I progressed through this PhD research, I started seeing the INVOLVE definition as more 
of an ‘umbrella’ definition for PPI. Its broad ranging and inclusive nature meant that it 
lacked specificity. This was useful at times as it allowed me to explore the methods and 
impact of a wide variety of involvement approaches and methods, including once-off 
involvement in Chapters 3 and 4, participatory approaches in Chapter 5 and task-specific 
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involvement in Chapter 6. But casting such a wide net also caused problems. For 
example, while conducting the search for the systematic review in Chapter 5, 18,453 
articles were identified for title and abstract screening. This felt like a never-ending 
process. Adopting a broad definition of PPI also shaped the implications of the findings 
in this thesis. My research shows that the context and nature of involvement can have 
important implications for its impact but I cannot definitively say ‘this type of 
involvement leads to this type of impact’.  
And so, each time I repeated the INVOLVE definition, I became more aware that I also 
needed to provide some specificity. I followed the definition with information on the 
different levels or approaches to involvement. I wrote/ spoke about Arnsteins’ seminal 
ladder of involvement (33) which has been recently refined by Boote, Telford and Cooper 
(7). I wrote/ spoke about what PPI looks like at different stages of the research process. 
I always highlighted the importance of involvement principles such as respect, support, 
transparency, responsiveness, diversity, and accountability; all of which are discussed in 
detail in the background chapter of this thesis. This additional information was given with 
the aim of creating a clearer picture of what PPI looks like in practice and enabling myself 
and other researchers to expand beyond the definition to successfully operationalise and 
evaluate PPI activities.  
 
7.8 Conclusion  
This research shows that although there are a wide variety of methods used to involve 
PPI contributors, the method used can have an important influence on the impact of 
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involvement. The results suggest that it may be more suitable and useful to involve PPI 
contributors separately rather than simultaneously with other stakeholder groups. This 
finding may assist researchers and PPI contributors in designing and conducting more 
meaningful and effective involvement activities. This research found that PPI can 
influence the research process by creating and fostering trust between researchers and 
participants and PPI contributors can help researchers to communicate more effectively 
with research participants. Although, the results suggest that PPI did not make a 
difference to participants’ understanding of results, suggestions for how researchers 
should approach future evaluations of the methods and impact of PPI have been put 
forward. This research paves the way forward for building an evidence base for PPI to 
ensure that a shared understanding of what works, when, how and why is developed 
among researchers, patients, members of the public and research funders.  
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Appendix 1- Supplementary Data for Chapter 3 




Appendix 1.2: PPI recruitment strategies  
The information flyer was distributed over an 8-week period from 11/08/18 – 11/10/18. 
The strategies used to circulate the flyer included social marketing (e.g. social media), 
community outreach (e.g. community and religious groups), health system (e.g. GP 
practices and hospital waiting rooms), and partnering with community and advocacy 
organisations (e.g. national organisations and educational institutions). 
Recruitment 
strategy 









‘Diabetes in Ireland’ 
Facebook support 
group) to post the 
information flyer on 
Facebook and 
twitter.  








We posted the 
information flyer on 
our research team 
twitter page 
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information flyer to 
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them to advertise on 
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Appendix 1.3: PPI Recruitment Survey Results 
Table A 1.3: PPI Recruitment Survey Results   
Variable  Total 
(N=20) 
% 
Age   
    25-44 5 25 
    45-64 9 45 
    65-84 6 30 
Gender   
    Female 12 60 
    Male  8 40 
Location   
    Urban 14 70 
    Rural  6 30 
Healthcare cover   
    Full Medical Card  7 35 
    GP Visit Card 1 5 
    Private Health Insurance 13 65 
Nationality and Ethnicity   
    White Irish  20  100 
Education*   
    Junior Certificate/ Intercert 1 5.3 
    Apprenticeship 3 15.8 
    Leaving Certificate 5 26.3 
    Diploma 2 10.5 
    Undergraduate Degree 4 21.1 
    Master’s Degree 2 10.5 
    Doctorate 2 10.5 
Marital status*   
    Single 2 10.5 
    Married 14 73.7 
    Separated 1 5.3 
    Widowed 2 10.5 
Diabetes   
    Type 1 10 50 
    Type 2 9 45 
    No diabetes 1 5 
Diabetes diagnosis*   
    < 12 months 4 21.1 
    1-5 years  8 42.1 
    5-10 years 1 5.3 
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    10+ years 6 31.6 
Research Experience   
    Previous participation in research  6 30 
    Previous involvement in research  3 15 
Diabetes support and education experience   
     Previous attendance at diabetes support group 16 80 
     Previous attendance at diabetes education session 9  45 
Diabetic Retinopathy Screening   
    Familiar with term ‘diabetic retinopathy screening’ 19 95 
    Attended diabetic retinopathy screening* 18 94.7 
    Attended screening at hospital** 3 16.7 
    Attended screening at RetinaScreen provider** 11 61.1 
    Attended screening at local optician** 4 22.2 
Other health conditions   
    Heart Disease  7 35 
    Asthma 2 10 
    Arthritis 4 20 
    Any emotional or psychiatric problems (such as 
depression or anxiety) 
2 10 
    Stomach ulcers 1 5 
Attitude to medical appointments   







Appendix 1.4: Experience Questionnaire  
A 1.4.1. Additional Information on questionnaire development  
Existing validated measures that were deemed unsuitable included questionnaires that 
measured group dynamics in workplace and organizational settings where participants 
worked together on an on-going basis (1-3). and a questionnaire that measured 
participants’ experiences of being a research subject (as opposed to being actively 
involved in a participatory research process) (4). Therefore, we developed our own 
questionnaire based on sample items from a non-validated survey instrument published 
by Schulz et al. (5). These questionnaire items were deemed suitable for our research 
objective and context as they were developed to evaluate individual experiences of 
group dynamics and short-term measures of partnership effectiveness within 
community-based participatory research partnerships. Schulz et al. provided 90 sample 
questionnaire items arranged into 15 categories were developed based on a review of 
the group dynamics literature, previous instruments (where available) and extensive 
input from community stakeholders involved in three separate participatory research 
partnerships. The sample questionnaire items were designed to be used selectively 
based on their relevance to the topics being evaluated and not combined together as 
one single instrument. As there were some overlap between items and some items were 
not relevant to our study objective, we selected 11 items from seven categories. This 
helped to ensure the questionnaire was relatively short and straightforward to complete 
at the end of the two-hour consensus meetings (6). Categories included were: (1) 
comfort level for expressing opinions: communication, (2) level of influence and power 
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of self and others in the group, (3) perceived level of trust, (4) personal, organizational 
and community benefits of participation, (5) sense of ownership/ belonging to the group: 
cohesion, (6) group empowerment and (7) community empowerment. Categories 
excluded were: (1) Leadership and participation, (2) How well the group recognizes and 
addresses conflicts and problems, (3) Decision-making procedures, (4) Problem solving 
processes, (5) Meeting organisation, agenda setting, facilitation and staffing, (6) 
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A 1.4.2 Experience questionnaire   
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Appendix 1.5: Observation Guide and Grid 









































































Appendix 2- Supplementary Data for Chapter 4 

























































Appendix 2.5 Results of self-completion survey of intervention components  


















1 Provide a personal story from someone 
else with diabetes who is a similar age and 
profile to them and explains how 
screening was a way for them to take 
charge of their health 
People with diabetes 0 1 (10%) 9 (90%) 10 (100%) 0 3 (33.3%) 6 (66.7%) 9 (100%) * 
Combined  1 (9.1%) 1 (9.1%) 9 (81.8%) 11 (100%) 1 (9.1%) 1 (9.1%) 9 (81.8%) 11 (100%) 
HCP 1 (16.7%) 1 (16.7%) 4 (66.7%) 6 (100%) 1 (16.7%) 0 5 (83.3%) 6 (100%) 
Did not attend 0 1 (50%) 1 (50%) 2 (100%) 0 1 (50%) 1 (50%) 2 (100%) 
Total 2 (6.9%) 4 (13.8%) 23 (79.3%) 29 (100%) 2 (7.1%) 5 (17.9%) 21 (75%) 28 (100%) 
2 Provide a personal story from someone 
else with diabetes who has retinopathy 
and tells them about the benefits of 
screening (e.g. reassured all is ok, 
treatment stops things getting worse) * 
People with diabetes  0 0 10 (100%) 10 (100%) 0 0 9 (100%) 9 (100%) * 
Combined  0 1 (9.1%) 10 (90.9%) 11 (100%) 1 (9.1%) 1 (9.1%) 9 (81.8%) 11 (100%) 
HCP  0 1 (16.7%) 5 (83.3%) 6 (100%) 0 1 (16.7%) 5 (83.3%) 6 (100%) 
Did not attend  0 0 2 (100%) 2 (100%) 0 1 (50%) 1 (50%) 2 (100%) 
Total 0 2 (6.9%) 27 (93.1%) 29 (100%) 1 (3.6%) 3 (10.7%) 24 (85.7%) 28 (100%) 
3 Provide a personal story from someone 
else with diabetes who has retinopathy 
and tells them it is important to go to 
screening before it is too late, there may 
be no symptoms and everyone with 
diabetes is at risk* 
People with diabetes  0  0 10 (100%) 10 (100%) 0 2 (22.2%) 7 (77.8%) 9 (100%) * 
Combined* 0 2 (18.2%) 9 (81.8%) 11 (100%) 1 (9.1%) 2 (18.2%) 8 (72.7%) 11 (100%) 
HCP  1 (16.7%) 0 5 (83.3%) 6 (100%) 2 (33.3%) 0  4 (66.7%) 6 (100%) 
Did not attend 0 0 2 (200%) 2 (100%) 0 0 2 (100%) 2 (100%) 
Total  1 (3.4%) 2 (6.9%) 26 (89.7%) 29 (100%) 3 (10.7%) 4 (14.3%) 21 (75%) 28 (100% 
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4 Provide a personal story from someone 
else with diabetes who wishes they went 
to screening sooner who prompts the 
person to think about the regret they will 
feel if they do not attend screening* 
People with diabetes 0 2 (20%) 8 (80%) 10 (100%) 0 3 (33.3%) 6 (66.7%) 9 (100%) * 
Combined 2 (18.2%) 3 (27.3%) 6 (54.5%) 11 (100%) 1 (9.1%) 2 (18.2%) 8 (72.7%) 11 (100%) 
HCP 2 (33.3) 1 (16.7%) 3 (50%) 6 (100%) 3 (50%) 1 (16.7%) 2 (33.3%) 6 (100%) 
Did not attend 0 0 2 (100%) 2 (100%) 0 0 2 (100% 2 (100%) 
Total  4 (13.8%) 6 (20.7%) 19 (65.5%) 29 (100%) 4 (14.3%) 6 (21.4%) 18 (64.3%) 28 (100%) 
5 Provide a personal story from someone 
else with diabetes who explains there is 
no harm from drops used 
during screening and the overall benefits 
outweigh the short-term discomfort 
People with diabetes  0 0 10 (100%) 10 (100%) 1 (11.1%) 1 (11.1%) 7 (77.8%) 9 (100%) * 
Combined  1 (9.1%) 2 (18.2%) 8 (72.7%) 11 (100%) 1 (9.1%) 1 (9.1%) 9 (81.8%) 11 (100%) 
HCP  1 (16.7%) 0 5 (83.3%) 6 (100%) 1 (16.7%) 0 5 (83.3%) 6 (100%) 
Did not attend 0 0 2 (100%) 2 (100%) 0 1 (50%) 1 (50%) 2 (100%) 
Total 2 (6.9% 2 (6.9%) 25 (86.2%) 29 (100%) 3 (10.7%) 3 (10.7%) 22 (78.6%) 28 (100%) 
6 Provide a personal story from someone 
else with diabetes who provides an 
observable example that shows them how 
to consent or attend* 
People with diabetes 
only 
0 2 (20%) 8 (80%) 10 (100%) 0 3 (33.3%) 6 (66.7%) 9 (100%) * 
Combined 1 (9.1%) 3 (27.3%) 7 (63.6%) 11 (100%) 1 (9.1%) 4 (36.4%) 6 (54.5%) 11 (100%) 
HCP 1 (16.7%) 0 5 (83.3%) 6 (100%) 1 (16.7%) 1 (16.7%) 4 (66.7%) 6 (100%) 
Did not attend 0 0 2 (100%) 2 (100%) 0 1 (50%) 1 (50%) 2 (100%) 
Total 2 (6.9%) 5 (17.2%) 22 (75.9%) 29 (100%) 2 (7.1%) 9 (32.1%) 17 (60.7%) 28 (100%) 
7 Provide a personal story from someone 
else with diabetes who delivers a message 
recognising the anxiety people might feel 
but emphasizes the positive consequences 
of attending* 
People with diabetes 0 0 10 (10%) 10 (10% 0 2 (22.2%) 7 (77.8%) 9 (100%) * 
Combined 0 3 (27.3%) 8 (72.7%) 11 (100% 1 (9.1%) 4 (36.4%) 6 (54.5%) 11 (100%) 
HCP 0 0 6 (100%) 6 (100%) 0 1 (16.7%) 5 (83.3%) 6 (100%) 
Did not attend 0 0 2 (100%) 2 (100%) 0  1 (50%) 1 (50%) 2 (100%) 
Total 0 3 (10.3%) 26 (89.7%) 29 (100%) 1 (3.6%) 8 (28.6%) 19 (67.9%) 28 (100%) 
8 Provide a personal story from someone 
else with diabetes who prompts the 
People with diabetes  2 (10%) 8 (80%) 0 10 (100%) 0 4 (44.4%) 5 (55.6%) 9 (100%) * 
Combined 3 (27.3%) 8 (72.7%) 0 11 (100%) 2 (18.2%) 1 (9.1%) 8 (72.7%) 11 (100%) 
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person to imagine the outcomes of 
attending vs. not attending (knowing all is 
ok, treatment available vs. not knowing, 
they could have eye damage) * 
HCP 3 (50%) 3 (50%) 0 6 (100%) 1 (16.7%) 2 (33.3%) 3 (50%) 6 (100%) 
Did not attend 0 2 (100%) 0 2 (100%) 0 1 (50%) 1 (50%) 2 (100%) 
Total 8 (27.6%) 21 (72.4%) 0 29 (100%) 3 (10.7%) 8 (28.6%) 17 (60.7%) 28 (100%) 
9 Someone in the practice could encourage 
the person to attend screening* 
People with diabetes 0 0 10 (100%) 10 (100%) 0 1 (11.1%) 8 (88.9%) 9 (100%) * 
Combined 1 (9.1%) 0 10 (90.9%) 11 (100%) 2 (18.2%) 1 (9.1%) 8 (72.7%) 11 (100%) 
HCP 0 0  6 (100%) 6 (100%) 0 0 6 (100%) 6 (100%) 
Did not attend  0 0 2 (100%) 2 (100%) 0 0 2 (100%) 2 (100%) 
Total 1 (3.4%) 0 28 (96.6%) 29 (100%) 2 (7.1%) 2 (7.1%) 24 (85.7%) 28 (100%) 
10 Someone in the practice could tell the 
person that they approve of screening and 
hope the person will attend* 
People with diabetes 
only 
0 0 10 (100%) 10 (100%) 0 0 9 (100%) 9 (100%) * 
Combined 2 (18.2%) 0 9 (81.8%) 11 (100%) 1 (9.1%) 2 (18.2%) 8 (72.7%) 11 (100%) 
HCP 0 0 6 (100%) 6 (100%) 0 0 6 (100%) 6 (100%) 
Did not attend  0 0 2 (100%) 2 (100%) 0 0 2 (100%) 2 (100%) 
Total 2 (6.9%) 0 27 (93.1%) 29 (100%) 1 (3.6%) 2 (7.1%) 25 (89.3%) 28 (100%) 
11 Someone in the practice could persuade 
the person they will be able to attend 
screening (e.g. help them to think about 
times they successfully managed their 
diabetes or attended appointments) 
People with diabetes  0 2 (20%) 8 (80%) 10 (100%) 0 3 (33.3%) 6 (100%) 9 (100%) * 
Combined  1 (9.1%) 2 (18.2%) 8 (72.7%) 11 (100%) 2 (18.2%) 3 (27.3%) 6 (54.4%) 11 (100%) 
HCP  0 3 (50% 3 (50%) 6 (100%) 0  3 (50%) 3 (50%) 6 (100%) 
Did not attend 0 0 2 (100%) 2 (100%) 0 0 2 (100%) 2 (100%) 
Total 1 (3.4%) 7 (24.1%) 21 (72.4%) 29 (100%) 2 (7.1%) 9 (32.1%) 17 (60.7%) 28 (100%) 
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12 Someone in the practice could send or 
give a take-home reminder to the person 
to consent and attend their screening 
appointment* 
People with diabetes 
only 
0 1 (10%) 9 (90%) 10 (100%) 0 1 (11.1%) 8 (88.9%) 9 (100%) * 
Combined 0 1 (9.1%) 10 (90.9%) 11 (100%) 1 (9.1%) 0  10 (90.9%) 11 (100%) 
HCP 0 0 6 (100%) 6 (100%) 1 (16.7%) 0 5 (83.3%) 6 (100%) 
Did not attend 0 1 (50%) 1 (50%) 2 (100%) 1 (50%) 1 (50%) 0 2 (100%) 
Total 0 3 (10.3%) 26 (89.7%) 29 (100%) 3 (10.7%) 2 (7.1%) 23 (82.1%) 28 (100%) 
13 Someone in the practice could explain the 
difference between routine eye checks 
and the screening test, what both tests 
can and cannot tell them, and that routine 
checks are not a substitute 
People with diabetes  0 1 (10%) 9 (90%) 10 (100%) 0 2 (22.2%) 7 (77.8%) 9 (100%) * 
Combined  1 (9.1%) 0  10 (90.9%) 11 (100%) 1 (9.1%) 2 (18.2%) 8 (72.7%) 11 (100%) 
HCP  0 0 6 (100%) 6 (100%) 0 0 6 (100%) 6 (100%) 
Did not attend 0 0 2 (100%) 2 (100%) 0 0 2 (100%) 2 (100%) 
Total 1 (3.4%) 1 (3.4%) 27 (93.1%) 29 (100%) 1 (3.6%) 4 (14.3%) 23 (82.1%) 28 (100%) 
14 Someone in the practice could explain 
there is no harm from drops used during 
screening and the overall benefits 
outweigh the short-term discomfort* 
People with diabetes 
only 
0 0 10 (100%) 10 (100%) 0 0 9 (100%) 9 (100%) * 
Combined 1 (9.1%) 2 (18.2%) 8 (72.7%) 11 (100%) 2 (18.2%) 3 (27.3%) 6 (54.5%) 11 (100%) 
HCP 0 0 6 (100%) 6 (100%) 0 0 6 (100%) 6 (100%) 
Did not attend  0 0 2 (100%) 2 (100%) 0 0 2 (100%) 2 (100%) 
Total 1 (3.4%) 2 (6.9%) 26 (89.7%) 29 (100%) 2 (7.1%) 3 (10.7%) 23 (82.1%) 28 (100%) 
15 Someone in the practice could advise the 
person how to consent to screening and 
to ask for help if they are unable/unsure 
about how to do this 
People with diabetes 0  0 10 (100%) 10 (100%) 0 0 9 (100%) 9 (100%) * 
Combined 1 (9.1%) 0 10 (90.9%) 11 (100%) 2 (18.2%) 0  9 (81.8%) 11 (100%) 
HCP 0 0 6 (100%) 6 (100%) 1 (16.7%) 1 (16.7%) 4 (66.7%) 6 (100%) 
Did not attend 0 0 2 (100%) 2 (100%) 0 0 2 (100%) 2 (100%) 
Total 1 (3.4%) 0 28 (96.6%) 29 (100%) 3 (10.7%) 1 (3.6%) 24 (85.7%) 28 (100%) 
16 People with diabetes  0 0 10 (100%) 10 (100%) 0 1 (11.1%) 8 (88.9%) 9 (100%) * 
259 
 
Someone in the practice could tell the 
person that after their appointment they 
will be reassured, or they can get treated 
in time to stop things getting worse 
Combined  0 0 11 (100%) 11 (100%) 1 (9.1%) 0 10 (90.9%) 11 (100%) 
HCP  0 1 (16.7%) 5 (83.3%) 6 (100%) 0 2 (33.3%) 4 (66.7%) 6 (100%) 
Did not attend  0 0 2 (100%) 2 (100%) 0 0 2 (100%) 2 (100%) 
Total  1 (3.4%) 28 (96.6%) 29 (100%) 1 (3.6%) 3 (10.7%) 24 (85.7%) 28 (100%) 
17 Someone in the practice could explain 
how it’s important to go to screening 
before it is too late, they personally are at 
risk and that screening applies to them* 
 
People with diabetes 
only 
0 0 10 (100%) 10 (100%) 0 0 9 (100%) 9 (100%) * 
Combined 0 1 (9.1%) 10 (90.9%) 11 (100%) 1 (9.1%) 2 (18.2%) 8 (72.7%) 11 (100%) 
HCP 1 (16.7%) 0 5 (83.3%) 6 (100%) 1 (16.7%) 0 5 (83.3%) 6 (100%) 
Did not attend  0 0 2 (100%) 2 (100%) 0 0 2 (100%) 2 (100%) 
Total 1 (3.4%) 1 (3.4%) 27 (93.1%) 29 (100%) 2 (7.1%) 2 (7.1%) 24 (85.7%) 28 (100%) 
18 Someone in the practice could encourage 
the person to think of screening not as 
something extra, but as part of the whole 
package of self-management* 
People with diabetes 0 0 9 (100%) 9 (100%) * 0 0 8 (100%) 8 (100%) * 
Combined 0 1 (9.1%) 10 (100%) 11 (100%) 1 (9.1%) 2 (18.2%) 8 (72.7%) 11 (100%) 
HCP 0 0 6 (100%) 6 (100%) 0  1 (16.7%) 5 (83.3%) 6 (100%) 
Did not attend  0 0 2 (100%) 2 (100%) 0 0 2 (100%) 2 (100%) 
Total 0 1 (3.6%) 27 (96.4%) 28 (100%) 1 (3.7%) 3 (11.1%) 23 (85.2%) 27 (100%) 
19 Someone in the practice could help the 
person to make a plan about when and 
where they will consent and how they will 
attend when they get their appointment 
People with diabetes  0 3 (30%) 7 (70%) 10 (100%) 0 3 (33.3%) 6 (66.7%) 9 (100%) * 
Combined  1 (9.1%) 3 (27.3%) 7 (63.6%) 11 (100%) 3 (27.3%) 5 (45.5%) 3 (27.3%) 11 (100%) 
HCP  0  2 (3.3%) 4 (66.7%) 6 (100%) 1 (16.7%) 0 5 (83.3%) 6 (100%) 
Did not attend 0 0 2 (100%) 2 (100%) 0 0 2 (100%) 2 (100%) 
Total 1 (3.4%) 8 (27.6%) 20 (69.0%) 29 (100%) 4 (14.3%) 8 (28.6%) 16 (57.1%) 28 (100%) 
20 Arrange for support from family/friends 
(e.g. encouragement to consent/attend) 
People with diabetes 
only 
1 (10%) 1 (10%) 8 (80%) 10 (100%) 2 (22.2%) 2 (22.2%) 5 (55.6%) 9 (100%) * 
Combined 2 (18.2%) 2 (18.3%) 7 (63.6%) 11 (100%) 5 (45.5%) 3 (27.3%) 3 (27.3%) 11 (100%) 
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HCP 0 2 (33.3%) 4 (66.7%) 6 (100%) 2 (33.3%) 0  4 (66.7%) 6 (100%) 
Did not attend  0  2 (100%) 0 2 (100%) 0 2 (100%) 0 2 (100%) 
Total 3 (10.3%) 7 (24.1%) 19 (65.5%) 29 (100%) 9 (32.1%) 7 (25%) 12 (42.9%) 28 (100%) 
21 Advise/arrange for practical support from 
family/friends (e.g. identify 
transportation) * 
People with diabetes  0 2 (20%) 8 (80%) 10 (100%) 0 2 (22.2%) 7 (77.8%) 9 (100%) * 
Combined  1 (9.1%) 4 (36.4%) 6 (54.5%) 11 (100%) 6 (54.5%) 2 (18.3%) 3 (27.3%) 11 (100%) 
HCP  2 (33.3%) 0 4 (66.7%) 6 (100%) 2 (33.3%) 2 (33.3%) 2 (33.3%) 6 (100%) 
Did not attend 0 1 (50%) 1 (50%) 2 (100%) 0 2 (100%) 0 2 (100%) 
Total 3 (10.3%) 7 (24.1%) 19 (65.5%) 29 (100%) 8 (28.6%) 8 (28.6%) 12 (42.9%) 28 (100%) 
22 Provide a message from the screening 
service about why they want the person 
to attend (e.g. our priority is to preserve 
your vision) and a reminder the service is 
free- 
People with diabetes 
only 
0 1 (10%) 9 (90%) 10 (100%) 0 1 (11.1%) 8 (88.9%) 9 (100%) * 
Combined 1 (9.1%) 0 10 (90.9%) 11 (100%) 2 (18.2%) 1 (9.1%) 8 (72.7%) 11 (100%) 
HCP 0 0 6 (100%) 6 (100%) 0 0 6 (100%) 6 (100%) 
Did not attend  0 0 2 (100%) 2 (100%) 0 0 2 (100%) 2 (100%) 
Total  1 (3.4%) 1 (3.4%) 27 (93.1%) 29 (100%) 2 (7.1%) 2 (7.1%) 24 (85.7%) 28 (100%) 
23 Draw the person’s attention to the 
number of people like them who have 
attended 
People with diabetes 1 (10%) 4 (10%) 5 (50%) 10 (100%) 2 (22.2%) 2 (22.2%) 5 (55.6%) 9 (100%) * 
Combined 2 (18.3%) 2 (18.2%) 7 (63.6%) 11 (100%) 2 (18.2%) 4 (36.4%) 5 (45.5%) 11 (100%) 
HCP 1 (16.7%) 2 (33.3%) 3 (50%) 6 (100%) 1 (16.7%) 1 (16.7%) 4 (66.7%) 6 (100%) 
Did not attend 0 1 (50%) 1 (50%) 2 (100%) 0 1 (50%) 1 (50%) 2 (100%) 
Total 4 (13.8%) 9 (31%) 16 (55.2%) 29 (100%) 5 (17.9%) 8 (28.6%) 15 (53.6%) 28 (100%) 
24 The person ticks off a checklist when they 
have consented/attended* 
People with diabetes  0 3 (30%) 7 (70%) 10 (100%) 0 3 (33.3%) 6 (66.7%) 9 (100%) * 
Combined  2 (18.2%) 2 (18.2%) 7 (63.6%) 11 (100%) 2 (18.2%) 2 (18.2%) 7 (63.6%) 11 (100%) 
HCP  1 (16.7%) 3 (50%) 3 (50%) 6 (100%) 1 (16.7%) 3 (50%) 2 (33.3%) 6 (100%) 
Did not attend 0  1 (50%) 1 (50%) 2 (100%) 0 1 (50%) 1 (50%) 2 (100%) 
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Total 3 (10.3%) 9 (31%) 17 (58.6%) 29 (100%) 3 (10.7%) 9 (32.1%) 16 (57.1%) 28 (100%) 
25 Provide practice with observable 
example/information on how to check 
and register people with diabetes 
People with diabetes 0 0 10 (100%) 10 (100%) 0 0 9 (100%) 9 (100%) * 
Combined 0 0 11 (100%) 11 (100%) 2 (18.2%) 0 9 (81.8%) 11 (100%) 
HCP 0 0 6 (100%) 6 (100%) 1 (16.7%) 1 (16.7%) 4 (66.7%) 6 (100%) 
Did not attend  0 0 2 (100%) 2 (100%) 0 0 2 (100%) 2 (100%) 
Total 0 0 29 (100%) 29 (100%) 3 (10.7%) 1 (3.6%) 24 (85.7%) 28 (100%) 
26 Prompt practice to check the register 
during consultation and register person if 
necessary (e.g. electronic reminder) * 
People with diabetes 0 0 10 (100%) 10 (100% 0 0 9 (100%) 9 (100%) * 
Combined 1 (9.1%) 0 10 (90.9%) 11 (100%) 2 (18.3%) 2 (18.3%) 7 (63.6%) 11 (100%) 
HCP 1 (16.7%) 1 (16.7%) 4 (66.7%) 6 (100%) 2 (33.3%) 0 4 (66.7%) 6 (100%) 
Did not attend 0 0 2 (100%) 2 (100%) 0 0 2 (100%) 2 (100%) 
Total 2 (6.9%) 1 (3.4%) 26 (89.7%) 29 (100%) 4 (14.3%) 2 (7.1%) 22 (78.6%) 28 (100%) 
27 Prompt practice to encourage the person 
to consent/attend & provide information 
on the benefits 
People with diabetes  0  0 10 (100%) 10 (100%) 0 0 9 (100%) 9 (100%) * 
Combined  1 (9.1%) 0 10 (90.9%) 11 (100%) 1 (9.1%) 3 (27.3%) 7 (63.6%) 11 (100%) 
HCP  0 0 6 (100%) 6 (100%) 0 0 6 (100%) 6 (100%) 
Did not attend 0 0 2 (100%) 2 (100%) 0 0 2 (100%) (100%) 
Total 1 (3.4%) 0 28 (96.6%) 29 (100%) 1 (3.6%) 3 (10.7%) 24 (85.7%) 28 (100%) 
28 Provide a new resource to the practice 
(e.g. researcher checks if person 
registered, consented and/or attended) * 
People with diabetes 
only 
0 2 (22.2%) 7 (77.8%) 9 (100%) * 0  3 (30%) 7 (70%) 10 (100%) 
Combined 1 (10%) 2 (20%) 7 (70%) 10 (100%) * 4 (36.4%) 3 (27.3%) 4 (36.4%) 11 (100%) 
HCP 1 (16.7%) 1 (16.7%) 4 (66.7%) 6 (100%) 1 (16.7%) 1 (16.7%) 4 (66.7%) 6 (100%) 
Did not attend 0  1 (50%) 1 (50%) 2 (100%) 0 1 (50%) 1 (50%) 2 (100%) 
Total 2 (7.4%) 6 (22.2%) 19 (70.4%) 27 (100%) 5 (17.2%) 8 (27.6%) 16 (55.2%) 29 (100%) 
29 People with diabetes  0 2 (20%) 8 (80%) 10 (100%) 0 3 (33.3%) 6 (66.7%) 9 (100%) * 
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Provide checklist of ways to encourage 
consent/attendance 
Combined  1 (9.1%) 2 (18.2%) 8 (72.7%) 11 (100%) 2 (18.2%) 3 (27.3%) 6 (54.5%) 11 (100%) 
HCP  0 2 (33.3%) 4 (66.7%) 6 (100%) 1 (16.7%) 2 (33.3%) 3 (50%) 6 (100%) 
Did not attend  0 0 2 (100%) 2 (100%) 0 0 2 (100% 2 (100%) 
Total 1 (3.4% 6 (20.7%) 22 (75.9%) 29 (100%) 3 (10.7%) 8 (28.6%) 17 (60.7%) 28 (100%) 
30 Establish a way for the practice to monitor 
and record their efforts to promote 
attendance 
People with diabetes 
only 
1 (11.1%) 0 8 (88.9%) 9 (100%)* 0 2 (20%) 8 (80%) 10 (100%) 
Combined 1 (9.1%) 0 10 (90.9%) 11 (100%) 3 (27.3%) 3 (27.3%) 5 (45.5%) 11 (100%) 
HCP 1 (16.7%) 0 5 (83.3%) 6 (100%) 1 (16.7%) 2 (33.3%) 3 (50%) 6 (100%) 
Did not attend  0 0 2 (100%) 2 (100%) 0 0 2 (100%) 2 (100%) 
Total 3 (10.7%) 0 25 (89.3%) 28 (100%) 4 (13.8%) 7 (24.1%) 18 (62.1%) 29 (100%) 
31 Identify someone in the practice to help 
the person to register and consent* 
People with diabetes 0 2 (20%) 8 (80%) 10 (100%) 0 2 (22.2%) 7 (77.8%) 9 (100%) * 
Combined 0 3 (27.3%) 8 (72.7%) 11 (100%) 2 (20%) 3 (30%) 5 (50%) 10 (100%) * 
HCP 1 (16.7%) 1 (16.7%) 4 (66.7%) 6 (100%) 1 (16.7%) 2 (33.3%) 3 (50%) 6 (100%) 
Did not attend 0 0 2 (100%) 2 (100%) 0 0 2 (100%) 2 (100%) 
Total 1 (3.4%) 6 (20.7%) 22 (75.9%) 29 (100%) 3 (11.1%) 7 (25.9%) 17 (63%) 27 (100%) 
32 Tell practices about the benefits to the 
practice when their patients attend (e.g. 
receiving timely results, they have access 
to local service) 
People with diabetes  0 1 (11.1%) 8 (88.9%) 9 (100%) * 0 2 (20%) 8 (80%) 10 (100%) 
Combined  0 2 (18.2%) 9 (81.8%) 11 (100%) 0 3 (27.3%) 8 (72.7%) 11 (100%) 
HCP  0 1 (16.7%) 5 (83.3%) 6 (100%) 0 1 (16.7%) 5 (83.3%) 6 (100%) 
Did not attend 0 1 (50%) 1 (50%) 2 (100%) 0 1 (50%) 1 (50%) 2 (100%) 
Total 0 5 (17.9%) 23 (82.1%) 28 (100%) 0 7 (24.1%) 22 (75.9%) 29 (100%) 
33 Tell practices about consequences when 
their patients do not attend (e.g. eye 
damage, costs of missed appointments) 
People with diabetes 
only 
1 (10%) 2 (20%) 7 (70%) 10 (100%)  0 0 8 (100%) 8 (100%) * 
Combined 2 (18.2%) 2 (18.2%) 7 (63.6%) 11 (100%) 0 3 (27.3%) 8 (72.7%) 11 (100%) 
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HCP 0 1 (16.7%) 5 (83.3%) 6 (100%) 0 2 (33.3%) 4 (66.7%) 6 (100%) 
Did not attend 0 1 (50%) 1 (50%) 2 (100%) 0 1 (50%) 1 (50%) 2 (100%) 
Total 3 (10.3%) 6 (20.7%) 20 (69%) 29 (100%) 0 6 (22.2%) 21 (77.8%) 27 (100%) 
 
34 
Use a personal story from a patient to tell 
practices the benefits and risks to patients 
of attending/not attending* 
People with diabetes 0 2 (20%) 8 (80%) 10 (100%) 0  2 (25%) 6 (75%) 8 (100%) * 
Combined 3 (27.3%) 1 (9.1%) 7 (63.6%) 11 (100%) 1 (9.1%) 3 (27.3%) 7 (63.6%) 11 (100%) 
HCP 2 (33.3%) 1 (16.7%) 3 (50%) 6 (100%) 1 (16.7%) 3 (50%) 2 (33.3%) 6 (100%) 
Did not attend 0 1 (50%) 1 (50%) 2 (100%) 0 1 (50%) 1 (50%) 2 (100%) 
Total 5 (17.2%) 5 (17.2%) 19 (65.5%) 29 (100%) 2 (7.4%) 9 (33.3%) 16 (59.3%) 27 (100%) 
35 Use a personal story from a patient to tell 
practices patients are more likely to 
attend screening if a health professional 
prompts or encourages them to do so* 
People with diabetes 0 1 (10%) 9 (90%) 10 (100%) 0 1 (12.5%) 7 (87.5%) 8 (100%) * 
Combined 2 (18.2%) 1 (91. %) 8 (72.7%) 11 (100%) 1 (9.1%) 2 (18.2%) 8 (72.7%) 11 (100%) 
HCP 0  1 (16.7%) 5 (83.3%) 6 (100%) 0 1 (16.7%) 5 (83.3%) 6 (100%) 
Did not attend  0 0 2 (100%) 2 (100%) 0 0 2 (100%) 2 (100%) 
Total 2 (6.9%) 3 (10.3%) 24 (82.8%) 29 (100%) 1 (3.7%) 4 (14.8%) 22 (81.5%) 27 (100%) 
36 Give practices feedback on number of 
their patients who have not registered, 
consented or attended 
People with diabetes 0 0 10 (100%)  10 (100%) 0 3 (33.3%) 6 (66.7%) 9 (100%) * 
Combined 1 (9.1%) 0 10 (90.9%) 11 (100%) 0 2 (18.2%) 9 (81.8%) 11 (100%) 
HCP 0 0 6 (100%) 6 (100%) 0 0 6 (100%) 6 (100%) 
Did not attend  0 0 2 (100%) 2 (100%) 0 0 2 (100%) 2 (100%) 
Total 1 (3.4%) 0 28 (96.6%) 29 (100%) 0 5 (17.9%) 23 (82.1%) 28 (100%) 
37 Give practices feedback on the differences 
between % attending from their practice 
and other practices 
People with diabetes 0 3 (30%) 7 (70%) 10 (100%) 0 3 (37.5%) 5 (62.5%) 8 (100%) * 
Combined 2 (18.2%) 1 (9.1%) 8 (72.7%) 11 (100%) 0 4 (36.4%) 7 (63.6%) 11 (100%) 
HCP 0  1 (16.7%) 5 (83.3%) 6 (100%) 0 1 (16.7%) 5 (83.3%) 6 (100%) 
Did not attend 0 1 (50%) 1 (50%) 2 (100%) 0 1 (50%) 1 (50%) 2 (100%) 
Total 2 (6.9%) 6 (20.7%) 21 (72.4%) 29 (100%) 0 9 (33.3%) 18 (66.7%) 27 (100%) 
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38 Give practices feedback on national or 
international uptake or targets 
People with diabetes 0 2 (20%) 8 (80%) 10 (100%) 0 0 8 (100%) 8 (100%) * 
Combined 2 (18.2%) 0 9 (81.8%) 11 (100%) 0 2 (18.2%) 9 (81.8%) 11 (100%) 
HCP 0 0 6 (100%) 6 (100%) 0 0 6 (100%) 6 (100%) 
Did not attend  0 1 (50%) 1 (50%) 2 (100%) 0 1 (50%) 1 (50%) 2 (100%) 
Total 2 (6.9%) 3 (10.3%) 24 (82.8%) 29 (100%) 0 3 (11.1%) 24 (88.9%) 27 (100%) 
39 Use a trusted source to deliver feedback 
and messages (e.g. colleague) 
People with diabetes 0 0 9 (100%) 9 (100%) * 0 2 (20%) 8 (80%) 10 (100%) 
Combined 2 (18.2%) 1 (9.1%) 8 (72.7%) 11 (100%) 2 (18.2%) 1 (9.1%) 8 (72.7%) 11 (100%) 
HCP 0 1 (16.7%) 5 (83.3%) 6 (100%) 0 1 (16.7%) 5 (83.3%) 6 (100%) 
Did not attend 0 0 2 (100%) 2 (100%) 0 1 (50%) 1 (50%) 2 (100%) 




Appendix 2.6 Changes made to survey of intervention components following PPI 
feedback 
 
Based on PPI feedback, the following changes were made to the invitation letter: 
• Included a sentence at the start to make it sound less of a ‘chore’- exciting opportunity 
to be involved.  
• Made the meeting date/time and location clearer. 
• Removed any non-essential information and inserted two headings for the two things 
we were asking them to do before the meeting. 









Appendix 2.7 Changes made to invitation letter following PPI feedback  
 
Based on PPI feedback, the following changes were made to the survey of intervention 
components: 
• Changed to ‘yellow questionnaire’. 
• Reduced from 5 pages to 3 pages. 
• Made the instructions clearer and included an example to illustrate how it should be 
filled out.  
• Inserted headings for each section to avoid repetition and make it easier to read.  
• Inserted rating headings (e.g. acceptable and feasible) at the top of each page.  
• Included definitions of the rating headings to make it more understandable.  
• Combined some of the items to make it shorter and easier to complete. 












Appendix 2.8 Facilitator Guide  
The aim of these discussions is to find out the best way to make the acceptable ideas work in 
practice – ‘what would this look like in practice’,  thinking about the mode, who should 
receive or deliver it, and when it should happen. 
 
TURN ON RECORDER (if not already one) 
ASK PEOPLE TO MOVE THEIR PHONES AWAY FROM RECORDER (static on recording) 
 
Group lead: ___________ 
 




Small group discussion 1 
 
Focus: other ideas to encourage person to consent or attend screening 
 
If they focus on one particular way of doing things 
• Why do you think that? 
• If that were not possible what else could be done? 
• What could have the most impact? 
 
Specific prompts [put a tick beside the prompts you use] [√] 
• Using a checklist – how would that work? 
• How to draw people’s attention to people who have attended (face to face, letter, 
leaflet, phone call, text, poster) [  ] 
• Should screening programme should provide message or not [  ] 
• How support would be arranged ‘what would this look like’ – ‘ how would this work?’ [  
] 
 
 What did they decide? Did everyone agree? 




















Small group discussion 2 
 
Focus: messages to be given to patients either by personal story or by practice 
 
If they focus on one particular way of doing things 
• Why do you think that? 
• If that were not possible what else could be done? 
• What could have the most impact? 
 
Specific prompts [put a tick beside the prompts you use] [√] 
• Would this message be best as a personal story or should it come from the practice? [  ]  
• Personal stories 
o who should this person be (i.e. someone who attended or not, someone with 
eye damage or not, someone the same age?) [  ] 
o when should it be delivered? [  ] 
o how (face to face, letter, leaflet, video, text, phone call)? [  ] 
• For messages to be delivered by the practice 
o who should deliver this (GP, practice nurse or someone else?) [  ] 
o when should it be delivered 
o how (face to face, leaflet, letter, text, phone call) [  ] 
 
 
 What did they decide? Did everyone agree? 
Any difference within 
group? 













Small group discussion 3 
 
Focus: encouraging practices staff to make sure patient attends 
 
If they focus on one particular way of doing things 
• Why do you think that? 
• If that were not possible what else could be done? 
• What could have the most impact? 
 
Specific prompts [put a tick beside the prompts you use] [√] 
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• What is the best way to prompt or remind practices (e.g. electronic reminder, 
checklist)? [  ] 
• How should practices monitor and record efforts? [  ]  
o Who should be responsible for this? [  ] 
• If we provide a resource to practices, how would this work? [  ] 
• Who should give messages to practice (researchers or using personal story) [  ] 
o How (face to face, letter, leaflet, phone call) [  ] 
• How should feedback be given to practices:  
o who should it be given to (GP, practice nurse) [  ] 
o how (face to face, letter, email, phone call) [  ] 
o by who (colleague) [  ]  
o how often? [  ] 
o What comparator is best to use [  ] 
 
 What did they decide? Did everyone agree? 
Any difference within 
group? 














Feedback (who receives, who 








Appendix 2.9 Recommendations that were within scope but not included in the 
intervention 
Recommendation Meeting 1 Meeting 2 Meeting 
3 
Reason for exclusion (based on APEASE 
criteria) 
Practice Level Recommendations   
 
Have a chart at 
practice with the % 
numbers they want to 
achieve  
✓ - - This was only put forward by people with 
diabetes in meeting 1, as it is a practice 
level recommendation and it was not 
mentioned by HCPs in meeting 2 or 3, it was 
not incorporated (acceptability). 
Inform practices that 
they can market 
themselves as a 
practice known for 
good diabetes care  
✓ - - Same as above.  
Patient Level Recommendations 
 





✓ ✓ - Not all GP practices have DNS. DNS are not 
employed by HSE (national health service), 
therefore not possible for practice staff to 
ask them to deliver message (practicality, 
equity). 




✓ ✓/ - Wrong individual could access and read text 
messages. Not all patients may own or use 
mobile phones. Not all practices use this 
mode and will have established acceptable 
consent processes (practicality, 
acceptability, safety, equity). 
Email 
 
✓ ✓/ - Not all patients use email and have 
established acceptable consent processes. 
Participants in meeting 2 and 3 agreed 
phone call would work better (practicality, 
equity, safety). 
Poster/ TV ad in GP 
waiting room 
 
- ✓/x ✓/ Not every practice allows posters/ has a tv. 
Participants in meeting 2 and 3 felt that it 
would only reach people that are attending 
anyway (acceptability, equity).  
When should the message be delivered?  
 
Before patient collects 
next prescription  
 
- - ✓ It would not be acceptable to ask practices 
to do this. Screening attendance is 
voluntary, not acceptable to coerce people 
to attend (acceptability). 
What should the message contain? 
 
Personal stories or 
testimonials -would 
need to be tailored to 
be effective 
✓ ✓ ✓ It would be too difficult to tailor personal 
testimonials to suit all age groups, gender 
etc. and target them at individual patients 
(practicality). 
Personal story from 
celebrity 
 
- - ✓ Put forward by participants in meeting 3 
only and not mentioned in meeting 1 and 2.  
It would not be possible to identify a 
suitable celebrity and the resources were 
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not available to cover the costs 
(acceptability, practicality, affordability). 
GP should recommend 
that the patient talks 
to another patient at 
the practice 
✓ - - Put forward by participants in meeting 1 
only and not mentioned in meeting 2 and 3. 
It would be difficult to identify and gain 
consent from another patient at practice. It 
would not be possible to identify suitable 
patients for different age groups, gender 
etc. Also issues re: consent and patient 




HBA1c and retinal 
screening-  
✓ ✓ - The research team felt that this 
recommendation was already captured in 
the intervention by outlining the 
asymptomatic nature of retinopathy and 
outlining the difference between regular 
eye-checks and retinopathy screening.  
Provide a link to 
further information 
 
- - ✓ Only put forward by participants in meeting 
3 and not mentioned in meeting 1 and 2. 
This was deemed not feasible as SMS and 
email were not feasible (see previous).  
Ask patients to attend 
as a favour to the 
practice to get their 
numbers up 
- - ✓ It would not be appropriate to ask practice 
staff to do this and not acceptable to ask all 





Appendix 3- Supplementary Data for Chapter 5 




Search terms  
1 Clinical 
trials 
exp Clinical Trial as Topic/ OR Trial* 926,679 
2 PPI (Consumer* or citizen* or client* or carer* or communit* or lay or patient* or public or service user* or user* or survivor* or 
stakeholder* or famil* or relative* or parent*) N3 (involv* or collaborat* or engag* or partner* or consult* or advis* or 
emancipat* or empower* or advocat* or embed* or represent* or test* or driven) 
 
418,794 
3 PPI exp Participatory research/ or exp Patient Participation/ or community-based or participatory research or consumer 
participation or patient participation or user-tested or participant-developed or consumer-centred or patient-centered 
90,982 
4 PPI 2 OR 3 492,456 
5 Retention exp Patient Dropout/ or exp follow up/ studies or retention or attrition or follow-up or followup or withdr* or adher* or 




Impact* or effect* or adapt* or modif* or chang* or develop* or design* or improv* or worse* or increas* or boost* or 
decreas* or reduc* or differ* or edit* or suggest* or max* or min* 
17, 513, 948 
7  1 and 4 and 5 and 6 9,207 





Search terms  
1 Clinical 
trials 
exp Clinical Trial as Topic/ OR Trial* 2,183,933 
273 
 
2 PPI (Consumer* or citizen* or client* or carer* or communit* or lay or patient* or public or service user* or user* or survivor* or 
stakeholder* or famil* or relative* or parent*) N3 (involv* or collaborat* or engag* or partner* or consult* or advis* or 
emancipat* or empower* or advocat* or embed* or represent* or test* or driven) 
 
2,143 
3 PPI exp Participatory research/ or exp Patient Participation/ or community-based or participatory research or consumer 
participation or patient participation or user-tested or participant-developed or consumer-centred or patient-centered 
50,800 
4 PPI 2 OR 3 52,946 





Impact* or effect* or adapt* or modif* or chang* or develop* or design* or improv* or worse* or increas* or boost* or 
decreas* or reduc* or differ* or edit* or suggest* or max* or min* 
21,830,244 
7  1 and 4 and 5 and 6 2,168 






Search terms  
1 Clinical 
trials 
exp Clinical Trial as Topic/ OR Trial* 784,046 
2 PPI (Consumer* or citizen* or client* or carer* or communit* or lay or patient* or public or service user* or user* or survivor* or 
stakeholder* or famil* or relative* or parent*) N3 (involv* or collaborat* or engag* or partner* or consult* or advis* or 
emancipat* or empower* or advocat* or embed* or represent* or test* or driven) 
 
172 
3 PPI exp Participatory research/ or exp Patient Participation/ or community-based or participatory research or consumer 
participation or patient participation or user-tested or participant-developed or consumer-centred or patient-centered 
20,491 
4 PPI 2 OR 3 20,491 





Impact* or effect* or adapt* or modif* or chang* or develop* or design* or improv* or worse* or increas* or boost* or 
decreas* or reduc* or differ* or edit* or suggest* or max* or min* 
1,251,794 
7  1 and 4 and 5 and 6 5,934 
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Search terms  
1 Clinical 
trials 
exp Clinical Trial as Topic/ OR Trial* 174,373 
2 PPI (Consumer* or citizen* or client* or carer* or communit* or lay or patient* or public or service user* or user* or survivor* or 
stakeholder* or famil* or relative* or parent*) N3 (involv* or collaborat* or engag* or partner* or consult* or advis* or 
emancipat* or empower* or advocat* or embed* or represent* or test* or driven) 
 
147,308 
3 PPI exp Participatory research/ or exp Patient Participation/ or community-based or participatory research or consumer 
participation or patient participation or user-tested or participant-developed or consumer-centred or patient-centered 
41,474 
4 PPI 2 OR 3 180,281 





Impact* or effect* or adapt* or modif* or chang* or develop* or design* or improv* or worse* or increas* or boost* or 
decreas* or reduc* or differ* or edit* or suggest* or max* or min* 
3,685,244 
7  1 and 4 and 5 and 6 2,051 






Search terms  
1 Clinical 
trials 
exp Clinical Trial as Topic/ OR Trial* 414 846 
2 PPI (Consumer* or citizen* or client* or carer* or communit* or lay or patient* or public or service user* or user* or survivor* or 
stakeholder* or famil* or relative* or parent*) N3 (involv* or collaborat* or engag* or partner* or consult* or advis* or 





3 PPI exp Participatory research/ or exp Patient Participation/ or community-based or participatory research or consumer 
participation or patient participation or user-tested or participant-developed or consumer-centred or patient-centered 
51 690 
4 PPI 2 OR 3 378  665 
5 Retention exp Patient Dropout/ or exp follow up/ research subject retention or retention or attrition or follow-up or followup or withdr* or 




Impact* or effect* or adapt* or modif* or chang* or develop* or design* or improv* or worse* or increas* or boost* or 
decreas* or reduc* or differ* or edit* or suggest* or max* or min* 
2 818 954 
7  1 and 4 and 5 and 6 4482 





Appendix 3.2: Data extraction template 
 
 (1) The RCT  
 













Similar to trial 
target 




            
 





Retention Rate  
Overall 




as Link between PPI and retention  
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Appendix 3.3: Enhancing transparency in reporting the synthesis of qualitative 
research: the ENTREQ statement 
No Item Guide and description Reported on page no. 





Identify the synthesis methodology or 
theoretical framework which underpins the 
synthesis, and describe the rationale for 
choice of methodology (e.g. meta-
ethnography, thematic synthesis, critical 
interpretive synthesis, grounded theory 
synthesis, realist synthesis, meta-
aggregation, meta-study, framework 
synthesis). 
6&7 
3 Approach to 
searching 
Indicate whether the search was pre-
planned (comprehensive search strategies to 
seek all available studies) or iterative (to 
seek all available concepts until they 




Specify the inclusion/exclusion criteria (e.g. 
in terms of population, language, year limits, 
type of publication, study type). 
4&5 
5 Data sources Describe the information sources used 
(e.g. electronic databases (MEDLINE, 
EMBASE, CINAHL, psycINFO, Econlit), grey 
literature databases (digital thesis, policy 
reports), relevant organisational websites, 
experts, information specialists, generic web 
searches (Google Scholar) hand searching, 
reference lists) and when the searches 
conducted; provide the rationale for using 





Describe the literature search (e.g. provide 
electronic search strategies with population 
terms, clinical or health topic terms, 
experiential or social phenomena related 
terms, filters for qualitative research, and 
search limits). 




Describe the process of study screening 
and sifting (e.g. title, abstract and full text 
review, number of independent reviewers 




Present the characteristics of the included 
studies (e.g. year of publication, country, 
population, number of participants, data 









Identify the number of studies screened 
and provide reasons for study 
exclusion (e,g, for comprehensive searching, 
provide numbers of studies screened and 
reasons for exclusion indicated in a 
figure/flowchart; for iterative searching 
describe reasons for study exclusion and 
inclusion based on modifications t the 
research question and/or contribution to 
theory development). 
8 
10 Rationale for 
appraisal 
Describe the rationale and approach used 
to appraise the included studies or selected 
findings (e.g. assessment of conduct (validity 
and robustness), assessment of reporting 
(transparency), assessment of content and 




State the tools, frameworks and criteria 
used to appraise the studies or selected 
findings (e.g. Existing tools: CASP, QARI, 
COREQ, Mays and Pope [25]; reviewer 
developed tools; describe the domains 
assessed: research team, study design, data 




Indicate whether the appraisal was 
conducted independently by more than 





Present results of the quality assessment 
and indicate which articles, if any, were 
weighted/excluded based on the 




Indicate which sections of the primary 
studies were analysed and how were the 
data extracted from the primary 
studies? (e.g. all text under the headings 
“results /conclusions” were extracted 
electronically and entered into a computer 
software). 
6&7 
15 Software State the computer software used, if any. n/a 
16 Number of 
reviewers 
Identify who was involved in coding and 
analysis. 
6&7 
17 Coding Describe the process for coding of 





Describe how were comparisons made 




No Item Guide and description Reported on page no. 
studies were coded into pre-existing 
concepts, and new concepts were created 
when deemed necessary). 
19 Derivation of 
themes 
Explain whether the process of deriving the 
themes or constructs was inductive or 
deductive. 
6 
20 Quotations Provide quotations from the primary 
studies to illustrate themes/constructs, and 
identify whether the quotations were 





Present rich, compelling and useful results 
that go beyond a summary of the primary 
studies (e.g. new interpretation, models of 
evidence, conceptual models, analytical 





Appendix 3.4: GRIPP 2 (Short Form) checklist scores 
Study  Aim: Report 
the aim of 








used for PPI 





































those that did 





Adams et al. 2015 
(a)  
✓ ✓ ✓ ✓ ✓ 5 
Adams et al. 2015 
(b)  
✓ ✓ ✓ ✓ ✓ 5 
Angell et al. 2003  ✓ ✓ ✓ ✓ ✓ 5 
Arean et al. 2003 
(a)  
✓ ✓ ✓ ✓ - 4 
Arean et al. 2003 
(b)  
✓ ✓ ✓ ✓ - 4 
Arjadi et al. 2018  ✓ ✓ ✓ - - 3 
Ashton et al. 2017  ✓ ✓ - ✓ - 3 
August et al. 2006  ✓ ✓ - ✓ ✓ 4 
Burlew et al. 2011  ✓ ✓ ✓ - - 3 
Buscemi et al. 
2015  
✓ ✓ ✓ ✓ - 4 
Chacko and 
Scavenius. 2018  
✓ ✓ - ✓ - 3 
Chang et al. 2010  ✓ ✓ ✓ - - 3 
Chhatre et al. 
2018  
✓ ✓ ✓ - - 3 
Chung et al. 2017  ✓ ✓ ✓ ✓ ✓ 5 
Corbie-Smith et 
al. 2003  
✓ ✓ ✓ - - 3 
De Marco et al. 
2012  
✓ ✓ ✓ ✓ - 4 
Edwards et al. 
2011  
✓ ✓ ✓ ✓ ✓ 5 
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Elder et al. 2006  ✓ ✓ ✓ - - 3 
Estreet et al. 2017  ✓ ✓ ✓ ✓ - 4 
Fischer et al. 2017  ✓ ✓ ✓ - - 3 
Foster et al. 2015  ✓ ✓ - ✓ - 3 
Fouad et al. 2014  ✓ ✓ ✓ ✓ ✓ 5 
Gappoo et al. 
2009  
✓ ✓ - ✓ - 3 
Garcia et al 2016 
(a)  
✓ ✓ ✓ ✓ ✓ 5 
Garcia et al 2016 
(b)  
✓ ✓ ✓ ✓ ✓ 5 
Garcia et al 2016 
(c)  
✓ ✓ ✓ ✓ ✓ 5 
Garcia et al 2016 
(d)  
✓ ✓ ✓ ✓ ✓ 5 
Harris et al. 2001  ✓ ✓ ✓ ✓ - 4 
Jeffries et al. 2005  ✓ ✓ - ✓ - 3 
Johnson et al. 
2015  
✓ ✓ ✓ ✓ - 4 
Ka'opua et al. 
2011  
✓ ✓ ✓ ✓ - 4 
Keown et al. 2018  ✓ ✓ - ✓ - 3 
Kogan et al. 2016  ✓ ✓ ✓ ✓ ✓ 5 
Koniak-Griffin et 
al. 2015  
✓ ✓ ✓ ✓ ✓ 4 
Lloyd et al. 2017  ✓ ✓ ✓ ✓ ✓ 5 
Loughery et al. 
2017  
✓ ✓ ✓ ✓ ✓ 5 
McGillicuddy et 
al. 2013  
✓ ✓ ✓ - - 3 
Merriam et al. 
2009  
✓ ✓ ✓ ✓ ✓ 5 
Okely et al. 2011  ✓ ✓ ✓ ✓ - 4 
Rhodes et al. 
2011  
✓ ✓ ✓ - - 3 
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Stineman et al. 
2011  
✓ ✓ ✓ 
 
✓ - 4 
Swartz et al. 2004  ✓ ✓ - ✓ - 3 
Tanjasiri et al. 
2015  
✓ ✓ ✓ - - 3 
Vincent et al. 
2013  
✓ ✓ ✓ ✓ - 4 
Williams et al. 
2007  
✓ ✓ ✓ - - 3 
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Appendix 4- Supplementary Data for Chapter 6 
Appendix 4.1: Focus Group Topic Guide 
Topic Guide 
The objective of this study is to use a public and patient (PPI) strategy to develop a 
preferred method of receiving end-of-trial information for participants who were 
enrolled in the TRUST study. The aim is then to compare the information developed 
through the standard end-of-trail documents developed by the co-ordinating study site 
in Glasgow.  
Thank participants, introduce researcher & study. 
Briefly go through information sheet and consent form. 
Outline general housekeeping rules which will be said to participants at the beginning 
of the focus groups. 
-If it is ok with you, I will audio record this group discussion so I can give you my full 
attention. However, the research assistant will be taking field notes during the 
discussion just to ensure that we don’t miss anything. 
-Everything we discuss will be confidential and your identity will remain anonymous. 
We may use direct quotes from this discussion but your identity and position will be 
kept completely anonymous and your name will not be used on any reports or 
publications.  
-You can choose to withdraw from the discussion at any time. 
-Do you have any questions before we get started? 






Can you each give your first name only 
please? 
-Distribute name tags 
Trial Experience 
How did you first become aware of the 
TRUST study? 
Who told you about it? GP? Other 
healthcare provider? Advertising 
campaign? Other? 
When you first heard about the trial 
what did you think? 
Were you interested in the trial straight 
away? 
Positive/Negative first impression? 
Did you think it would be useful for you? 
 
How was your experience of the TRUST 
Thyroid trial? 
 
Tell me about your initial contact with 
your GP? 
What was it like when you were first 
recruited? 
How did you find the study visits? 
(research team, doctors etc.) Were they 
helpful? 
How do you feel now that the trial has 
ended? 
 
What was your most positive and 
negative experience of the TRUST study? 
 
How do you think this could be improved 
upon? 
In your opinion do you think the 
information you received at study visits 
was informative? 
 
Too much information? Too little? What 
other information would you have liked? 
Did you seek information from other 
sources-GP, internet, other? If so what 
kind of information? 
During the trial, did you think you were 
on the placebo or the active drug? 
If you had a choice at the beginning of 
the trial, which one would you have 
picked? Why? 
Most participants have requested to be 
un-blinded. Why do you think this is? 
Do you think this is important to know? 
How would you feel if no one ever told 
you? 
Result Dissemination 
Do you want to find out the final study 
results? Why? 
 
Do you think this is important? Why? 
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When the final results of the trial are 
known, how would you like to find out? 
By post/telephone contact/email/face to 
face meeting? 
In your opinion do you think study 
participants should be involved in 
formulating information leaflets for 
research studies? 
 
Yes- in what capacity? 
 
No- why not? 
Would you be interested in helping to 
write the information leaflet that we will 
send to all participants about the final 
study results?  
 
Is there anything in particular you would 
like to be included in this leaflet?  
 




Would you have any interest in being 





































Your Understanding of the TRUST Thyroid Trial. 
 




Please read carefully:  
We would like to know if the information we gave you about the TRUST 
Thyroid Trial was useful to you. This questionnaire asks some questions about 
the TRUST Thyroid Trial, levothyroxine and the results of the trial. 
Subject’s Understanding   
• I understand that my participation is voluntary.  
• I understand that I will not be identified by name in the final report.  
• I am aware that all documents will be kept confidential in the secure 
possession of the researcher.  
• I understand that I may withdraw from the study at any with no adverse 
repercussions. 
 
Under the Data Protection Acts 1998 and 2003 you are entitled to make an 
access request for a copy of your personal information relating to this study. If 
you wish to make a request for access to your data, please contact Professor 
Patricia Kearney (021) 4205502 or patricia.kearney@ucc.ie 
If you agree to the above, please sign here:  
Full Name: _____________________________    
    











Appendix 4.6: Costs of Conducting PPI 
Phase   PPI Activity  Description Cost  












Catering costs   90 
Gift vouchers for participants 400 
Printing and Stationary   11.30 




Public and Patient 
Expert Sessions (4 
sessions)  





NALA review  
  
Plain English Editing- PPI 
results letter 
230 
Plain English Review –PPI 














Printing  36.05 
Postage   332 








Appendix 5- Activities undertaken to promote PPI in research. 
Appendix 5.1: ‘LIstening to the Voice of Experience (LIVE)’: A podcast series to 
promote Patient and Public Involvement (PPI) in Research. 
 
Emmy Racine, Samantha Dick, Avril Byrne, Aileen Callanan, Ciaran Dawson, Pawel 
Hursztyn, Anne O’ Leary, Dawn Steacy, John Walsh, Elizabeth Walsh, Sheena McHugh. 
Patricia M. Kearney.  
 
Introduction  
Patient and Public Involvement (PPI) is increasingly recognised as an essential 
component of research. However, lack of public knowledge about research and PPI has 
been identified as a barrier (13, 99). Innovative communication methods are needed to 
raise public awareness and understanding of PPI. 
Aim: To develop and broadcast a podcast series about PPI partners’ experiences of being 
involved in research.  
 
Methods 
We have two PPI groups in the School of Public Health, University College Cork: the IDEAs 
group (5 people with diabetes who contribute to an intervention to Improve Diabetes 
Eye-screening Attendance) and the MiUSE group (10 students who contribute to an 
intervention to reduce substance use in third level students). Podcasts were developed 
as following: 1) Development: Researchers and PPI contributors worked together to 
develop podcast content; 2) Recording: Researchers, contributors and the UCC 98.3fm 
station manager recorded the podcast. Recording equipment was provided by 
UCC98.3fm; 3) Editing: Final editing was carried out by UCC 98.3fm; 4) Launch: A public 
launch event was held in the School of Public Health.  
 
Results 
15 contributors were invited and 7 participated. Two podcasts were developed focusing 
on PPI contributors’ perspectives on the research topics and experiences of being 
involved (see Appendix 5). You can listen to the podcast here: 
https://soundcloud.com/ucc98-3fm/ppi-podcast. The podcast was launched by Dr 
Martin Galvin, UCC Community and Civic Engagement Officer in the School of Public 
Health UCC on the 9/12/19 (see Appendix 5.1). Attendees included PPI contributors, 
school staff, students, and members of the public. The launch was hosted by Emmy 
Racine and included talks from Dr Martin Galvin and Dawn Steacy, a PPI contributor who 
participated in the podcast recording. The podcast has been broadcasted on UCC98.3fm 
(approx. 10,000 listeners each week) and disseminated widely online. 
 
Conclusion 
This podcast, targeting the public, highlights the different aspects of research and the 
diversity of opportunities available for them to become involved. It is an innovative way 
to communicate our PPI activities to the public. The podcast is also a useful teaching 
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resource that can be used to increase researchers’ and students’ awareness of the value 




Appendix 5.2: Photos of podcast recording and podcast launch event. 
 
Photo A5.1 LIVE podcast participants during the recording session 
 
 




Photo A5.3 LIVE Podcast participants attending the public event held at the School of 
Public Health, UCC 
 
Photo A5.4 LIVE Podcast participants attending the public event held at the School of 




Photo A5.5 Dr Martin Galvin, UCC Civic and Community Engagement Officer speaking at 




Appendix 5.3: ‘Patient and Public Involvement (PPI) in research: from tick-box 
tokenism to meaningful involvement’: An educational seminar for 
researchers/academic community at University College Cork. 
 
Introduction 
Patient and Public Involvement (PPI) has received considerable attention in the last two 
decades and has now become a prerequisite for some research funders and academic 
journals. However, the attitudes of academic researchers and the perceived importance 
of PPI have been identified as important barriers (13).  
Aim: To design and deliver an educational seminar on the methods and impact of PPI to 
researchers based at University College Cork.  
 
Methods 
A PowerPoint presentation was developed for the seminar. Slides included information 
on the definition of PPI, stages of the research cycle that PPI can be conducted, the 
rationale for PPI, advice for planning PPI activities and preparing the PPI sections of grant 
applications, a case example of the IDEAs (Improving Diabetes Eye-Screening Attendance 
study) PPI group, guidance for the payment of PPI contributors and examples of the 
impact of PPI. One week before the seminar, an invitation email to advertise the seminar 
was circulated amongst the School of Public Health email list (n=128) and amongst all 
academic staff within the University (n=3202).  
 
Results 
A one-hour seminar was delivered the 27th of November 2019 at the School of Public 
Health, UCC. The slides used during the seminar are available in Appendix A 5.4. Over 40 
people attended the seminar from a variety of University schools including but not 
limited to the School of Public Health, School of Nursing, School of Applied Social Studies, 
Cork University Business School, and the School of Applied Psychology. Slides were 
circulated to attendees after the seminar. Follow-up contact was received from seven 
individuals who attended the seminar. Two of these individuals sought help preparing 
the PPI section of funding applications, two asked for input to their previously planned 
PPI activities, one requested help with facilitating PPI activities, one requested guidance 
on how to incorporate PPI into a doctoral research proposal and one wanted more 




This one-hour seminar was a useful way to educate researchers at University College 
about the methods and impact of PPI. The results show that there is an appetite for 
learning more about PPI amongst researchers at University College Cork. The slides used 

















































Appendix 5.5: ‘Participants’ Perspectives and Preferences on Clinical Trial Result 
Dissemination: The TRUST Thyroid Trial Experience’: A blog post published on the 
SPHeRE blog platform. 




The results of clinical trials are not traditionally disseminated to clinical trial participants. 
While there is a growing awareness that participants should receive study results, little 
is known about the most appropriate methods of doing so. The Thyroid Hormone 
Replacement for Subclinical Hypothyroidism Trial (TRUST) was a multi-centre, double-
blind, randomised, placebo-controlled trial which tested the efficacy of thyroxine 
replacement in subclinical hypothyroidism in older adults (≥65 years). We recently 
conducted A Study Within A Trial (SWAT) which used a Public and Patient Involvement 
(PPI) approach to identify, develop and evaluate a patient-preferred method of receiving 
the results of the TRUST Thyroid Trial. 
 
Using a mixed methods approach, an intervention study was undertaken at the Irish 
TRUST site. The first phase of the study used PPI (focus groups and 1-1 sessions with trial 
participants) to develop a patient-preferred result method. In the second phase, Irish 
TRUST participants (n=101) were randomised into the intervention (PPI method) and 
comparison groups (standard method). In the third phase, participants were sent a 
questionnaire. The primary outcome of the questionnaire was difference in the 
understanding of results between the two groups. 
 
The results from the first phase clearly established that the preferred method of 
receiving results was a postal letter containing a 2-3page summary of the trial, condition, 
treatment and overall aggregated results of the trial. In phase two, the intervention 
group received the PPI method of results and the comparison group received the 
standard method as developed by the lead study site in Glasgow, Scotland. In phase 
three of the study, 67 participants returned a completed questionnaire (response rate 
66%).  The results of the questionnaire showed no difference in patient understanding 
between the intervention and comparison groups. 
 
Little is understood about the impact and effectiveness of PPI in clinical trials.  While this 
study found that PPI has no real impact on patient understanding of trial results, it 
provides empirical evidence on participants’ perspectives and preferences of clinical trial 
result dissemination. It also provides a template for researchers to enhance patient and 
public involvement in their research 
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Appendix 5.6: ‘The Impact of PPI on clinical trials’: A blog post published on the HRB 
Open blog platform.  
 




20th May marks International Clinical Trials Day, a day dedicated to what is believed to 
be the first controlled clinical trial. In 1747, James Lind investigated the link between 
citrus fruits and scurvy using just 12 men on board the HMS Salisbury of Britain’s Royal 
Navy fleet. Over the years, clinical research has advanced, and is vital in helping us cure 
illnesses and to improve our health. So, in recognition of the importance of clinical trials 
and public involvement, we interviewed Emmy Racine, University of Cork, Ireland, to talk 
about her research article, published on HRB Open Research, investigating patient and 
public involvement in clinical trials and how the results should be disseminated. 
 
Why should patients and the public be involved in clinical research? 
There are many ethical, moral and political arguments for involving patients and 
members of the public in clinical research. One such argument is that those affected by 
or paying for research should have a say in how it is done. 
There are also pragmatic arguments being made for Patient and Public Involvement (PPI) 
based on the actual contribution that the public can make to research and its wider 
acceptability. There is some evidence that PPI can improve the quality, efficiency and 
impact of research but we really need stronger evidence on the impact of PPI before we 
can impart these claims. 
 
Why do you think it is important to share trial results? 
I think it is important to share trial results because trial participants invest a lot of time, 
effort and sometimes money (e.g. travel, parking, food expenses) in trials. Not only is it 
important to share trial results with participants but results should be shared in a way 
that is easy to read and understand. 
A recent European Union Clinical Trial Regulation now requires trial sponsors to provide 
summary results of clinical trials to participants in a format understandable to lay people. 
This may sound like an easy thing to do but since the results are interpreted in the 
context of existing scientific evidence and debate, it is often difficult for trial researchers 
to present this information in a simple and straightforward way. 
 
Were patients interested in receiving trial results? 
Yes, I found that trial participants wanted to receive trial results. Many participants 
reported that they felt they had made an individual contribution to the trial in terms of 
their time and personal information and receiving the results of the trial would provide 
acknowledgement of this individual contribution.  
They also believed that their participation contributed to a collective benefit or greater 
good and they wanted to know the results so they could better understand what this 
collective benefit was. They wanted to know how the results of the trial would be put 




How would they like the results to be presented to them?  
Participants were very clear that they wanted to receive the results in a way that was 
accessible and easy to understand. The majority said they would like to receive the 
results in a letter from the trial researchers posted to them directly. Although 
participants wanted an official statement of the results in a letter format, they also felt 
it was important to add a personal element to the letter. 
They suggested offering participants a phone number that they could call if they wished 
to discuss any further issues or concerns with the study team. They were clear that the 
format, content and language of the results letter should be easy to read and 
understand. All participants wanted the letter to be no longer than 2-3 pages and 
presented in a question and answer format. 
They stressed that it was important that the information presented to them was 




As part of my research, I developed a questionnaire to evaluate the impact of PPI on 
patient understanding of trial results. While levels of patient understanding were similar 
between the group that received the results letter developed by the PPI group 
(intervention) and the group that received the information developed by researchers at 
the lead trial site (control), we didn’t have enough people to confirm whether  the PPI 
letter made a difference. However, some additional analysis of the questionnaire 
suggested that it is a useful tool for measuring patient understanding of trial results. 
As the questionnaire can be easily adapted for use in other trials, it would be great to 
see it being used by other trial methodology researchers to add to our results and 




Appendix 6- Research Output and Dissemination 
Table A6.1: Peer-reviewed publications  
Year Peer-reviewed publication 
2020 Racine E, Phillip E, Riordan F, McHugh S and Kearney PM. ‘It just wasn’t 
going to be heard’: A mixed methods study to compare different ways of 
involving people with diabetes and healthcare professionals in health 
intervention research. Health Expectations. 2020; 00: 1-14. doi: 
10.1111/hex.13061. 
2020 Riordan F, Racine E, Smith SM, Murphy A, Browne J, Kearney PM, 
Bradley C, James M, Murphy M and McHugh SM. Feasibility of an 
implementation intervention to increase attendance at diabetic 
retinopathy screening: protocol for a cluster randomised pilot trial. Pilot 
and Feasibility Studies. 2020:6:64. doi: 10.1186/s40814. 
2020 Riordan F, Racine E, Phillip E, Bradley, C, Lorencatto F, Murphy M, 
Murphy A, Browne J, Smith SM, Kearney PM and McHugh S.  
Development of an intervention to facilitate implementation and uptake 
of diabetic retinopathy screening. Implementation Science. 2020. 15:34. 
doi: 10.1186/s13012. 
2020 Racine E, Soya A, Barry, P, Cronin F, Hosford O, Moriarty E, O Connor KA, 
Turvey S, Timmons S, Kearney PM and McHugh SM. ‘I’ve always done 
what I was told by the Medical people’- a qualitative study of the 
reasons why older adults attend multifactorial falls risk assessments 
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mapped to the Theoretical Domains Framework. BMJ Open. 2020; 
10:e033069. doi:10.1136/bmjopen-2019-033069 
2019 Tracey M, Racine E, Riordan F, McHugh S and Kearney PM. 
Understanding the uptake of a national retinopathy screening 
programme: An audit of people with diabetes in two large primary care 
centres. HRB Open. 2019, 2, 17. doi: 10.12688/hrbopenres.12926.3 
2019 Racine E, Hurley C, Cheung A, Sinnott C, Matvienko-Sikar, K, Smithson 
WH, Kearney PM. Participants’ perspectives and preferences on clinical 
trial result dissemination: The TRUST Thyroid Trial experience. HRB 
Open. 2019. 1:14. doi:10.12688/hrbopenres.12817.2 
2018 McHugh S, Sinnott C, Racine E, Timmons S, Byrne M and Kearney PM. 
‘Around the edges’: using behaviour change techniques to characterise a 
multilevel implementation strategy for a fall prevention programme. 
Implementation Science. 2018; 13:113. Doi: 10.1186/s13012-018-0798-6 
2017 Racine E, Hurley C, Cheung A. et al. Study within a trial (SWAT) protocol. 
Participants' perspectives and preferences on clinical trial result 
dissemination: The TRUST Thyroid Trial experience. Contemporary 
Clinical Trials Communications. 2017. 163-165. Doi: 
10.1016/j.conctc.2017.07.001. 
2017 Hurley C, Sinnott C, Clarke M, Kearney PM, Racine E, Eustace J and Shiely 
F. Perceived barriers and facilitators to Risk Based Monitoring in 




2015 Racine E, Chen YW and Collins N. Gone but not forgotten: the (re-






Table A 6.2: Other outputs 
Year Output 
2019 LIstening to the Voice of Experience (LIVE) Podcast. Available to listen:  
https://soundcloud.com/ucc98-3fm/ppi-podcast. 
2019 Public event to launch the LIstening to the Voice of Experience (LIVE) 
Podcast. School of Public Health, University College Cork. 
2019 Lunchtime seminar: ‘‘Patient and Public Involvement (PPI) in research: 
from tick-box tokenism to meaningful involvement’ at the School of 
Public Health, University College Cork. 
2019 Racine E, Cahill D, Sheehan C and Smithson HW. The Studying age 
Friendly Environments (SAFE) Project Report. Report prepared for the 
Age Friendly Alliance (unpublished). 2019. 
2018 HRB Open Blog. The Impact of PPI on clinical trials. Available: 
https://blog.hrbopenresearch.org/2019/05/23/the-impact-of-ppi-on-
clinical-trials/ 
2018 SPHeRE Blog. Participants’ Perspectives and Preferences on Clinical Trial 




2018 Soye A, Racine E and McHugh S.  Report Title. Report prepared for the 







Table A 6.3. Conference presentations during PhD 
Year  Title   Conference  
2019 LIstening to the Voice of 
Experience (LIVE): A podcast 
series to promote Patient and 
Public Involvement (PPI) in 
Research. 
Poster Psychology, Health and 
Medicine Conference. 
University College Cork, 
Ireland   
2020 LIstening to the Voice of 
Experience (LIVE): A podcast 
series to promote Patient and 
Public Involvement (PPI) in 
Research. 




Conference. 25th Feb. 
Dublin, Ireland. 
2019 ‘Us’ and ‘Them’: Identifying the 
most suitable approach to 
involving patients and healthcare 
professionals in a consensus 







Meeting, Society of Social 
Medicine. 4th-6th Sep. 
University College Cork, 
Ireland. 
2019 The Study of Age Friendly 
Environments (SAFE) Project. 
Oral ISS21 Ageing Cluster 
Research Day, 10th April, 
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University College Cork, 
Ireland.  
2019 ‘Us’ and ‘Them’: Identifying the 
most suitable approach to 
involving patients and healthcare 
professionals in a consensus 
process to inform intervention 
development. 




Conference. 26th Feb. 
Dublin, Ireland. 
2018 Seldom heard: Evaluating the 
impact of involving patients and 
the public in a consensus process 
to inform intervention 
development. 
Poster New Horizons Research 
Conference, School of 
Medicine Research 
Committee. 6th Dec. 
University College Cork, 
Ireland. 
2018 Seldom heard: Evaluating the 
impact of involving patients and 
the public in a consensus process 
to inform intervention 
development. 
Poster International 
Perspectives on the 
Evaluation of Patient and 
Public Involvement in 
Research, 15th and 16th 
November. Newcastle, 
UK.  
2018 Participants’ perspectives and 
preferences on clinical trial result 
Poster International 
Perspectives on the 
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dissemination: The TRUST 
Thyroid Trial experience.  
Evaluation of Patient and 
Public Involvement in 
Research, 15th and 16th 
November. Newcastle, 
UK. 
2018 Participants’ perspectives and 
preferences on clinical trial result 
dissemination: The TRUST 






Meeting, Society of Social 
Medicine. 5th-7th Sep. 
University of Glasgow, 
Scotland. 
2018 ‘I’ve always done what I was told 
by the Medical people’- a mixed 
methods study of older peoples 
reasons for attendance at a new 






Meeting, Society of Social 
Medicine. 5th-7th Sep. 
University of Glasgow, 
Scotland. 
2018 Participants’ perspectives and 
preferences on clinical trial result 
dissemination: The TRUST 
Thyroid Trial experience.  








2018 Older Adults Experiences of 
Attending Falls Risk Assessment 
Clinics.  
 




Conference. 11th Jan. 
Dublin, Ireland. 
2017 Participants’ perspectives and 
preferences on clinical trial result 
dissemination: The TRUST 
Thyroid Trial experience. 
Poster New Horizons Research 
Conference, School of 
Medicine Research 
Committee. 7th Dec. 
University College Cork, 
Ireland. 
2017 Participants’ perspectives and 
preferences on clinical trial result 
dissemination: The TRUST 
Thyroid Trial experience. 
Poster INFANT Research Day. 





Table A 6.4: Other conferences attended during PhD  
Year  Conference  
2019 European Patients Forum Congress ‘Advancing meaningful patient 
involvement: A path to more effective health systems’, 12th-14th 
November, Crowne Plaza Hotel, Brussels, Belgium. 
2018 Gender Equality in Higher Education, 20th-22nd August, Trinity College, 
Dublin, Ireland.  
2018 ‘Every voice matters’, PPI in Research Conference, 25th April, National 
University of Ireland Galway, Ireland.  
2017 ‘Transparency in Trials’, 3rd Annual Trial Methodology Symposium 2017, 





Appendix 7- PhD Education & Training 
 
Table A7.1 Training and workshops attended during PhD 
Year  Course 
Extra-credit modules, University College Cork 
2018 PG7016 Systematic Reviews for the Health Sciences (5 credits) 
2018 ST6013 Statistics and Data Analysis for Postgraduate Research Students 
(10 credits) 
2018 PG6025 Community-Based Participatory Research (5 credits) 
Other training completed during PhD 
2020 The impact of unpaid work on self-reported mental wellbeing, Kingston 
and St Georges Faculty of Health and Social Care Education (online 
workshop). 
2020 Digital Badge in Responsible Conduct of Research. Research Integrity 
Training, Epigeum (online component) and University College Cork (face-
to-face component).  
2019 Developing and Evaluating Complex Interventions Workshop, DECIPHer 
(Development and Evaluation of Complex Interventions for Public 
Health Improvement) research group held at University College Cork.  
2019 PPI in Clinical Trials: Design, Recruitment and Retention, Edinburgh 
Clinical Research Facility, Edinburgh, Scotland.  
2019 ICH- Good Clinical Practice (ICH- GCP) 
2018 The Odyssey Programme, Department of Human Resources, UCC. 
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2018 Training Institute for Dissemination and Implementation Research in 
Health (TIDIRH) Ireland, School of Public Health in collaboration with 
TIDIRH US, UCC.  
2018 Guidance for Developing and Evaluating Complex Interventions. Medical 
Research Council, University of Glasgow. 
2018 Writing lay summaries for research proposals. Health Research Board. 
National University of Ireland, Galway.  
2018 Training in Patient and Public Involvement in Research, Centre for Public 
Engagement, Kingston and St Georges University of London, England. 
2017 Introduction to Applied Biostatistics: Statistics for Medical Research, 
Osaka University, EdX Online Learning Platform.  
2017 PredictionX: John Snow and the Cholera Epidemic of 1854, Harvard 
University, EdX Online Learning Platform. 
2018 Normalisation Process Theory, School of Nursing and Midwifery, UCC.  
2018 Turbocharge your writing, Graduate Studies Office, UCC.  
2018 How to plan your PhD, Graduate Studies Office, UCC. 
2018 The Seven Secrets of Highly Successful Research Students, Graduate 





Appendix 8- Awards and additional funding obtained   
Table A 8.1 Awards obtained during PhD 
Year  Award 
2019 Best Rapid-Fire Presentation. Joint Society for Social Medicine 
and Population Health 63rd Annual Scientific Meeting and 
European Congress of Epidemiology Meeting, 4-6th September 
2019, University College Cork, Ireland. 
2019 Best Poster. 5th Annual Structured Population and Health-
services Research Education (SPHeRE) Conference. 26th Feb. 
Dublin, Ireland.  
2018 Best Rapid-Fire Presentation. Annual Scientific Meeting, Society 






Table A 8.2 Additional funding/ bursaries obtained during PhD 
Month/year  Award Amount  
April 2019 Travel bursary: College of Medicine and 
Health, UCC. 
€1000.00 
April 2019 Irish Research Council Postgraduate 
Scholarship Scheme: It’s a nice thing to do 
but…. Exploring the impact of Patient and 
Public Involvement on Randomised 
Controlled Trials.  
€18,250.00 
March 2019 Irish Research Council New Foundations 





Free place bursary: Annual Scientific 
Meeting, Society of Social Medicine. 5th-7th 
Sep 2018. University of Glasgow, Scotland. 
€870.00 
March 2018 Health Research Board- Trial Methodology 
Research Network (HRB TMRN), SWAT 
Funding Scheme: Seldom Heard: Listening to 







Appendix 9- Committee membership, contributions to teaching and funding 
applications 
 
Table A 9.1 Committee membership  
Year  Committee  Role  
2019 Local Organising Committee for the 
Joint Society for Social Medicine and 
Population Health 63rd Annual Scientific 
Meeting and European Congress of 
Epidemiology Meeting, 4-6th September 
2019, University College Cork.  
Early Career Researcher 
Representative. 
2019 Local Organising Committee for the 
Society for Social Medicine Early Career 
Researcher Event, 3rd September 2019, 




Working Group Committee for the 





Organisation and Culture Subcommittee 







Table A 9.2 Contributions to teaching, marking and supervision  
Academic Year  Contribution  
2019-2020 Supervision: Bsc Public Health Sciences Virtual work placement 
with the School of Public Health, University College Cork (5 
students in total).  
2019-2020 Teaching: EH 1006 Perspectives on Public Health. Lecture on 
Poverty, Social Exclusion and Community Development. 
2019-2020 Marking: MPH Public Health-MPH Thesis (3 in total) 
2018-2019 Teaching: EH 1006 Perspectives on Public Health. 2 hr lecture on 
Poverty, Social Exclusion and Community Development. 
2018-2019  Tutorial: EH 1006 Perspectives on Public Health. The Young 
Offenders (Film and discussion). 
2018-2019 Marking: BSc Public Health Sciences-Work Placement portfolios (2 
in total) 





Table A9.3 Contribution to research funding applications during PhD 
Month/year  Funding 
Body  



















UCC site activities, 


















Wrote the PPI 
section (including 
costings) and 
coordinated a PPI 








The role of 
Microbiota in the 
immune response 
in colorectal cancer.  
Prof Paul 
O’Toole  
Wrote the PPI 
section (including 
costings). 









Evidence and skills 
Development 
(CUSTOMISED) for 
policy and practice 
Dr Sheena 
McHugh 
Wrote the PPI 
section (including 
costings) and 
coordinated a PPI 
review of the 
application. 
March 2019 Irish 
Research 
Council  




Came up with and 
developed the idea 
for the project, 
wrote and submitted 
the application. 
March 2019   Evidence for 





Wrote the PPI 
section (including 
costings) and 
coordinated a PPI 
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Came up with and 
developed the idea 
for the project, 




 Children’s fOod 
Marketing Exposure 




Wrote the PPI 
section (including 
costings). 








Wrote the PPI 
section (including 
costings). 
March 2018  Seldom Heard: 
Listening to patients 





Came up with and 
developed the idea 
for the project, 







A feasibility study of 












health outcomes in 













Designed and Led 
Physical Activity 
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Abstract
Background: Guidelines recommend involving intervention users in the intervention 
development process. However, there is limited guidance on how to involve users in 
a meaningful and effective way.
Objective: The aim of this Study within a trial was to compare participants’ experi-
ences of taking part in one of three types of consensus meetings—people with dia-
betes-only, combined people with diabetes and health-care professionals (HCPs) or 
HCP-only meeting.
Design: The study used a mixed methods convergent design. Quantitative (question-
naire) and qualitative (observation notes and semi-structured telephone interviews) 
data were collected to explore participants’ experiences. A triangulation protocol 
was used to compare quantitative and qualitative findings.
Participants: People with diabetes (recruited via multiple strategies) were randomly 
assigned to attend the people with diabetes or combined meeting. HCPs (recruited 
through professional networks) attended the HCP or combined meeting based on 
their availability.
Results: Sixteen people with diabetes and 15 HCPs attended meetings, of whom 
18 participated in a telephone interview. Participants’ questionnaire responses sug-
gested similar positive experiences across the three meetings. Observation and semi-
structured interviews highlighted differences experienced by participants in the 
combined meeting relating to: perceived lack of common ground; feeling empowered 
versus undervalued; needing to feel safe and going off task to fill the void.
Conclusions: The qualitative theme ‘needing to feel safe’ may explain the dissonance 
(disagreement) between quantitative and qualitative data. In this study, involving pa-
tients and HCPs simultaneously in a consensus process was not found to be as suit-
able as involving each stakeholder group separately.
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1  | INTRODUC TION
For interventions to be successfully implemented in practice, 
they need to be acceptable, engaging and feasible to implement.1 
Intervention development guidelines recommend involving all ap-
propriate intervention users to maximize the chances of successful 
implementation.2 User involvement is a broad term that includes 
(but is not limited to) those receiving, eg patients and members of 
the public and delivering the intervention, eg healthcare profession-
als (HCPs).
Consensus methods are a way of involving multiple users 
simultaneously in the intervention development process.3-5 
Different users may have different priorities and preferences 
when making decisions about the content and delivery of an in-
tervention.6,7 For example, patients and members of the public 
may be concerned about how an intervention will be received 
by the target population, whereas HCPs may be more concerned 
about the cost involved (both time and money).7 Group dynam-
ics are complex, and some user groups may find it more difficult 
to voice their priorities and perspectives compared with others.8 
Despite increasing emphasis on user involvement, limited guid-
ance exists on how to involve users in a meaningful and effec-
tive way. To our knowledge, no research has been conducted on 
patients and HCPs experiences of being involved in consensus 
methods and whether their experiences differ according to group 
composition.
The aim of this Study Within A Trial was to compare participants’ 
experiences of taking part in one of three types of consensus meet-
ings—people with diabetes-only, combined people with diabetes and 
HCPs or HCP-only meeting.
1.1 | METHODS
This Study Within A Trial (SWAT) was conducted within the on-going 
Improving Diabetes Eye-screening Attendance (IDEAs) study. IDEAs 
is a feasibility study of a multifaceted intervention in general practice 
targeting HCPs and people with diabetes to improve the uptake of 
retinopathy screening. As part of the development phase of IDEAs, 
three separate consensus meetings were held to discuss the accept-
ability and feasibility of the proposed intervention content and suit-
able modes of delivery. Recommendations from each meeting were 
used to refine intervention components that could be delivered in 
general practice. The first consensus meeting consisted of people 
with diabetes only; the second meeting consisted of a combination 
of people with diabetes and HCPs and the third meeting consisted 
of HCPs only.
1.2 | Study design
The SWAT used a mixed methods convergent design to understand 
and compare participants’ experiences of taking part in the con-
sensus meetings (Figure 1). A one-phase design was used, where 
quantitative (experience survey) and qualitative (observation notes 
and semi-structured interviews) methods were used during the 
same timeframe and were given equal weight in the analysis.9
Quantitative and qualitative data were collected and an-
alysed separately. Results were merged during interpretation 
(mixed methods phase). A triangulation protocol was used in 
this phase to compare key concepts identified in each data-
set that related to participants’ experiences of taking part 
in the meetings.9,10 The Good Reporting of A Mixed Methods 
Study (GRAMMS) framework and the Consolidated Criteria for 
Reporting Qualitative Studies (COREQ) were used to guide re-
porting of the findings.11,12
1.3 | Recruitment of participants
People with diabetes were recruited using an information flyer de-
veloped by the research team and a graphic designer (Supplementary 
File 1). The flyer was distributed using a range of recruitment strate-
gies previously identified by Vat et al13 (Supplementary File 2).
All individuals who contacted the study team about involvement 
were sent a 26-item demographic survey (Supplementary File 3 for 
survey questions and results). The individuals who returned a de-
mographic survey were randomly assigned (using an online random 
number generator) to the meeting for people with diabetes-only or 
the combined meeting.
HCPs were recruited through professional networks known to 
the SWAT and IDEAs study teams. HCPs were initially sent an email 
or letter inviting them to take part in the consensus meeting. This 
was followed by a phone call to confirm their attendance. HCPs 
were either allocated to the HCP-only or combined meeting based 
on their availability to attend.
1.4 | Semi-structured consensus meetings
Before the meetings, the IDEAs study team (FR, SMH) developed 
(a) a short summary of existing evidence on barriers to and enablers 
of attendance at diabetic retinopathy screening, and interven-
tions to address non-attendance and (b) a survey asking partici-
pants to rate intervention components according to acceptability 
(like it, think it makes sense) and feasibility (think it can be done). 
K E Y W O R D S
consensus process, intervention development, patient and public involvement, user 
involvement
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F I G U R E  1   Procedural diagram of the convergent study design
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The survey was based on measures developed by Weiner et al14 
Materials were reviewed by adult literacy experts (Irish National 
Adult Literacy Agency) and a Patient and Public Involvement (PPI) 
group from another research project and revised based on their 
feedback. Before the meeting, the evidence summary and survey 
was sent to all meeting participants in electronic or paper format 
depending on participants’ preferences. Survey responses were 
collated and analysed descriptively by a member of the IDEAs 
study team (FR) and a summary of the results was prepared to be 
presented at each meeting.
Each consensus meeting was held from 6.30 to 8.30 pm in 
University College Cork. Before each meeting (at 6 pm), the lead 
SWAT researcher (ER) held an informal briefing for people with di-
abetes on key medical and research terms, the aim of the meeting 
and their role as patient contributors. Each meeting was facilitated 
by an experienced facilitator (male). During the meetings, a sum-
mary of the survey results was presented to participants, followed 
by a series of small group discussions facilitated by FR, SMH and 
EP. Participants were asked how each intervention component 
would work in practice and which mode of delivery would work 
best. Each small group was asked to nominate a lead to feed back 




At the end of each meeting, all participants were asked to com-
plete a questionnaire about their experience of the meeting. The 
objective of the questionnaire was to understand individual ex-
periences of taking part in the meeting, asking them to rate how 
they felt about their participation and the participation of other 
group members; how decisions were made by the group; and the 
potential impact of the decisions that were made. We were un-
able to find a suitable validated instrument that was appropriate 
for our questionnaire objective and context (one-off participa-
tory research process). Therefore, we developed our own ques-
tionnaire based on sample items from a non-validated survey 
instrument published by Schulz et al15 For additional information 
on the questionnaire development, please see Supplementary 
File 4. The original phrasing of the sample items was maintained, 
with the exception of some questions that were changed to 
statements to fit with a Likert scale format. Agreement with each 
statement was measured on a 5-point Likert scale ranging from 
‘strongly disagree’ to ‘strongly agree’. The questionnaire also 
contained an open-ended comment box for any other comments 
or suggestions. At the bottom of the questionnaire, participants 
were invited to ‘opt in’ if they were interested in participating in 
a follow-up interview on their experiences of taking part in the 
meeting.
1.5.2 | Quantitative data analysis
Questionnaire responses were entered into SPSS software (version 
24) and analysed using descriptive statistics. The five response cat-
egories were collapsed into three categories—‘Agree’, ‘Neither agree 
nor disagree’ and ‘Disagree’.
1.6 | Qualitative strand
1.6.1 | Observation notes
The SWAT lead researcher (ER) observed each consensus meeting 
and took comprehensive field notes. The objective of the observa-
tion was to understand how members participated and interacted 
with other meeting members and how they made decisions for the 
development of the intervention (group dynamics and decision-
making processes). An observation guide and grid were used to 
guide note taking and as a reminder of the events and issues of 
most importance (Supplementary File 5).16 The observation guide 
contained two overarching questions: ‘How is the group working 
overall?’ and ‘How is the group making decisions?’. The observa-
tion grid contained six constructs informed by group dynamics and 
decision-making processes literature.17-20 These constructs were 
as follows: participation/non-participation, dominance/submis-
siveness, in-groups/out-groups,1 body language and facial expres-
sions, gaze, and effect of expert/lay knowledge. After each 
meeting, the researcher met with the group facilitators to discuss 
and document their experiences and perspectives as supplemen-
tary information.
1.6.2 | Semi-structured interviews
Within 2 weeks of the consensus meetings, semi-structured tel-
ephone interviews were conducted with the consensus meeting 
participants who agreed to take part in an interview in the experi-
ence questionnaire. The objective of the interviews was to gain 
insights into individual experiences of taking part in the meeting 
in terms of: how comfortable they felt in the meeting; how they 
felt members of the group interacted with each other and how 
they felt they worked together to make decisions (ie, whether 
there was agreement, conflict, synergy). Interviews were audio-
recorded (see Supplementary File 6 for Interview Topic Guide). 
Interviews were conducted by ER, a young female PhD candidate. 
All participants were familiar with ER as she facilitated the brief-
ing session prior to the consensus meetings. At the beginning of 
each interview, the SWAT lead researcher (ER) stressed to par-
ticipants that she was independent to the trial study team that 
 1An in-group is a social group to which a person psychologically identifies as being a 
member. An out-group is a social group with which a person does not identify.
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were running the consensus meetings and therefore would not be 
offended if they described negative experiences.
1.6.3 | Qualitative data analysis
Field notes were collated, and audio recordings were transcribed 
verbatim. All qualitative data were managed using NVivo software 
(version 12). Thematic analysis was carried out following Braun and 
Clarke guidelines.21 Firstly, an extensive familiarization process was 
conducted by two researchers (ER, EP), where notes and transcripts 
were read and re-read multiple times. ER open coded all the observa-
tion notes and transcripts (using semantic and latent codes) and de-
veloped three separate sets of codes—one set for each meeting. The 
pattern and meanings of codes were then examined across the three 
meetings to identify one set of candidate or potential themes relat-
ing to participants’ experiences and group dynamics. Themes were 
developed using a conventional or ‘bottom-up’ approach, whereby 
themes were developed directly from the data.21 ER discussed each 
theme with EP to revise, refine and define themes.
1.7 | Mixed methods phase
After separate analysis of quantitative and qualitative data (as de-
scribed above), the data were compared using a triangulation proto-
col. Triangulation provides a visual and tabular representation of the 
findings from qualitative and quantitative data, allowing for a clearer 
comparison and broader interpretation.22 The steps taken to create 
the triangulation protocol are outlined in Table 1 below.
1.8 | Patient and Public Involvement 
(PPI) component
A PPI partner (GF) was involved in the SWAT from the outset. The PPI 
partner is a person with diabetes, previously known to the lead author 
(ER). She contributed to the initial discussions about the study which 
ultimately informed the SWAT grant application, reviewed the applica-
tion and made changes to its content. GF was also involved in the de-
velopment of materials used to recruit PPI contributors and assisted the 
research team with recruitment by posting recruitment flyers online via 
social media networks. In addition, she contributed to and reviewed 
each draft of this manuscript and is a co-author on this publication.
1.9 | Ethics
The study received ethical approval from the Social Research Ethics 
Committee (SREC) at University College Cork. Written informed 
consent was obtained from all participants prior to taking part in the 
consensus meetings and completing the questionnaire. Telephone 




A total of 36 people contacted the research team expressing an in-
terest in the SWAT. Of these, 20 completed the recruitment survey 
 Step Activity
1. Collate key findings from 
each dataset
This was done by examining the original data, 
interpretation and reports of analysis. For quantitative 
data, each questionnaire item was deemed as a 
separate key finding. For qualitative data, multiple 
key findings were identified within each theme, as 
themes were too broad in their descriptions to compare 
directly to quantitative findings
2. Group key findings into 
concepts
Key quantitative and qualitative findings were grouped 
together into concepts according to how they related 
to participants’ experiences and group dynamics (eg 
freedom of expression, balance of participation)
3. Create table for 
triangulation protocol
A table was created with each column representing the 
data source (questionnaire, observation and interview) 
and each row representing a key concept
4. Map key findings to table Key findings were then mapped to the table to 
examine where findings from each method agreed 
(convergence), offered complementary information 
on the same issue (complementarity), appeared to 
contradict each other (dissonance) or appeared in one 
method and not the other (silence)46
5. Explore intermethod 
discrepancies
This was done by examining the methodological rigour 
of each method and re-examining the data in light of 
the discrepancy47
TA B L E  1   Steps taken to create 
triangulation protocol
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(see Supplementary File 3 for recruitment survey results). These 20 
people were randomly assigned to either the people with diabetes-
only meeting (4 with type 1 diabetes and 6 with type 2 diabetes) or 
the combined meeting (6 with type 1 diabetes, 3 with type 2 diabe-
tes and 1 carer). All 10 people attended the people with diabetes-
only meeting (attendance rate 100%) and 6 people with diabetes 
attended the combined meeting (attendance rate 60%). An invitation 
to attend was sent out to 50 HCPs (practice nurses, diabetes nurse 
specialists, general practitioners and specialist physicians), of whom 
8 attended the combined meeting and 7 attended the HCP-only 
meeting (attendance rate 30%). Further details on the recruitment 
and response rates for each stage of the data collection are shown 
in Figure 2 below.
2.2 | Quantitative results
All consensus meeting participants (n = 31) completed the expe-
rience questionnaire (response rate 100%). Table 2 shows the re-
sults of the questionnaire stratified by meeting type (people with 
diabetes only, combined and HCP only). The descriptive statistics 
presented in Table 2 demonstrate that there were no differences 
in participants’ self-reported experiences of the three meetings. All 
participants across the three groups agreed with the statements ‘I 
felt comfortable expressing my opinion in the group’, ‘I felt my opinions 
were listened to and considered by other group members’ and ‘I did not 
feel pressured to go along with the decisions of the group even though 
they did not agree’. Some participants agreed with the statements 
that ‘I thought that certain individuals spoke more than others in the 
group’ and ‘I felt that certain individuals had more influence over the 
decision-making process than others’. A number of participants ex-
pressed doubt that they could influence the decisions made during 
the meeting.
2.3 | Qualitative results
In total, 18 questionnaire respondents agreed to be contacted for 
a follow-up interview. Interviews were conducted with participants 
from the people with diabetes-only (n = 6), combined (n = 7) and 
HCP-only (n = 5) meetings. Interviews were, on average, 34 minutes 
in duration (range 18-56 minutes).
Four themes were developed from the qualitative data relating 
to participants’ experiences and group dynamics: perceived lack of 
common ground; feeling empowered versus undervalued; needing 
to feel safe and going off task to fill the void.
F I G U R E  2   Flow diagram of recruitment and response rates






Neither agree nor 
disagree
N (%)
I felt comfortable expressing my 
opinion in the group
People with 
diabetes
10 (100) - -
Combined 14 (100) - -
HCP 7 (100) - -
I felt my opinions were listened 




10 (100) - -
Combined 14 (100)  -
HCP 7 (100) - -
I felt part of the group (like I 
belonged to the group)
People with 
diabetes
10 (100) - -
Combineda  12 (92.3) - 1 (7.7)
HCP 7 (100) - -
I felt pressured to go along with 
the decisions of the group even 
though I did not agree
People with 
diabetes
- 10 (100) -
Combined - 14 (100) -
HCP - 7 (100) -
I felt a sense of trust and 




10 (100) - -
Combined 13 (92.9) - 1 (7.1)
HCP 7 (100) - -
I thought that certain individuals 





3 (30) 6 (60) 1 (10)
Combined 4 (28.6) 6 (42.8) 4 (28.6)
HCP 3 (42.9) 3 (42.9) 1 (14.2)
I felt that I could influence the 
decisions made by the group
People with 
diabetes
7 ((70) - 3 (30)
Combined 8 (57.1) 1 (7.1) 5 (35.7)
HCPa  4 (66.7) - 2 (33.3)
I felt that certain individuals 
had more influence over the 




3 (30) 6 (60) 1 (10)
Combined 2 (14.3) 9 (64.3) 3 (21.4)
HCP 1 (14.3) 3 (42.9) 3 (42.9)
I have increased my knowledge 
about important topics since 
participating in this group
People with 
diabetesa 
8 (88.9) - 1 (11.1)
Combined 10 (71.4) 1 (7.1) 3 (21.4)
HCP 6 (85.7) - 1 (14.3)
By working together, we can 





10 (100) - -
Combined 13 (92.9) - 1 (7.1)
HCP 7 (100) - -
By working together, we can 




10 (100) - -
Combined 14 (100) - -
HCP 7 (100) - -
aMissing data. 
TA B L E  2   Results of the participant 
experience questionnaires stratified by 
meeting type
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2.4 | Perceived lack of common ground
In the people with diabetes-only meeting, there were differences 
between participants in terms of diabetes type, length of diagnosis 
and education level. In the HCP-only meeting, differences included 
profession (eg medical doctor, practice nurse, diabetes nurse spe-
cialist), experience of working with people with diabetes, and size, 
location and nature of their practices. During the interviews, par-
ticipants from these two meetings described these demographic, 
geographical and clinical differences as ‘small’ differences, which 
they welcomed as they felt it allowed them to bring different per-
spectives to the topics they were discussing. They focused on the 
common ground they shared with other meeting participants and 
identified with one another based on the shared experience of liv-
ing with diabetes or caring for people with diabetes. They felt that 
they were all ‘singing from the same hymn sheet’ (P3, person with 
diabetes, people with diabetes-only meeting) and described being 
able to come together to make decisions that incorporated different 
perspectives:
It was interesting to hear their views. We were all on the 
same page, but we were coming from different angles 
and we used that then; we came together and made the 
decisions together. 
(P2, person with diabetes, person with diabetes-only 
meeting)
In contrast, a lack of common ground was reported by partici-
pants in the combined meeting. This created a division in the group, 
a ‘them’ and ‘us’ attitude, which was evident in the interview and 
observation data. In the interview data, people with diabetes stated 
that there was a ‘complete clash of perspectives’ (P9, person with dia-
betes, combined meeting) between people who lived with the con-
dition and HCPs who cared for people with diabetes. HCPs reported 
that people with diabetes and HCPs were ‘two different sides of the 
divide’ (P11, HCP, combined meeting). The observation data also 
suggested a division between people with diabetes and HCPs in the 
combined meeting. At the beginning of the meeting, people with dia-
betes and HCPs sat on opposite sides of each small table. During the 
small group discussions, participants expressed their opinions as col-
lective opinions of their stakeholder group. Rather than expressing 
individual opinions (eg ‘I think that…’or ‘My experience is…’), people 
with diabetes spoke on behalf of all the people with diabetes in the 
group, and HCPs spoke on behalf of all HCPs in the group (eg ‘We 
feel that… don't we?’ and ‘As people with diabetes, we think that…’). 
Moreover, during the small group discussions, each stakeholder 
group focused their gaze on the other stakeholder group, resulting 
in people with diabetes and HCPs talking at each other, at opposite 
sides of each table. This was in contrast to the people with diabe-
tes-only and HCP-only meeting, where members focused their gaze 
on all members around the table.
Participants’ lacking a sense of shared experience was ac-
companied by differences in perceptions around the balance of 
participation. During all three meetings, it was observed that 
some participants spoke more frequently and for longer than 
others. In the interviews, participants from the people with di-
abetes-only and HCP-only meetings perceived this unbalanced 
participation as a natural consequence of any group dynamic. 
They mainly attributed it to different personalities. In contrast, 
HCPs from the combined meeting attributed the unbalanced par-
ticipation to people putting too much emphasis on their own per-
sonal experiences:
It was very much centred around them [people with di-
abetes] and a lot of the offerings that I had in terms of 
experience were nothing in comparison to what they felt 
as people that have the problem. Which is fine. But that 
wasn’t really the point. The point is that I don’t have di-
abetes, that is not my personal experience. But I am still 
the one left in the room everyday trying to deal with pa-
tients… But I just couldn't come out with it on the night. I 
just didn't. It wasn't going to be heard. 
(P12, HCP, combined meeting)
2.5 | Feeling empowered versus undervalued
In the interviews, participants from the people with diabetes- and 
HCP-only meetings reported learning from other meeting members 
and feeling empowered by the event. In the people with diabetes-
only meeting, participants stated that they learned from one another 
about how they can better manage their condition and about the dif-
ference between type 1 and type 2 diabetes. Those who had been 
diagnosed with diabetes for a long time described gaining a renewed 
compassion for those who were newly diagnosed. Participants from 
the HCP-only meeting reported learning about the importance of en-
couraging their patients to attend screening, about the roles of dif-
ferent HCPs and about the cultural difficulties and language barriers 
that some practices face due to a high number of non-English speak-
ing patients.
There were also some reports of learning in the combined meet-
ing. People with diabetes said they gained a new insight into the 
work practices of HCPs—in particular, the increased workload ex-
perienced by HCPs. The HCPs reported gaining an insight into the 
struggles of having to live with a medical condition:
I put in a couple of thousand eye drops a year, it doesn't 
mean anything to me like. But it obviously means some-
thing for patients who are having to go through this – and 
you know the awkwardness of getting appointments and 
driving to and from appointments and getting a lift and 
all that side of things. 
(P14, HCP, combined meeting)
However, participants from the combined meeting reported feel-
ing undervalued by the other stakeholder group. People with diabetes 
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felt that HCPs did not understand how it feels to live with a chronic 
illness, describing ‘a complete clash of the reality of living with diabetes 
versus a medical professional's perspective’ (P7, person with diabetes, 
combined meeting). Among some of the HCPs, there was a sense that 
any contributions they made during the meeting were not valued by 
people with diabetes because the experience of living with diabetes 
was deemed more important than the experience of caring for people 
with diabetes:
I've worked in four different GP practices at this stage 
and all very different. And yet I felt like as if any value 
that I had to add to the conversation was kind of almost 
either misheard or not really heard, or almost felt not 
quite as relevant because of their personal experiences. 
Which is fair enough. But that was not what the meeting 
was about. 
(P13, HCP, combined meeting)
2.6 | Needing to feel safe to express 
honest opinions
In the interviews, participants from the people with diabetes-only 
and HCP-only meetings reported an open, honest, relaxed and non-
judgemental environment, where everyone had a voice and was 
heard. This environment made participants feel safe and comfort-
able to express their opinions. They also indicated that the small 
group discussions added to their feelings of safety as people who 
do not like speaking in public felt less intimidated about expressing 
their opinions:
I’m not one really for expressing my opinions. I am kind of 
… I wouldn’t put my hand up the first time, let’s say. But 
I did feel very comfortable expressing my opinion in the 
small group. 
(P15, HCP, HCP-only meeting)
Conversely, participants from the combined meeting reported 
feeling uncomfortable and unable to express their opinions as they 
were conscious of the other stakeholder group in the room. Both peo-
ple with diabetes and HCPs said they felt they had to ‘hold back’ their 
opinions. People with diabetes reported feeling that they could not be 
honest about the ‘non-compliant’ (P9, person with diabetes, combined 
meeting) aspects of managing their diabetes as the HCPs may judge 
them for it:
I don’t think when you are sitting at a table with HCPs 
that you’re going to be discussing the non-compliant 
things you do… It’s probably not the best environment, 
let’s say, to get out some of the smaller things that people 
do that may not be approved by the other group in the 
room. 
(P8, person with diabetes, combined meeting)
On the other hand, HCPs were conscious of confidentiality is-
sues: they were concerned that if they mentioned a particular case, 
people with diabetes could potentially identify who that patient 
was, since ‘[this location] is a very small place’ (P11, HCP, combined 
meeting):
I felt a bit kind of reticent about how free [I could talk 
about my experiences as a healthcare professional]… It’s 
different when you are divulging, you know, work prac-
tices and difficulties and challenges and personal expe-
riences at work, when it is other medical professionals. 
But when you have effectively patients there, it is like a 
big difference. 
(P13, HCP, combined meeting)
In addition, the HCPs indicated that they did not feel comfortable 
talking about the service that they worked in as they felt anxious that 
people with diabetes would confront them on the long waiting times or 
other issues they had with that particular service.
2.7 | Going off task to fill the void
Analysis of interview data indicated that participants across all three 
meetings felt they were able to work together. They reported that 
the content for discussion was relevant to them as users and provid-
ers of health services.
However, the observation data show that although members of 
the combined meeting appeared to work together, both stakeholder 
groups were defensive about what intervention components would 
not work and at times in the meeting nothing seemed feasible. This 
resulted in each stakeholder group feeling uncomfortable in assert-
ing what they felt the other group should or should not do. To fill 
this void, participants began to go off task as they focused their dis-
cussions on the ‘other’. The ‘other’ took different forms throughout 
the meeting: the screening service, people with diabetes who were 
not in the room (eg those with type 2 diabetes), and funding and re-
source limitations in general practice. Even though they were being 
asked to discuss and make recommendations on how the interven-
tion would work in primary care, the combined meeting participants 
resorted to making recommendations about how screening uptake 
could be increased on a national basis through nationwide TV and 
radio campaigns.
2.8 | Mixed methods results
The results of the mixed methods analysis are presented in Table 3. 
Six key concepts relating to participants’ experiences and group dy-
namics were identified from the datasets: freedom of expression; 
understanding and respect; balance of participation; learning; pro-
ductive collaboration and group cohesion. When key findings were 
mapped to the overarching concepts, there were four instances of 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































     |  11RACINE Et Al.
dissonance (where data appeared to contradict each other), two in-
stances of convergence (where data agreed) and two instances of 
complementarity (where data offered complementary information 
on the same issue). There were no instances of silence (where data 
appeared in one method and not in the other).
The four instances of dissonance between quantitative and 
qualitative data were wholly due to the fact that in the question-
naire participants reported positive experiences of taking part in 
the meetings, whereas the observation and interview data high-
lighted some negative experiences and divergent opinions. For ex-
ample, in relation to freedom of expression, the questionnaire data 
showed that in all three meetings, participants reported feeling 
comfortable expressing their opinions and reported a sense of 
trust and openness between group members. In the observation 
data, participants in the combined meeting did not appear to be 
comfortable asserting what the other stakeholder group should/
should not do as part of the intervention. Furthermore, in the in-
terviews participants reported feeling uncomfortable and unable 
to express their opinions as they were conscious of the other 
stakeholder group in the room.
The instances of complementarity were largely due to the design 
of the data collection tools. The questionnaire items were designed 
to be concise and did not require the participants to give any addi-
tional details. Whereas in the interviews, participants had the op-
portunity to expand and give more detail. For example, in the key 
concept learning, the questionnaire item asked participants to indi-
cate how much they agreed with the statement ‘I have increased my 
knowledge about important topics since participating in this group’, 
whereas in the interviews participants had the opportunity to ex-
pand and give specific examples of what they had learned (eg people 
with diabetes learned how they can better manage their condition, 
HCPs leaned about the importance of encouraging their patients to 
attend screening, etc).
3  | DISCUSSION
3.1 | Summary of key findings
The aim of this study was to compare participants’ experiences 
of taking part in the three consensus meetings. The results of the 
questionnaire suggested that participants had largely positive ex-
periences of taking part in the consensus meetings and there were 
no differences in participants’ experiences between the three meet-
ings. However, results of the observation and interviews highlighted 
that participants in the combined meeting had different experiences 
from those in the other two meetings. The perceived lack of com-
mon ground between people with diabetes and HCPs in the com-
bined meeting led participants to feel undervalued by the other 
stakeholder group as they felt that the other group did not under-
stand their perspective. Participants in the combined meeting were 
reluctant to express their opinions and were defensive about what 
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result participants in the combined meeting went off task and made 
recommendations which were not entirely relevant for the interven-
tion. In this study, involving patients and HCPs simultaneously in a 
consensus process was not found to be as suitable as involving each 
stakeholder group separately.
3.2 | Links to existing literature
In the people with diabetes-only and the HCP-only meetings, par-
ticipants welcomed their diversity as it allowed them to hear differ-
ent perspectives on the topics they were discussing. This finding is 
consistent with existing literature, with many theorists arguing that 
knowledge diversity can improve group performance by enhancing 
a group's ability to be creative and to discover novel solutions.23-25 
In these meetings, participants focused on their common ground and 
described being able to come together to make decisions that incor-
porated a range of perspectives. Previous research suggests that con-
gruent groups—ie when group members are socially tied and share the 
same information—are more likely to be productive and successful.26
The perceived lack of common ground between people with di-
abetes and HCPs in the combined meeting created a ‘them’ and ‘us’ 
scenario, with participants reluctant to express their opinions. This 
raises questions about whether too much difference within groups is 
counterproductive or divisive. Existing research on the productivity 
of incongruent groups—ie when social and knowledge subgroups are 
present within a group has found that subgroups can create a divide 
between group members, undermining the groups’ ability to work 
together and be productive.26
Some HCPs in the combined meeting felt their contributions 
were not valued by people with diabetes because the experience of 
living with diabetes trumped the experience of caring for people with 
diabetes. This finding may reflect the changing nature of the patient/
HCP relationship over the last 20 years—from a paternalistic model 
where the patient seeks help and is compliant to the professional 
who makes the decisions, to a more patient-centred approach.27 This 
approach expects HCPs to enter the patient's world and to see the 
illness through the patient's eyes.27 This prioritization of the patient 
experience has benefited patient outcomes.28 However, as HCPs 
are often responsible for delivering interventions, their perspectives 
in the intervention development process are crucial for maximizing 
intervention feasibility. Involving multiple users in the intervention 
development process is not about understanding which perspective 
is more valid or more important, it is about understanding all the 
different perspectives so that the intervention is more acceptable, 
engaging and feasible to implement.
3.3 | Strengths and limitations
One of the strengths of this study was the use of a mixed methods, 
convergent design which produced a more complete understanding 
of participants’ experiences and group dynamics. It also allowed for 
the cross-validation of findings from each method resulting in more 
substantiated findings than sequential designs or quantitative or 
qualitative approaches alone.9 The qualitative theme ‘needing to feel 
safe’ may explain the instances of dissonance between quantitative 
and qualitative data as participants completed the questionnaire at 
the end of each meeting while they were still sitting close to other 
participants. Some small groups even filled out the questionnaire to-
gether. As a result, participants may not have felt comfortable voic-
ing concerns. In the interviews, on the other hand, participants may 
have felt safer in a one-to-one environment with a researcher who 
they were already familiar with. The fact that the researcher stressed 
that she was independent to the consensus meeting research team 
and her informal approach may have made them more comfortable 
to speak openly about their experiences of taking part in the meeting. 
The timing of the questionnaire may have also played an important 
role. The questionnaire was handed out at the end of the meeting, 
late in the evening. Participants may have been eager to get home 
and they may not have fully thought about the responses they were 
providing. However, in the interviews, participants had time to reflect 
on their experiences and provide a more comprehensive account as 
a result. This is consistent with Krosnick's theory of survey satisfic-
ing which is based on the assumption that optimal survey completion 
involves doing a great deal of cognitive work, so if the participant is 
not fully motivated to complete the survey, he or she is likely to offer 
responses that seem reasonable and easy to defend.29 Although ques-
tionnaires are a frequently used tool to evaluate consensus meetings, 
our findings suggest that they may not always provide a comprehen-
sive assessment of participants’ experiences. This is consistent with a 
number of previous studies on evaluating participant experiences.30-32
This study is not without limitations. First, the questionnaire 
that was used to understand participants’ experiences was based 
on non-validated questionnaire items. We were unable to conduct 
exploratory factor analysis to validate our questionnaire as our sam-
ple size did not meet the minimum criteria of 10 participants per 
questionnaire item.33 However, given the increasing importance 
of evaluating PPI and other participatory research activities,34 the 
questionnaire could be a useful tool in future studies which aim 
to understand stakeholders’ experiences in similar participatory 
research contexts. Use of the questionnaire in future studies may 
allow for reliability testing and validation to be carried out.35,36
Second, although the experience questionnaire suggested that 
there were no differences in participants’ experiences between the 
three meetings, due to the number of participants, there was limited 
power to detect a difference (n = 31). Thus, the comparison of partic-
ipants’ questionnaire responses between the groups is used as only 
an indicator of participants’ experiences. Given the small sample, we 
cannot rule out the possibility that differences between the groups 
could be detected had a larger sample size been used.
Despite using a range of strategies to recruit a representative 
sample of people with diabetes, another potential limitation of this 
study was the absence of people with type 2 diabetes in the com-
bined meeting. As the attendance rate of people with diabetes at 
the combined meeting (60%) was much lower than the people with 
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diabetes-only meeting (100%), it is plausible that people with type 
2 diabetes did not attend because they knew there would be HCPs 
attending. Existing research has established that people with type 1 
and type 2 diabetes have different experiences when managing their 
condition and engaging with HCPs.37-39 Therefore, the involvement 
of people with type 2 diabetes in the combined meeting could have 
potentially changed the nature of the relationship between patients 
and HCPs and led to different participant experiences and group 
dynamics.
Finally, participants were given a choice to participate in an in-per-
son or telephone interview. All participants chose telephone inter-
views due to time constraints and location convenience. This could be 
another potential limitation as researchers have previously expressed 
concerns about whether telephone interviews are appropriate for 
qualitative research.40,41 These concerns are largely due to the ab-
sence of visual cues which may result in the loss of informal communi-
cation and contextual information, the inability to develop rapport or 
to probe and the misinterpretation of responses.41 In this study, the 
quality of telephone data cannot be compared with in-person data as 
no in-person interviews were conducted. However, the researcher had 
considerable experience conducting phone interviews, maintained a 
friendly and engaging tone throughout and as mentioned previously, 
participants were found to be open and frank about their experiences.
3.4 | Implications
The results of this study provide much needed evidence on how differ-
ent ways of involving patients and health-care professionals can lead to 
differing participant experiences and group dynamics. Patient and pub-
lic involvement (PPI) in research is increasingly becoming a requirement 
in health research and for many research funders. INVOLVE, a national 
advisory body funded by the National Institute for Health Research 
(NIHR) in the UK, defines public involvement as research being carried 
out ‘with’ or ‘by’ members of the public rather than ‘to’, ‘about’ or ‘for’ 
them.42 In this study, the lines between research participation and in-
volvement were blurred, as is often the case with PPI.43 People with 
diabetes were research participants in the consensus meetings, expe-
rience questionnaire and semi-structured interviews. However, their 
role in the consensus meeting was to discuss and make decisions about 
the intervention content and mode of delivery which could be viewed 
as PPI.44,45 This study shows that the context and nature of involve-
ment can have important implications for its impact. These findings are 
not only relevant to health intervention researchers but to all individu-
als interested in involving patients and members of the public in health 
research, policy and in the planning and development of health care 
more broadly.
4  | CONCLUSION
Although the results of the experience questionnaire showed no 
differences in participants’ experiences across the three meetings, 
the results of the observation and interviews highlighted that par-
ticipants in the combined meeting had different experiences. In 
this study, involving patients and HCPs simultaneously in a con-
sensus process was not found to be as suitable as involving each 
stakeholder group separately. The study provides much needed 
evidence on how different ways of involving patients and health-
care professionals can lead to differing participant experiences 
and group dynamics.
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sufficient regardless of any pragmatic impact. However, PPI costs 
time and money, therefore pragmatic claims need scrutiny8. More 
substantive evidence is needed to evaluate the potential impact 
of PPI on the conduct and outcomes of research5,9. In 2001, 
the need to establish if PPI leads to actual, rather than merely 
perceived benefits for research processes and output was 
identified. Over fifteen years later, this need remains.
In clinical research, the results of clinical trials have not 
traditionally been shared with clinical trial participants. A recent 
survey carried out on a large registry of health research partici-
pants, found that while 95.6% of respondents said researchers 
should always or sometimes offer the results to participants, 
only 33% of respondents actually received the results of studies 
in which they had participated10. An upcoming European Union 
Clinical Trial Regulation requires sponsors to provide sum-
mary results of clinical trials in a format understandable to 
laypersons, including participants11. However, there is a lack 
of evidence on the most appropriate methods of sharing results 
with participants. Uncertainty persists around what information 
should be shared, how results should be shared and who should 
be responsible for sharing the results. Since the findings of 
clinical research often exist in a complex context of scientific 
exchange and debate, it is important that the information shared 
is accessible and relevant to participants12. The increasing 
understanding of the importance of sharing research results with 
study participants is somewhat linked to a wider movement 
towards transparency in trials. This movement is largely pro-
moted by initiatives such as SPIRIT, CONSORT and AllTrials. 
The SPIRIT Statement provides guidance to researchers to 
improve the completeness and quality of trial protocols13, the 
Consolodated Standards of Reporting Trials (CONSORT) State-
ment is an evidence based, minimum set of recommendations for 
reporting randomised trials14 and the AllTRials iniative calls for 
all past and present triasl to be registered and their full methods 
and summary results reported15. Some of these initiatives also 
include recommendations for disseminating results to research 
participants. For example, the SPIRIT statement states that study 
results must be released to participating physicians, referring 
physicians, patients and the general medical community13.
The Thyroid Hormone Replacement for Subclinical Hypothy-
roidism Trial (TRUST) was a multi-centre, double blind, 
placebo controlled, phase III clinical trial testing the efficacy of 
thyroxine replacement in subclinical hypothyroidism in older 
community dwelling adults16. The results of the TRUST trial 
were published in the New England Journal of Medicine on 3rd of 
April, 201716. This Study Within A Trial (SWAT) was 
conducted at the Irish TRUST trial site prior to and after pub-
lication of results. The aim of this SWAT was to investigate 
methods of disseminating trial findings to participants by using 
a PPI approach to identify, develop and evaluate a patient-based 
approach of receiving trial results.
Methods
Study design
This was a sequential mixed methods study with three phases. In 
this study, methods were combined for complementarity, where 
            Amendments from Version 1
This improved version contains some minor revisions as 
suggested by peer-reviewers.
Throughout the manuscript, the following changes have been 
made:
•    “patient- preferred” has been changed to “patient-based”.
•    “patient-preferred method” has been changed to “patient-
based approach”.
•    “Standard method” has been changed to “standard 
approach”.
Within the Abstract, the aim of the study has been re-worded to 
clarify that all TRUST participants were aged 65 and over.
Within the Introduction section, additional background information 
has been provided on the need to evaluate the impact of PPI. This 
serves as a rationale for doing the study. We have also introduced 
the recent movement towards transparency in trials including 
references to the SPIRIT, CONSORT and AllTrials initiatives.
Within the Methods section, additional details have been 
provided on the PPI group and how PPI partners were identified 
and recruited. Further information has also been provided on 
the Consensus Oriented Decision Making (CODM) model and 
how the model was specifically used in this study. We have also 
provided a clear distinction between adult literacy and health 
literacy.
Within the Results section, a footnote has been added to Table 1 
to clarify that only a subgroup of Irish participants were invited to 
the focus groups. A footnote has also been added to Table 2 to 
clarify how patient understanding was assessed.
Within the Discussion, the section entitled ‘Limitations of the 
study’ has now been reworded to ‘Strengths and limitations of the 
study’ and the paragraph that discusses how PPI partners were 





Patient and public involvement (PPI) is increasingly recognised 
as an essential component of clinical research. In the UK, the 
national advisory group supporting active public involvement 
in health services, public health and social care research 
(INVOLVE) defines PPI as ‘research being carried out ‘with’ or 
‘by’ members of the public rather than ‘to’ ‘about’ or ‘for’ them’1. 
In clinical trials, PPI has been defined as experimenting with 
participants instead of experimenting on participants2. PPI may 
occur at any stage during the research process from priority 
setting and drafting study protocols right through to conducting 
the study, interpreting the end results and communicating and 
disseminating research findings3,4. Research funders increasingly 
expect that PPI is prioritised and resourced within studies. This 
increasing expectation has heightened the risk of researchers car-
rying out ‘tick-box’ PPI rather than ‘meaningful’ involvement5. 
There are many moral and ethical arguments being made for 
PPI. Many believe that as citizens and taxpayers, members of 
the public have a right to influence research that is being funded 
by public money6. PPI researchers are also making pragmatic 
arguments for PPI and providing anecdotal accounts about how 
PPI can make research more relevant, accessible and accept-
able to participants7. The ethical arguments are often seen as 
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each method addressed a different aspect of the study aim17. The 
first phase used a qualitative approach to identify and develop a 
patient-based approach to disseminating the results, the second 
phase used a SWAT intervention to compare the dissemination 
approaches and the third phase used a quantitative patient under-
standing questionnaire to evaluate the patient-based approach. 
The full study protocol has been published elsewhere18, but a 
summary follows here.
Setting
The study sites for the TRUST trial were the University of 
Glasgow, Scotland (lead site); Leiden Academy on Vitality and 
Ageing, The Netherlands; Leiden University Medical Centre, The 
Netherlands; University of Berne, Switzerland; and University 
College Cork, Ireland. A total of 738 participants with subclinical 
hypothyroidism were recruited to the trial over a three-and-a-
half year period from 2013–201716. The trial completed recruit-
ment in November 2016 and the results were published in 
April 201716.
This SWAT was conducted at the Irish TRUST site. The hub 
centre for the Irish TRUST site was located at the Mercy 
University Hospital, Cork where 38 participants were recruited. 
A further 77 participants were recruited from five satellite sites.
Population
As this SWAT was embedded in an ongoing clinical trial the 
study sample was determined by the TRUST Thyroid trial. There 
were 115 TRUST participants recruited in the Irish site, 11 of 
these participants withdrew over the course of the trial. Our study 
sample included all remaining TRUST participants (n=104).
Phase One: Identification and development of 
patient-based approach (qualitative and PPI phase)
The first phase of the study used a qualitative approach to 
iteratively identify and develop a patient-based approach to 
disseminate the results of TRUST trial. This was done in three 
separate stages: qualitative focus groups, a PPI group and an 
adult literacy review.
Focus groups
Three semi-structured focus groups were conducted with four 
to eight TRUST trial participants per group. All Cork-based 
patients (n = 38) were contacted via letter and invited to 
participate. A €20 shopping voucher was given to all participants 
to cover travel expenses. Each session was led by trained quali-
tative researchers (WHS, ER, CH). A topic guide was used to 
guide the focus groups. The topic guide was reviewed and refined 
by all members of the SWAT research team (see Supplementary 
File 1: Focus group topic guide).
The Consensus-Oriented-Decision-Making (CODM) model 
was used to guide the group to reach a consensus19. The CODM 
model is accepted as a flexible model for reaching decisions19. 
In this study some of the steps were initiated by the focus group 
facilitator and others occurred naturally as a follow on from 
the previous step. Below is an outline of each of the seven 
steps of the CODM model and how they were used in this study:
1.    Framing the topic: The focus group facilitator intro-
duced the idea of sharing results with participants and 
provided some context on the reasons why results are/ are 
not shared with participants.
2.    Open discussion: The facilitator asked the group 
whether or not they think results should be shared with 
trial participants and whether or not they would like to 
receive the results of the TRUST trial.
3.    Identifying underlying concerns: The previous discussion 
naturally followed on to participants asking questions 
and expressing concerns about the result method, content 
and language that would be used.
4.    Collaborative proposal building: The group worked 
together to agree on the important elements of the results 
in terms of result method, content and language.
5.    Choosing a direction: This step occurred naturally as 
part of the previous step.
6.    Synthesizing a final proposal: The facilitator re-iterated 
the proposal the group had agreed upon and asked the 
group for feedback.
7.    Closure: This step occurred naturally as part of the 
previous step.
Analysis. Focus group recordings were transcribed verbatim 
and entered into NVivo Version 11 for data management 
during thematic analysis. Braun and Clarke guidelines20 for 
conducting thematic analysis were followed. Initial focus group 
transcripts were analysed independently by two researchers 
(ER and AC). Each transcript was read multiple times (data 
familiarisation) and initial codes were identified. These codes 
were then used to identify emerging themes. Both researchers 
discussed emerging themes and conducted further refinement. 
The refined themes were then discussed and agreed upon with 
other members of the research team (ER, CH, AC, KMS). 
Researchers (ER, CH, AC) then used the focus group findings 
to develop an initial draft of a patient-based approach for the 
dissemination of results (see Supplementary File 2: Draft one of 
patient-based result letter).
PPI group
A PPI group was established to develop and refine the 
content of the patient-based appproach for the dissemination of 
results. During the focus groups, three TRUST trial participants 
volunteered to take part in the PPI group. In addition to these 
three PPI partners, an additional partner was identified from a 
previous qualitative research study undertaken by the research 
team. This individual was keen to learn more about research 
and expressed an interest in being involved in future projects. 
While this individual had previous experience of taking part in 
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research (as an interview participant), she had no experience of 
taking part in a clinical trial or being involved as a PPI partner. 
Originally, we intended to conduct these sessions in a group 
format, due to difficulties with PPI partners’ schedule commit-
ments, one-to-one sessions were conducted. At the one-one 
session, a researcher (ER) and the PPI partner discussed the 
layout, content and language of the initial draft of the result 
method. Researchers and PPI partners worked together to edit 
different sections of the document. These discussions were not 
audio recorded but comprehensive field notes were taken by the 
researcher (ER). These notes were then collated by the researcher 
and used to further ensure that the results letter reflected 
PPI partners’ perspectives and preferences.
Adult literacy review
While the PPI group had significant input into the format and 
language used in the patient-based approach, the research team 
felt that it would be of additional benefit to collaborate with the 
National Adult Literacy Agency (NALA) to ensure the document 
adhered to national “Plain English” standards. These standards 
ensured that the information presented to trial participants was 
sufficiently easy to read and understand (literacy). This would 
help to ensure that trial participants were able to make sound 
health decisions based on the information presented (health 
literacy)21. This review was an iterative process with several 
drafts exchanged for editing. Although the review was taken as an 
additional step to the published protocol for the study, the research 
team felt it was helpful to further ensure that the document 
was accessible and easy to understand.
At the end of the first phase of the study, a final draft of the 
patient-based result letter was approved by researchers, PPI group 
and adult literacy experts (see Supplementary File 3: Final draft 
of patient-based result letter).
Phase Two: Dissemination of trial results 
(intervention phase)
The second phase of the study used a SWAT intervention to 
disseminate the results of the TRUST Thyroid Trial to trial par-
ticipants. This was done using a prospective, randomised, single 
blind, parallel trial design. It is important to note that when the 
term randomisation is used, it refers to the allocation of patients 
to intervention/control within the SWAT and not the TRUST 
Thyroid trial. Irish TRUST participants were randomised to 
intervention or control groups using an online random number 
generator. The intervention group received the patient-based letter 
format (see Supplementary File 3: Final version patient-based 
results letter) and the control group received a copy of the 
TRUST results press release, which was made available by 
the lead study site on the TRUST Thyroid Trial Website (see 
Supplementary File 4: Standard results letter). Participants 
were blinded to their intervention group. One member of 
the research team was un-blinded in order to perform the 
randomisation and distribute the results of the trial. As they 
were un-blinded to perform these two important tasks, they 




The third phase of the study used a quantitative patient under-
standing questionnaire to evaluate the patient-based approach 
to disseminating trial results. The questionnaire was developed 
in consultation with experts in the area of subclinical hypothy-
roidism and scale (questionnaire) development (PK and KMS). 
The early development of the questionnaire was guided by a 
consultation document, which accompanies the EU Clinical 
Trials Regulation No 536/201422. This document highlights the 
information which should be presented to trial participants in 
the trial summary at the end of a trial. However, initial question-
naire items were modified to allow for psychometric testing. 
The final questionnaire contained 12 questions; six items were 
measured on a five point LIKERT scale, there were four 
multiple-choice questions and two vignettes. The first six items 
measured patients’ perceived understanding of results, the four 
multiple choice measured patients’ actual understanding of 
results by requiring them to select the correct answer. To further 
test participants’ understanding of the trial results, two vignettes 
describing two typical patient case studies of older adults with 
subclinical hypothyroidism were provided with a question 
on whether a doctor should prescribe thyroxine for the hypo-
thetical patient described. The questionnaire was reviewed by 
the PPI group to assess content and face validity. It then under-
went further review by NALA to ensure adherence to the national 
‘Plain English’ standard. The final version of the questionnaire 
can be seen in Supplementary File 5: Patient understanding 
questionnaire.
The questionnaire was sent to all Irish TRUST participants 
(intervention and control group) one week after they received 
the results of the trial. A reminder questionnaire was sent to 
non-responders 3 weeks later.
Analysis. The primary outcome was the difference in levels 
of patient understanding between the intervention and control 
groups. This measured the impact of PPI on patient understand-
ing of end of trial results. The psychometric properties and 
construct validity of the questionnaire were examined with 
exploratory factor analysis. Principal component analysis (PCA) 
was conducted on the six LIKERT scale items. Internal consist-
ency of the questionnaire was investigated using Cronbach’s 
alpha coefficient. Completed questionnaires were entered into 
SPSS software (version 24) and analysed using descriptive and 
inferential (Chi-square test and Fishers Exact) statistics. The 
researcher carrying out data input and analysis was blinded to 
the participants’ allocation status.
Costs of conducting PPI
The lead researcher (ER) kept a detailed account of all direct 
costs associated with conducting PPI for the purpose of this 
study. These costs included researcher salary, travel and expenses 
for PPI participants, adult literacy review and printing and 
postage costs.
This paper has been written in adherence to the Guidance for 
Reporting Involvement of Patients and Public 2 (GRIPP 2)23. 
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The GRIPP 2 checklist is a tool, developed to improve the report-
ing of patient and public involvement in research and guide 
the development of a transparent, consistent and high-quality 
PPI evidence base. The Good Reporting of a Mixed Methods 
Study (GRAMMS) framework was also used to inform the 
reporting of the findings24.
Results
Characteristics of the trial participants stratified by participation 




Three focus groups were held with 19 out of 38 participants 
accepting an invitation to join. Participants who attended the focus 
groups were similar in age, gender, education level to those who 
did not attend.
Focus group findings indicate that participants want to receive 
the results of the trial in which they are taking part. Three main 
themes emerged in relation to participants’ perspectives of and 
preferences for receiving trial results: ‘acknowledgement of indi-
vidual contribution’, ‘contributing for a collective benefit’ and 
‘receiving accessible and easy to understand results’.
Acknowledgement of individual contribution
Many participants reported feeling they had made an individual 
contribution to the trial in terms of their time and personal infor-
mation while attending the trial study visits. As such, participants 
felt that receiving the results of the trial would provide an 
acknowledgement of this individual contribution:
‘Yes,Imeanit’skindofinstinctive…whenyougointoa[clini-
caltrial]andyouspendandinvestthattimeinit.Imeanokay
I had the time to invest but you knowat the endof theday,
[receivingtheresult]iskindoflikeyourpayoff.’ (FG2 P3)
Contributing for a collective benefit
While participants spoke about making an individual contribu-
tion to the trial, they felt that their involvement contributed to a 
collective benefit or greater good. Participants reported that 
receiving the results of the trial would help them to feel that they 
had contributed to this greater good:
‘I’m not really interested in my own personal results but
as the results of the scheme as a whole.You know the idea
is, does the study help or hinder old people and that’s
whatIwanttoknow’ (FG2 P1)
This feeling of contributing for a collective benefit was further 
reinforced when participants discussed their desire to understand 
how the results of the trial will be implemented by medical experts 
and ultimately how it will affect others who have the condition:
‘I would like to know, if they found out, okay, do we treat
these people or not.That would be good. Do we treat them
or don’t we treat them? I think that is what it’s all about’
(FG3P4)
Receiving accessible and easy to understand results
Participants expressed a clear need to receive the results of the 
trial in an accessible and easy to understand way. This preference 



























   Male 61 (58.7%) 14 (73.7%) 31 (60.8%) 28 (56%) 26 (68%) 16 (52%)
   Female 43 (41.3) 5 (26.3%) 20 (39.2%) 22 (44%) 12 (32%) 15 (48%)
Age 
   65–74 57 (54.8%) 12 (63.1%) 32 (62.7%) 24 (48%) 25 (66%) 12 (45%)
   75+ 47 (45.2%) 7 (36.9%) 19 (37.3%) 26 (52%) 13 (34%) 17 (55%)
Education 
   Primary only 22 (21.2%) 2 (10.5%) 12 (23.6%) 9 (18%) 10 (26%) 8 (26%)
   Secondary/Tertiary 47 (45.1%) 12 (63.2%) 24 (47.1%) 22 (44%) 19 (50%) 11 (35%)
   Unknown 35 (33.7%) 5 (26.3%) 15 (29.3%) 19 (38%) 9 (24%) 12 (39%)
1A subgroup of Irish TRUST participants (n=38) were invited to focus groups.
2RR=Response Rate
3Total Irish TRUST participants (n=104) excluding PPI partners (n=3)= n=101.
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The majority of participants said they would like to receive 
the results in a letter format posted to them directly from the 
TRUST trial. Participants felt that this method would be acces-
sible to them as they could read the results ‘in text’ (FG3 P4) 
and keep a ‘hardcopy’ (FG P1). While participants wanted an 
official statement of the results in a letter format, they also felt 
it was important to add a personal element to the letter. They 
suggested this could be done by offering participants a phone 
number that they could call if they wished to discuss any further 
issues or concerns with the TRUST study team:
‘Could you attach a helpline on to it? If you know, some-
body had some kind of serious medical question or that
they thought was a bit personal element or whatever. That
they’d like to talk to a medical person or whatever. Instead
of just talking to your GP, maybe that would add another
dimensionofcarearoundtheTRUST’ (FG2 P3)
Participants agreed that the format, content and language of 
the results letter needed to be easy to read and understand. All 
participants wanted the letter to be no longer than 2–3 pages 
and presented in a question and answer format. Participants 
believed the content of the results letter should include ‘pertinent
information’ (FG1 P7) relating to the trial itself, the study drug 
(including side effects) and the results of the trial. They stressed 
the importance that this information needed to be informed 
by medical experts and ‘from a good authoritative source’ 
(FG2 P2) but it should be presented to them in a language that 
fits their current context and could be easily understood by 
those who do not have scientific or medical backgrounds.
‘Just in ordinary language that we can understand
ourselves, youknow thatwedon’twantbigand longexpla-
nationor that, just thatwecanpick itupstraightaway that
it’s without any huge number of pages. Just the bare, to me
anyway,answerstothequestions.’ (FG3- P2)
It was evident from the focus groups that participants want to 
receive the results of the trial both to acknowledge their indi-
vidual contribution to the trial and also help them to feel that 
they had contributed to a greater good. Participants expressed a 
clear preference to receive the results in an accessible and easy 
to understand way. These results were used by the researcher 
(ER) to develop an initial draft of the results letter (see 
Supplementary File 2: Draft one patient-based result letter).
PPI group
The initial draft of the results letter was then further iteratively 
developed by the PPI group. There were four PPI partners in 
total (three trial participants and one older adult) Each partner 
toook part in one-to-one session. Each session contained an 
open discussion between the researcher (ER) and PPI partners 
on the layout, content and language of the document. Research-
ers and PPI partners worked together to write, re-write, edit and 
change different sections of the document.
Health literacy review
This draft was then iteratively reviewed and approved by health 
literacy experts from the NALA (see Supplementary File 3: Final 
version patient-based results letter).
Phase Two: Dissemination of trial results 
(intervention phase)
There were a total of 101 Irish TRUST participants randomised 
to the SWAT intervention. Trial participants from the PPI group 
(n = 3) were excluded from randomisation as they reviewed the 
content of the intervention method prior to the intervention. 
The intervention group (n=51) received the patient-based letter 
format (see Supplementary File 3: Final version patient-based 
results letter) and the control group (n=50) received a copy of 
the TRUST results press release, which was made available 
by the lead study site on the TRUST Thyroid Trial Website 
(see Supplementary File 4: Standard results letter).
Phase Three: Evaluation of patient-based approach 
(quantitative phase)
The overall response rate for the patient understanding question-
naire was 68% (69/101). The response rate for the intervention 
group was 74% (38/51) and the response rate for the control 
group was 62% (31/50). There were no significant differences 
in age, gender and education between those who returned the 
questionnaire and those who did not.
Post hoc power calculations showed that the study was under-
powered to detect an effect. Power for each of the patient 
understanding components ranged from .01 to. 58.
Table 2 below shows the results of patients’ perceived under-
standing of the purpose and context of the TRUST Thyroid 
Trial. Due to low participant numbers across the five Likert 
responses, the questionnaire response bands have been contracted 
from ‘Strongly Agree’ and ‘Agree’ to ‘Yes, ‘Strongly Disagree’ 
and ‘Disagree’ to ‘No’ and ‘Neither agree nor disagree’ to ‘Neutral’. 
The results show that patients’ perceptions of understand-
ing are similar between the intervention and control groups. 
Subgroup analysis showed patient’s understanding was not 
significantly impacted by age, gender or educational level.
Figure 1 shows patients’ actual understanding of the primary 
aim, side effect and results of the TRUST Thyroid Trial. Almost 
82% (n=31) of the intervention group and 65% (n=20) of the 
control group correctly understood the primary aim of the 
TRUST trial (p=0.108). Almost 40% (n=15) of the intervention 
group and 36% (n=9) of the control group correctly understood 
the associated side effects of the active drug (p=0.734). In total 
50% of the intervention group (n=19) and 58% of the control 
group correctly understood the results of the trial (p=0.504). 
There were no differences in patient understanding of trial results 
between the intervention and control groups.
In terms of patient understanding of hypothetical patient case 
studies, 43% (n=13) of the intervention group gave the correct 
answer to Vignette A; this was lower than the control group 
(62.1%, n=18, p=0.15). In total 77% (n=23) of the intervention 
group gave the correct answer to Vignette B, this was higher than 
the control group (66%, n=19, p=0.344).
Psychometric testing
An exploratory principal components analysis (PCA) was con-
ducted on the patient understanding questionnaire to determine 
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Table 2. Patient perceptions of understanding presented by group1.
Item Group Yes No Neutral p-value




























































I understand the impact of Levothyroxine on thyroid 















I understand how doctors will use the results of the 
















1Patient perceptions of understanding were assessed using a five point LIKERT scale.
Figure 1. Patient understanding of primary aim, side effect and trial result of the TRUST Thyroid Trial presented by group1.
1Patient understanding of primary aim, side effect and trial result was assessed using multiple choice questions.
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its usefulness as a measure of perceived understanding. The 
Kaiser-Meyer-Olkin (KMO) measure verified the sampling 
adequacy for the analysis, KMO= .83. Bartlett’s test of spheric-
ity indicated that the correlation matrix was significantly dif-
ferent from an identity matrix, X2 (.852) = 283.92, p<.001. An 
examination of eigenvalues greater than Kaiser’s criterion of 
one, suggested the extraction of one factor; this was supported 
by inspection of Cattell’s scree plot. An examination of the 
constituent items for this factor structure also indicated that items 
loaded most highly on a single factor. This single factor repre-
sents a measure of perceived understanding of trial results. PCA 
was then conducted using an oblique (direct oblimin) rotation, 
specifying the extraction of one factor. This model explained 
a combined 69.58% of the variance in patients understanding of 
the TRUST thyroid trial.
Cost of conducting PPI
The total cost of this study amounted to €8,049 (see Supplementary 
File 6: Costs of conducting PPI).
Discussion
While PPI is increasingly recognised as an important element 
of clinical research, evidence on optimal methods and potential 
impact is lacking4,9. Previous research conducted on the impact 
of PPI has largely focused on the experiences of participants 
and researchers25 and on the research process in broad terms26. 
In this study, our primary outcome was specific: a quantitative 
measure of patient understanding of trial results between those 
who received the patient-based approach and the standard 
approach. To our knowledge there has been no previous research 
conducted on the impact of PPI on patient understanding of trial 
results.
The involvement of clinical trial participants in this study offered 
insightful perspectives on the information needs of the study 
population in terms of receiving end of trial results. Study find-
ings show that trial participants want to receive the results of the 
clinical trial in which they had participated. This is supported 
by much of the available literature on patients’ preferences of 
receiving results, with up to 90% of participants in previous 
studies reporting a desire to receive results27. Focus group find-
ings showed that participants felt that receiving results would 
provide an acknowledgement of their individual contribution to 
the trial. This finding complements previous commentaries about 
result sharing being an ‘ethical imperative or ‘moral obligation’. 
Fernandez et al. points out that many participants place their trust 
in science and researchers owe a debt to participants to fulfil their 
trust and recognise their altruism12,28.
Unsurprisingly, findings also show that participants want to 
receive results that are accessible and easy to understand. In 
this study, the preferred format of receiving results was a letter 
posted to them directly from the TRUST trial. This preference 
is also consistent with the literature on patient preferences of 
receiving results. A previous study investigating prefrences of 
individuals taking part in a cardiac rehabilitation trial found 
that 80% of trial participants preferred to receive the results 
by post29. The patient-based approach identified in this study 
was feasible for researchers to develop with significant 
involvement from trial participants and adult literacy experts.
Previous studies exploring participants’ reactions found that 
sharing trial results with participants can cause some negative 
impacts such as anxiety, anger, guilt, upset and confusion30–32. 
As far as researchers in this study are aware, providing results 
did not cause any negative impacts. This may have been due 
to the fact that the TRUST trial had a low risk of morbidity or 
mortality compared to some of the other studies citing negative 
impacts. Both result methods contained the telephone number, 
email address and postal address of the research team and 
participants were urged to contact should they have any 
questions or concerns relating to the study. The research team 
did not receive any queries.
Previous systematic reviews highlight the lack of evidence on 
economic analysis of PPI and call for researchers to consider the 
costs of its implementation26,33. As discussed previously research 
funders are increasingly demanding that PPI be carried out in 
research. However, the costs of PPI are often underestimated 
and can cause a significant financial burden on research project 
budgets26,33–35. It is extremely important that researchers 
plan PPI at the grant proposal stage and estimate the costs 
appropriately. If these costs are not correctly estimated during 
the initial stages of developing research proposals, they may 
cause a financial burden on PPI partners.
Participants in this study were not paid for their time but were 
provided with a €20 voucher to cover travel expenses. When 
PPI is not the primary focus of a study, researchers do not 
consider the cost implications at the beginning of the study 
and are often tied with limited resources to carry out PPI34–36. 
INVOLVE, the national advisory group supporting active public 
involvement in health services, public health and social care 
research in the UK, have recommended that PPI partners should 
be paid for their involvement37. Despite this, existing research 
suggests that institutional difficulties make negotiating the 
mechanisms of paying participants very difficult34. One study 
reported that in order for participants to be remunerated for their 
efforts, they needed to be registered as employees, a process 
that incurred much paperwork and time delays34. This study out-
lines the cost of conducting PPI and includes a full breakdown 
of costs (see Supplementary File 6: Costs of conducting PPI). 
This breakdown provides a template to other researchers who 
plan to carry out and evaluate PPI as part of their research. It is 
important to note that not all costs associated with carrying out 
the study were included in this amount. For example, the only 
salary costed was that of the research assistant. The expertise 
provided by other members of the study team were not included 
in the total cost as they were being paid by the University 
or other research grants. The total cost of conducting this 
study was €8,049 which is not insignificant but should be 
considered in the context of the cost of large-scale trials.
Strengths and Limitations of the study
While this study provides important insights into patients’ prefer-
ences of receiving trial results, it is not without limitations. Firstly, 
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existing PPI literature states that ‘to understand the research 
needs and challenges, PPI has to engage people who are able to 
offer perspectives from the study population’3. All PPI partners 
in this study were active members of the research community 
as they had taken part in the TRUST trial and had agreed to 
long-term follow up. This is a strength of the SWAT as they were 
able to offer perspectives from the study population, however 
it does have an important implication for their reporting of 
understanding the results of the trial. They may be more 
inclined to rate their understanding as high because of their 
investment in the trial38, thus potentially minimising differences 
between the intervention and control conditions and minimising 
inferences that can be drawn about the intervention. Previous 
research suggests that people that actively choose to engage 
in research either as research participants or involvement part-
ners are more likely to be middle-class and highly educated39,40. 
In this study, those that attended the focus groups and PPI group 
were similar in education level to those that did not attend. 
This is not surprising considering the entire study sample 
had already actively volunteered to take part in the TRUST trial. 
Secondly, the results of the patient understanding question-
naire show that the levels of patient understanding were similar 
between the two groups. However, this study was underpowered 
to detect an effect. As this was a Study Within A Trial (SWAT), 
the power was limited by the sample size that was available to 
us from the trial (n=115). Furthermore, validation of the patient 
understanding questionnaire was limited by the sample size 
in this study. While validation of the questionnaire was 
limited, exploratory factor analysis provided some evidence that 
the questionnaire is a useful tool for measuring patient under-
standing of trial results. The developed questionnaire can be 
tailored for use in other trials in future examinations of patients 
understanding of trial results. This would provide insight into 
patient understanding and provide further validation data.
Thirdly, all SWATparticipants were aged 65 and over. The lay-
out, format and language of this patient-based approach which 
was identified and developed may only be relevant for this 
study population. Other trial populations may prefer to receive 
the results via email, online or in person from a member of the 
study team12. The evidence on patient preferences of receiving 
trial results is limited, therefore further research is needed to 
explore patient preferences of receiving trial results amongst 
different study populations.
It is also important to point out that the control group in this 
study received a copy of the trial results in a press release for-
mat. Most trial participants do not receive this. While this control 
method was a step further than normal procedure, the researchers 
in this study felt this was appropriate. The information pre-
sented in the press release was similar to that of the patient-based 
approach. However, the format and layout of the press release 
was different. Information was writtern in four long paragraphs 
separated by individual headings. It was also much shorter 
(1 page in total) that the patient-based approach (3 pages 
in total). Given the fact that press releases are written by 
public relations professionals with a view to communicating 
effectively and efficiently, this may have potentially minimised 
differences between the intervention and control conditions. The 
primary outcome of this study was assessing the impact of PPI 
on patient understanding of results, however, this was not 
the only potential impact. In hindsight, we adopted a limited 
approach to PPI in this study as we did not involve our PPI 
partners from the outset of the SWAT. Involving PPI partners in 
the development of core outcome sets for this SWAT could have 
identified other more appropriate primary outcome measures41.
The aim of this SWAT was to investigate methods of dissemi-
nating trial findings to trial participants by using a PPI approach 
to identify, develop and evaluate a patient-based method of 
receiving trial results. The PPI approach actively involved 
focus group participants in making decisions about the result 
method and worked with PPI partners to co-develop the 
result letter. However, PPI partners were not involved in other 
aspects of the research process such as research design, data 
collection or analysis. This is partly due to the fact that PPI is 
a relatively new concept in clinical trials. As the majority of 
the literature has only been published in the last 12 months, 
there is little evidence available on the impact of PPI and no gold 
standard or comprehensive guidelines for researchers to follow29. 
Thornton2 suggests that in order for PPI to develop it is impor-
tant to record its social and cultural history by collecting 
comprehensive databases and undertaking ongoing reviews of 
the impact of PPI. This paper along with the study protocol have 
been written in adherence with the Guidelines for Reporting 
Involvement of Patients and the Public23, thus providing tem-
plates for involving patients and the public in clinical trial design 
and development. This study is an important step forwards 
in documenting the process of conducting PPI as part of a SWAT 
and evaluating its impact. Future research is needed to further 
develop PPI in clinical trial settings. As there is currently 
no gold standard or comprehensive guidelines for researchers 
to follow when evaluating the impact of PPI, further research is 
needed. This research should involve PPI partners in the devel-
opment of core outcome sets for evaluating PPI impact. These 
would significantly enhance the literature in the area.
Conclusion
Patient and Public Involvement (PPI) is advocated for every step 
of the trial process. We have demonstrated that it is feasible to 
involve PPI partners in the development of dissemination mate-
rials. Sharing clinical trial results with participants in a format 
understandable to laypersons will soon be a legal requirement11. 
However, there is a significant lack of evidence as to the most 
appropriate methods of sharing results with participants. The study 
identified and developed a patient-based approach to disseminat-
ing clinical trial results for trial participants. Although, in this 
study PPI did not influence patients’ final understanding of results, 
it documents the process of conducting PPI within the clinical 
trial setting. This process may be useful for other trialists inter-
ested in conducting and evaluating the impact of PPI in clinical 
trials.
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The research was approved in Ireland by the Clinical Research 
Ethics Committee of the Cork Teaching Hospitals, UCC, Ref 
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All participants provided signed informed consent to take part 
in the study.
Data availability
The raw data from this study cannot be sufficiently de-identified, 
and therefore are not publicly available. However, the data from 
the current study are available for further (collaborative) research 
purposes on reasonable request. Available datasets include 
transcripts from focus groups, field notes from PPI sessions 
and responses from the patient understanding questionnaire. 
To access the data, please contact the corresponding author 
(emmy.racine@ucc.ie) or the Principal Investigator (patricia. 
kearney@ucc.ie). Researchers must provide a written proposal 
on how the data will be used in research before access is 
granted.
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